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ABSTRACT 
 
Nasal polyposis is a common disease affecting 2-4 % of the general population.  The aetiology 
and pathogenesis are far from clear.  Recent publications have suggested up-regulation of 
several pro-angiogenic factors including VEGF.  The aim of this study was to assess and 
quantify the degree of angiogenesis in nasal polyposis and to determine if angiogenesis was 
the driving force behind polyposis.  We started by developing a novel triple stain to assess 
remodelling in the nasal mucosa.  For the first time we were able to categorically refute the 
common belief of angiogenesis driven polyposis. We then carried out genomic studies and 
identified upregulation of genes controlling the cell cycle and apoptosis, suggesting cell 
turnover is an important part of the pathogenesis of nasal polyps. Our gene expression data 
was confirmed by TUNEL staining, indicating an increased level of apoptosis in nasal polyp 
tissue, counterbalancing the increased cell proliferation.  Inflammatory genes are also 
upregulated, however the data collected so far cannot distinguish between different types of 
inflammatory response.  We carried out proteomic studies using the luminex system but this 
did not clarify the situation despite using matched samples that were used in the gene array.  
They highlight the protein differences occurring in the polyps themselves.  We have shown 
chemoattractants for eosinophils & macrophages (which are found in polyps), and 
significantly in iNOS, which is novel. 
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1  General Introduction   
1.1 Angiogenesis 
1.1.1 What is angiogenesis?  
1.1.1.1  Definition 
Angio genesis (Latin) is the growth of new blood vessels from an existing vasculature, and is 
an important natural process occurring both in health and in disease.  This occurs mainly in the 
capillaries and may affect venules. 
1.1.1.2 History 
The term “angiogenesis” was first used in 1787 by the Scottish surgeon Dr. John Hunter to 
describe blood vessels growing in reindeer antler after the annual shedding (Palmer, 1837).  
This process is multifactorial and related to day light length changes and sexual hormone level 
variations. In 1935, Boston pathologist Dr Arthur Tremain Hertig (Hertig, 1935) was the first 
to describe the actual process of angiogenesis in the placenta of pregnant monkeys.  This again 
is multifactorial and regulated by cyclical hormonal variations.   
In 1971 Dr Judah Folkman (Folkman et al., 1971) showed a soluble factor separable from 
human and animal tumours that was mitogenic for endothelial cells and responsible for 
formation of new capillaries  He hypothesized that tumour growth in all mammals studied 
(including man) was dependent upon angiogenesis and thus antiangiogenic therapy could be 
developed as a treatment modality in solid tumours. 
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Cartilage, which has no blood supply but receives its nutrition by diffusion, was the first tissue 
found to inhibit angiogenesis and Drs. Henry Brem and Judah Folkman hypothesized that with 
further purification, morselised cartilage may prove useful as a means of maintaining tumour 
dormancy by “anti-angiogeneisis” (Brem and Folkman, 1975).  The factor was unknown. 
In vitro studies of tissue culture allowed the identification and extraction of these growth 
factors. The first angiogenic factor (subsequently identified as basic fibroblast growth factor, 
bFGF) was purified at Harvard Medical School in 1984 because of its affinity to heparin, 
which allowed its extraction. Basic fibroblast growth factor stimulated capillary endothelial 
cell proliferation (Shing et al., 1984), although it proved to be a non-specific mitogen so 
unsuitable for targeted therapy.   
Vascular endothelial growth factor (VEGF) which is one of the most important angiogenic 
factors was discovered simultaneously by Dr. Napoleone Ferrara (Ferrara and Henzel, 1989) 
and by Dr Jean Plouet in 1989 (Plouet et al., 1989).  It turned out to be identical to a molecule 
called vascular permeability factor (VPF) discovered 6 years previously by Dr. Harold Dvorak 
(Senger et al., 1983).   
The first anti-angiogenic compound, angiostatin, was discovered by O’Reily and Folkman in 
1994 (O'Reilly et al., 1994) from serum and urine of tumour bearing mice. 
1.1.1.3  Clinical relevance  
Angiogenesis is ubiquitous in health and in many disease processes.  Physiological 
angiogenesis occurs in a variety of conditions, most notably; wound healing to restore blood 
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flow to tissues after injury or assault, menstruation to rebuild the uterus lining, to mature the 
egg during ovulation, during pregnancy to build the placenta, lactation, formation of adipose 
tissue, and during endurance training in skeletal muscle.  Pathological angiogenesis is equally 
common occurring in both neoplastic and non- neoplastic pathologies. Neoplastic conditions 
include both benign and malignant tumours anywhere in the body and the non-neoplastic 
conditions include diabetic blindness, age related macular degeneration, atherosclerosis, 
rheumatoid arthritis and psoriasis (Folkman, 1995).  Diseases in which there is insufficient 
angiogenesis include, ischaemic heart disease, peripheral vascular disease, stroke, delayed 
would healing, and certain muscular dystrophies.  The body controls angiogenesis through a 
series of angiogenesis stimulating growth factors balanced with angiogenesis inhibitors.  A 
better understanding of the complex processes and controls of angiogenesis will undoubtedly 
help develop better management strategies in many of these conditions. 
1.1.2 Types of angiogenesis   
Angiogenesis is a mechanism by which a pre-existing microvascular network is expanded in 
response to a changing metabolic and mechanical environment (Hudlicka et al., 1992).  There 
are a number of discreet processes, through which new blood vessels are formed; sprouting 
angiogenesis, splitting angiogenesis – intussusceptive and longitudinal splitting, elongation 
and vasculogenesis. 
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1.1.2.1 Sprouting Angiogenesis 
During this process, endothelial cells form sprouts that break through the basement membrane 
and begin tube formation that grows as endothelial cells proliferate, forming a new capillary.  
This new capillary then fuses with another capillary and blood starts to flow through it 
enabling it to mature into a functional capillary with reformation of the basement membrane 
and recruitment of perivascular cells (Ausprunck and Folkman, 1977, Hudlicka, 1991, 
Carmeliet, 2000).  This is most often seen in tumour angiogenesis, but the blood supply of a 
tumour is rarely as patent and well organized as the normal vasculature.  Vessels are often 
leaky, badly organised and have blind ending tubes (Papetti and Herman, 2002), and may be 
lined with non-endothelial cells (Folberg and Maniotis, 2004). 
1.1.2.2 Splitting Angiogenesis 
Capillaries can split in vivo in two different ways (Figure 1.1), by intussusception and luminal 
division.   
1.1.2.2.1 Intussusceptive Angiogenesis 
This was first described in rat lung and occurs when interstitial cells press into the capillary, 
forming a column which then propagates down the capillary, resulting in the formation of two 
separate capillaries (Burri and Tarek, 1990).  Intussusceptive angiogenesis is thought to be an 
important process during development and possibly some tumours (Djonov et al., 2003). 
1.1.2.2.2 Luminal Division 
In contrast to this, luminal division (also known as longitudinal splitting) involves endothelial 
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initiation (as opposed to interstitial initiation), whereby endothelial cells send filopodial 
processes into the capillary lumen, which join and form a septation that propagates down the 
capillary (Zhou et al., 1998, Egginton et al., 2001).  This has been seen in adult rat and mouse 
skeletal muscle in response to increased blood flow and is a different process to 
intussusceptive angiogenesis (Williams et al., 2006b, Zhou et al., 1998, Egginton et al., 2001).  
The clinical relevance of luminal division is unclear, as it has not been investigated, but as it is 
associated with much less mitotic activity than the traditional (sprouting) form of angiogenesis 
it may be more efficient in terms of energy cost and rapidity of response (Egginton, 2011). 
1.1.2.3  Elongation 
During the menstrual cycle, endometrial angiogenesis occurs by a combination of capillary 
splitting (whether luminal division or intussusception is unknown) and capillary elongation 
(Rogers and Gargett, 1998).  This capillary elongation is a specialised process that increases 
capillary supply mainly due to the unique spiral shape of capillaries found in the endometrium.  
Capillary elongation is difficult to detect using the standard two dimensional measurements of 
angiogenesis commonly used, thus may be more prevalent than currently realised. 
 
1.1.2.4 Vasculogenesis 
This is another method of new blood vessel formation first described in chick embryos 
(Gonzalez-Crussi, 1971, Watterson, 1949).  It is not the same as angiogenesis, which requires 
pre-existing endothelial lined vessels.  Vasculogenesis is the de novo formation of blood 
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vessels from mesodermal endothelial precursors which coalesce to form a blood island, and 
then form endothelial tubes resulting in immature and isolated vascular beds, that 
subsequently form complex networks through angiogenesis (Risau, 1997).  Circulating 
endothelial precursor cells (EPCs) may also lead to new blood vessel formation, which some 
authors have stated as being a type of vasculogenesis (Asahara et al., 1997, Ribatti et al., 
2001).  EPCs are clinically relevant as they may be incorporated into tumour vasculature 
(Peters et al., 2005). This appears to be a different process to classic embryonic 
vasculogenesis. 
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Figure 1.1 Four morphological forms of angiogenesis; sprouting angiogenesis, splitting 
(both luminal division and intussusception) angiogenesis and capillary elongation. 
 
Despite there being morphological differences between the different types of angiogenesis 
there are many processes that are required in all of them, such as alteration of cell contacts, 
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disruption of basement membrane, endothelial cell proliferation, and capillary maturation.  All 
these processes require very precise spatial and temporal control, which in turn requires a 
complex balance of pro and anti angiogenic factors.  Numerous pro and anti-angiogenic 
factors and inflammatory mediators have been described (Folkman, 1996, Friedlander et al., 
1996), mainly from in vitro studies, but what is becoming apparent is that angiogenesis in vivo 
involves a cascade of feed-forward and feed-back pathways.  Vascular endothelial growth 
factor (VEGF) and the angiopoietins are the most specific for endothelial cells and may 
therefore have the most important role in angiogenesis (Gale and Yancopoulos, 1999). 
1.1.3 Molecular Basis of Angiogenesis   
1.1.3.1 The vascular endothelial growth factor system 
Vascular endothelial growth factor (VEGF) is the most important factor in the promotion of 
angiogenesis (Clauss et al., 1990). A single allele knockout is lethal in utero (Carmeliet et al., 
1996) and it is essential for maintaining vascular integrity (Tang et al., 2004).  VEGF was first 
described in 1989 (Ferrara and Henzel, 1989) and has since been found in a range of different 
tissues (Ferrara, 2004).  Members of the vascular growth factor family (VEGF [VEGF-A], 
placental derived growth factor, VEGF-B, VEGF-C, and VEGF-D) are currently known as the 
major inducers of angiogenesis and lymphangiogenesis (Saaristo et al., 2000a).  VEGF is also 
known to be more potent than histamine in increasing capillary permeability to plasma 
proteins (Dvorak et al., 1995), and VEGF signalling often plays a critical rate limiting step in 
physiological angiogenesis (Ferrara, 2004, Ferrara and Davis-Smyth, 1997).   
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VEGF-A, commonly referred to simply as VEGF, is the most abundant type and has four 
isoforms, having 121, 165, 189 and 206 amino acids respectively, after signal sequence 
cleavage (VEGF121, VEGF165, VEGF189 and VEGF206) (Houck et al., 1991, Ferrara, 2004).   
VEGF-B also has a wide tissue distribution and is particularly abundant in the heart and 
skeletal muscle (Olofsson et al., 1996).  VEGF-C and VEGF-D are closely related and form a 
subfamily of the VEGF-related proteins (Achen et al., 1998, Robinson and Stringer, 2001).  
They are more specific for lymphatic channels and are involved in lymphangiogenesis (Kukk 
et al., 1996, Jeltsch et al., 1997, Joukov et al., 1996, Ristimaki et al., 1998).  The VEGF family 
mediate their effects through binding with varying affinity to vascular endothelial growth 
factor receptors (VEGFR) that form the family of receptor tyrosine kinases (Robinson and 
Stringer, 2001, Ferrara et al., 2003).  Three VEGF receptor types (R1-R3) have been 
identified.  VEGFR-1 and VEGFR-2 are both high affinity receptors for VEGF-A whereas 
VEGFR-3 binds to VEGF-C and VEGF-D and appears to be localised to lymph vessels 
(Karkkainen et al., 2002).  VEGF-B seems to selectively bind only to VEGFR-1 (Olofsson et 
al., 1998).  VEGFR-2, also called Flk-1 (for foetal liver kinase, or KDR for kinase insert 
domain receptor), mediates most of the direct effects of VEGFs on the endothelial cell, and 
binds the remaining VEGFs (Waltenberger et al., 1994).  VEGFR-1 is also known as Flt-1 (for 
fms –like tyrosine kinase-1) and may mediate secondary effects such as tissue factor 
upregulation as apposed to direct proliferative effects on endothelial cells (Clauss et al., 1990, 
Park et al., 1994). 
1.1.3.2 Basic fibroblast growth factor 
Basic fibroblast growth factor (bFGF), also known as fibroblast growth factor-2 (FGF-2) was 
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originally described as an angiogenic fraction from a tumour line and was found to be a 
heparin binding protein in 1984 (Shing et al., 1984, Folkman et al., 1971) capable of inducing 
angiogenesis in vivo and cell proliferation in vitro (Presta et al., 2005).  They are in fact a 
family of heparin binding growth factors and like VEGF, exist as four isoforms (18, 21.5, 22 
and 24 kDa) (Bikfalvi et al., 1998).  bFGF is much less specific in its expression and action on 
endothelium than VEGF and can stimulate angiogenesis in a variety of in vivo models (Yayon 
and Klagsbrun, 1990, Presta et al., 2005).  VEGF knockout mice die in utero from vascular 
defects (Carmeliet et al., 1996, Ferrara et al., 1996), whereas bFGF knockout mice are viable 
although with impaired wound healing (Ortega et al., 1998), suggesting that VEGF is more 
important in angiogenesis. 
1.1.3.3 Platelet derived growth factor  
Platelet derived growth factor (PDGF) is a dimeric glycoprotein that has five isoforms (A, B, 
C, D, and AB) that activate cellular response.  It plays an important role in regulating cell 
growth and division, particularly in blood vessel formation (Matsui et al., 1989).  The receptor 
for PDGF, PDGFR is a cell surface receptor tyrosine kinase.  Two types of PDGFRs have 
been identified, alpha (PDGFRA) and beta (PDGFRB) (Heidaran et al., 1991) that dimerise 
upon binding resulting in tyrosine phosphorylation, leading to enzymatic activity.  Expression 
of both receptors and each of the five isoforms is under independent control.  In addition, 
different external stimuli such as inflammation, embryonic development or differentiation 
modulate cellular receptor expression and some cell types display only one of the PDGFR 
isoforms while other cells express both isoforms simultaneously or separately (Heldin and 
Westermark, 1999).  PDGF has been shown to recruit pericytes and promote vessel maturation 
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(Carmeliet, 2000).  It can help wound healing (Robson et al., 1992) and was the first licensed 
clinical pro-angiogenic factor for treating diabetic foot ulcers (Steed, 1995).  Thus the 
PDGF/PDGFR system has many complex external controlling mechanisms affording it high 
flexibility in regulating cell growth and division, particularly in angiogenesis.   
1.1.3.4 Tumour necrosis factor  
Tumour necrosis factors (or the TNF family) refer to a group of cytokines, each with 157 
amino acids that can cause apoptosis as well as a wide range of pro-inflammatory actions.  
TNF-alpha (TNF-α) is the most well known, and is a multifunctional inflammatory cytokine 
released by leukocytes and endothelial cells, with effects on lipid metabolism, coagulation, 
insulin resistance, and the function of endothelial cells lining blood vessels (Yoshida et al., 
1997, Huang et al., 2000).  TNF acts via the TNF receptor (TNF-R) and blocking the action of 
TNF has been shown to be beneficial in reducing inflammation.  It has an important role in 
angiogenesis and can have pro- or anti- angiogenic effects, depending on the system studied 
(Patterson et al., 1996).  It also affects angiogenesis through leukocyte behaviour (Norrby, 
1997, Polverini, 1997).  
1.1.3.5 Nitric oxide 
Nitric oxide (NO) is a gaseous signalling molecule that has several potential effects on 
angiogenesis.  It is synthesised from arginine by one of three nitric oxide synthases (NOS) – 
endothelial (eNOS/NOS3), neuronal (nNOS/NOS1) or inducible (iNOS/NOS2). In skeletal 
muscle, eNOS is found in endothelial cells, whilst nNOS is found at a high level in the 
sarcolemma of muscle fibres and iNOS can be induced in the endothelium by inflammatory 
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factors (Stamler and Meissner, 2001).  Whilst eNOS has been thought of as being most 
important in angiogenesis (Smith et al., 2002, Lee et al., 1999, Amano et al., 2003), both 
nNOS and iNOS are capable of exposing the endothelium to higher concentrations of nitric 
oxide (Kavdia and Popel, 2004).  Nitric oxide has a very short half life in the blood and is 
constitutively produced as a tonic vasodilating agent, which may in part explain its angiogenic 
activity (Egginton, 2009). 
NO can upregulate the mitogen-activated protein (MAP) kinase pathway and lead to secretion 
of VEGF in vitro (Ziche and Morbidelli, 2002), and addition of exogenous eNOS can 
stimulate angiogenesis (Smith et al., 2002), however nitric oxide may also have an anti-
angiogenic role (Bussolati et al., 2001, Lau and Ma, 1996, Pipili-Synetos et al., 1993).  
NO is also found in exhaled air and most originates from the paranasal sinuses (Lundberg et 
al., 1995).  This will be discussed further in section 1.2.1.5 
1.1.3.6 Matrix metalloproteinases 
The matrix metalloproteinases (MMPs) are a family of zinc and calcium dependent 
endopeptidases that can collectively degrade almost all extra cellular matrix (ECM) 
components and are implicitly involved in ECM remodelling.  Proteolysis of the extracellular 
matrix is essential for angiogenesis to physically enable capillaries to grow into an existing 
tissue (Nguyen et al., 2001).  There are over 20 MMPs (Rundhaug, 2005), of which 1, 2, 3, 
and 9 are produced by endothelial cells (Haas and Madri, 1999).  The activity of MMPs is 
tightly regulated, as with all the components of the angiogenic response, by a four-fold 
mechanism.  Transcriptional control of MMPs is tightly regulated by a host of factors which 
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up- or down-regulate MMP production (Chase and Newby, 2003).  After transcription, MMPs 
must be converted from a latent to an active form, and this active form is inhibited by the 
activity of the tissue inhibitors of metalloproteinases (TIMPs) (Silletti et al., 2001), although 
the TIMPs may be necessary for activation of MMPs.  Once MMPs are activated, the products 
they generate can inhibit them.  MMPs are thought to be of critical importance in 
angiogenesis, and inhibition of MMPs results in abolition of angiogenesis in rat skeletal 
muscle (Haas et al., 2000) when examining the sprouting form of angiogenesis where 
interstitial migration of endothelial cells is essential. It appears not to be important for 
longitudinal splitting, where the interstitium is unaffected (Williams et al., 2006c) (Williams et 
al 2006).   
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1.2 The Nose 
1.2.1 Functions of the nose 
1.2.1.1 Anatomy:  
The nose is made up of bone and cartilage. The septum is a part bony and cartilaginous 
structure that divides the nose into two similar halves. The nose contains shelf-like structures 
called turbinates that help trap particles entering the nasal passages. Material deposited in the 
nose is transported by ciliary action to the back of the throat in 10-15 minutes.  A space called 
the meatus lies inferior to the turbinates and is a drainage pathway for mucociliary flow to the 
postnasal space. The cribriform plate of the ethmoid bone internally forms the roof of the 
nose.  
1.2.1.2 Physiology:  
The nasal cavity is divided into two segments: the respiratory and the olfactory segment. The 
respiratory segment is lined with ciliated pseudostratified columnar epithelium, whereas the 
olfactory segment is lined with olfactory epithelium, which contains receptors for the sense of 
the smell.  
The nose has two primary functions: olfaction, and filtration & humidification of inhaled air. 
The turbinates on the lateral wall of nasal cavity interrupt the airflow into the nasal passage, 
forcing it through narrow passages that are covered with moist nasal mucosa.  The airflow 
across this mucosal surface is humidified and warmed by the turbulent flow and greater 
surface area created by the turbinates. 
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1.2.1.3 Blood flow in the nose 
 
Blood supply comes from branches of the carotid artery, including the facial and the maxillary 
arteries. The arteries within the nose are the anterior ethmoidal artery, the Sphenopalatine and 
Greater palatine arteries that are branches of the maxillary artery, as well as facial arteries that 
supply to the anterior part of the nasal cavity.  
1.2.1.4 Nasal cycle 
The nasal cycle is the alternating congestion and decongestion of the nasal airway, every two 
to six hours, controlled by the autonomic nervous system. Changes in hormone levels, 
temperature, and humidity all affect the nasal cycle(Chaaban and Corey, 2011). 
1.2.1.5 Nitric oxide  
Most of the NO that can be detected in exhaled air is from the paranasal sinuses (Lundberg et 
al., 1995).  It is involved in ciliary motility; being low in Kartagener’s Syndrome (Lundberg et 
al., 1994) and also correlates with ciliary beat frequency (Lindberg et al., 1997).  Infusion of 
NO donors increases ciliary beat frequency and blood flow (Runer and Lindberg, 1998) 
whereas NO inhibition causes vascular constriction and nasal decongestion (Rinder and 
Lundberg, 1996). 
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1.3 Vascular responses in nasal disease 
 
1.3.1 Asthma 
The nose and lungs are anatomically and physiologically closely related organs. The nose 
plays an important role within the airways, as a filter and humidifier, together with other 
important functions. Asthmatic patients are said to have an increased swelling of the nasal 
mucosa, which results in a reduced ability to filter air and nasal diseases are associated with 
several lower airways diseases such asthma. Other upper airway conditions, such nasal 
polyposis and chronic sinusitis are thought to be factors involved in influencing lower airway 
function hence asthma exacerbation.  
1.3.2 Allergic rhinitis 
Rhinitis is simply inflammation of the nasal passages. Allergic rhinitis is inflammation of the 
nasal passages through an allergic mechanism. Allergic rhinitis can be seasonal or perennial.  
The symptoms of allergic rhinitis are: sneezing; rhinorrhea or runny nose, usually clear and 
colorless in allergy; itching of the nose; and obstructed nasal passages. 
20 - 30% of the population forms a type of antibody (IgE) to the offending allergens. The IgE 
antibody sits on mast cells and basophils which contain granules of mediators especially 
histamine. When the allergen becomes bound by the IgE antibodies on the surface of these 
cells, it causes them to release their histamine and other mediators. Histamine released during 
this reaction causes dilatation of blood vessels which causes them to leak fluid. Histamine also 
creates itching. Moreover as the allergic reaction continues, other cells such as eosinophils are 
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called from the blood that release other toxic granules that further inflame the surrounding 
tissue in a more long-lasting fashion (Braido et al., 2011). 
 
Allergic patients have a twofold increase in nasal nitric oxide (NO) concentration (Arnal et al., 
1997) 
1.4 Nasal polyps 
1.4.1 Definition: 
Nasal polyps are oedematous, semi translucent, benign masses that develop from mucosal 
linings of the paranasal cavity, usually originating from the mucosa in the osteomeatal 
complex,(Larsen and Tos, 2004) so strictly speaking should be referred to as sinonasal polyps.  
They protrude into the nasal cavity as grape-like structures causing nasal blockage and 
obstructing airflow to olfactory mucosa.  Polyps consist of loose connective tissue, oedema, 
inflammatory cells (predominantly eosinophils), capillaries and some glands, mainly covered 
with respiratory pseudostratified epithelium with cilia and goblet cells.   The relationship 
between sinonasal polyposis and chronic rhinosinusitis is much debated, but should now be 
regarded as part of the same disease spectrum.(Fokkens et al., 2007)  
1.4.2 Tissue remodelling and angiogenesis in nasal polyps 
Ito et al. first described expression of VEGF messenger RNA and its receptor VEGFR-1, in 
nasal polyps using northern blotting and in situ hybridisation (Ito et al., 1995b).  They revealed 
VEGF mRNA expressing cells that were scattered in the oedematous stroma of nasal polyps.  
Yang et al. used immunohistochemistry to compare nasal polyps with inferior turbinate 
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mucosa and identified expression of both VEGF protein and its receptor VEGFR-2, to be in 
greater abundance in the vascular endothelium and glands of nasal polyps (Yang et al., 1998a).  
In 2000 Coste et al., demonstrated in vitro expression of VEGF mRNA and in vitro secretion 
of VEGF protein from primary human cultures of nasal epithelial cells (Coste et al., 2000a).  
The authors concluded that VEGF, inducing oedema and angiogenesis, was involved in the 
pathogenesis of nasal polyps.  Lee et al.,(Lee et al., 2000) demonstrated respiratory syncytial 
virus (RSV) to be a potent stimulator of VEGF and suggested VEGF had an important role in 
the pathogenesis of RSV-induced disorders.  Guo et al.,(Guo et al., 2001a) used 
immunohistochemistry to compare nasal polyps with middle turbinate mucosa.  They 
demonstrated VEGF positivity in vascular endothelium and in glandular cells that was 
significantly higher in their nasal polyp group and concluded that VEGF played a key role in 
the formation of nasal polyps.  Li et al.,(Li et al., 2001) evaluated the expression of VEGF and 
basic fibroblastic growth factor (bFGF or FGF-2) in nasal polyps from patients with different 
degrees of polyposis, using immunohistochemistry.  The detection rates were significantly 
higher in the group with more severe nasal polyposis and the authors concluded that the 
overexpression of VEGF and bFGF in nasal polyps might contribute to their growth and 
development.  Jiang et al.,(Jiang et al., 2001 ) demonstrated that VEGF expression was 
upregulated in nasal polyps, supporting the potential role of VEGF in nasal polyposis.  Jiang et 
al.,(Jiang et al., 2002, Jiang et al., 2003) used cultured human nasal epithelial cells from 
polyps and showed them to be actively producing vast amounts of VEGF in response to 
hypoxia.  They suggested that this was the major cause for nasal polyp formation in the middle 
meatus of the nose, a site at which most of the paranasal sinuses drain into the nasal cavity and 
where minimal mucosal oedema can result in complete occlusion, with resultant hypoxia in 
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the sinus cavities.  In 2002 Wittenkindt et al.,(Wittekindt et al., 2002) studied the 
immunohistochemical expression of VEGF and VEGF receptors 1 and 2 in nasal polyps.  
They demonstrated strong immunostaining for VEGF in nasal polyps as well as VEGFR-1 in 
the vascular endothelium in polyps.  Mononuclear round cells and the endothelium of 
capillaries revealed immunoreactivity to VEGFR-2.  In 2004, using immunohistochemistry, 
Wang et al.,(Wang et al., 2004b) showed increased expression of VEGF and its receptors in 
nasal polypoid tissue as compared to normal nasal mucosa.  They conclude that VEGF and its 
receptors participate in the regulation and formation of nasal polyps. 
To summarise, VEGF is a potent stimulator of angiogenesis and permeability.  There is a body 
of evidence to support the presence of VEGF in the nasal mucosa in patients with nasal 
polyposis.  VEGF protein and its receptors have been shown in nasal polyps, around 
inflammatory cells, in the mucosal glands and in the vascular endothelium of the nasal 
mucosa.  VEGF-C and VEGFR-3 are usually found in lymphatics, however, Saaristo et 
al.,(Saaristo et al., 2000a, Saaristo et al., 2000b) demonstrated both VEGF-C and its receptor 
VEGFR-3 in the vascular endothelium of the nasal mucosa.  The remaining splice variants of 
VEGF have not specifically been looked for in the nasal mucosa.   
The VEGF-C/ VEGFR-3 signalling pathway is critical for lymphangiogenesis (Jeltsch et al., 
1997).  Northern blot analysis in mouse and human embryos were used to isolate mRNA from 
nasal mucosa and immunohistochemistry with in situ hybridisation used to measure VEGF-C 
protein and VEGR-3 expression (Saaristo et al., 2000a, Saaristo et al., 2000b).  Both VEGF-C 
and VEGFR-3 expression were demonstrated in the nasal mucosa.  In situ hybridisation of 
mouse embryos showed strong expression of VEGF-C mRNA in the developing nasal conchae 
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and VEGFR-3 mRNA in the submucosal plexus, suggesting this ligand-receptor may have an 
important role in the modelling of this unique vascular plexus. (Saaristo et al., 2000a, Saaristo 
et al., 2000b)   
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1.5 Pathogenesis of nasal polyposis 
The reason why polyps develop in some patients and not in others is unknown. It is a 
heterogeneous condition associated with chronic sinus inflammation.  Symptomatic polyposis 
occurs in up to 4% of the general population (Hedman et al., 1999)  but there is a higher 
prevalence in patients with specific conditions such as asthma, aspirin sensitivity, and cystic 
fibrosis.  Autopsy studies have demonstrated prevalence rates of 32-42% in unselected 
cadavers (Larsen and Tos, 1996, Larsen and Tos, 2004) suggesting that a large proportion of 
patients with polyposis remain asymptomatic.  The pathogenesis of nasal polyposis is far from 
clear, with suggestions of them being adenoma formations (Billroth, 1885), arising from 
inflammation (Bachert et al., 2000a, Jenkins, 1932), oedema (Krajina, 1963), epithelial rupture 
(Tos, 1990), or pseudocysts (Bachert et al., 2000b). A number of studies have proposed a role 
for angiogenesis (Caye-Thomasen et al., 2004, Ito et al., 1995b, Coste et al., 2000a) however 
none of these theories explain all of the histopathological findings and research is now moving 
toward molecular biology, gene array and proteomic array technologies (Figueiredo et al., 
2007, Wang et al., 2006). 
 
1.5.1 Allergy:   
 
Chronic rhinosinusitis (CRS) can be subdivided according to the presence or absence of 
sinonasal polyps.(Fokkens et al., 2007)   Mucosal inflammation in CRS without polyposis is 
usually neutrophil predominant, but when sinonasal polyposis is present is eosinophil 
predominant.  This eosinophilic infiltrate, the fact that patients commonly complain of watery 
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rhinorrhoea with nasal obstruction, and have a degree of mucosal swelling has lead many 
groups to believe that allergy plays a significant role in polyp formation.  However, there is no 
difference in the prevalence of allergy in patients with sinonasal polyposis compared to the 
general population, and there is no difference in prevalence of nasal polyps in patients with 
allergy.(Caplin et al., 1971b, Drakelee et al., 1984, Bunnag et al., 1983)  Polyps are found in 
0.5 to 1.5% of patients with positive skin prick tests for common allergens.(Settipane and 
Chafee, 1977, Caplin et al., 1971b)  Moreover, specific treatment by allergen avoidance and/ 
or antihistamines have no effect on polyp size(Haye et al., 1998) and conditions associated 
with a high prevalence of polyposis, such as the Samter triad group, are not based on IgE 
mediated allergy.  The exception is allergic fungal rhinosinusitis.  This condition is found in 
up to 8% of CRS patients requiring surgery(Bent and Kuhn, 1994) and polyposis occurs in 
almost all patients with this condition.  Specific IgE to the fungal allergen can be demonstrated 
in sinus mucin in 71% of this patient group.(Collins et al., 2004)   
 
1.5.2 Samter’s triad:   
Up to 96% of patients with asthma and aspirin (or non steroidal inflammatory drug (NSAID)) 
intolerance develop polyposis(Caplin et al., 1971b) demonstrating a very strong relationship.  
This relationship was described by Samter in 1967 (Samter and Beers, 1967) and represents 
the most aggressive form of the disease, however, not all asthmatics with NSAID sensitivity 
develop nasal polyps.  It is not an IgE mediated allergy, but rather a pharmacological 
intolerance due to dysregulation of prostaglandin and leukotriene metabolism.  Asthmatics 
  
 
 
 
36 
without an intolerance to aspirin have a prevalence of polyposis of up to 13%, which is greater 
than that of non-asthmatics.(Drakelee et al., 1984, Settipane, 1996) 
 
1.5.3 Cystic fibrosis, primary ciliary dyskinesia, Young’s syndrome:   
37% of adults with cystic fibrosis (CF) have nasal polyps visible at nasal endoscopy.(Hadfield 
et al., 2000)  Similarly deficient mucociliary clearance and recurrent bacterial infections result 
in sinonasal polyposis in 40% of patients with primary ciliary dyskinesia (PCD)(Pedersen and 
Mygind, 1982).  PCD is classically manifested in Kartagener’s syndrome, which is inherited in 
an autosomal recessive manner.(Afzelius, 1986)  Young’s syndrome encompasses a 
combination of bronchiectasis, rhinosinusitis +/- nasal polyposis and reduced 
fertility.(Handelsman et al., 1984)  In all three conditions nasal polyps have a lymphocyte/ 
neutrophil infiltrate as opposed to an eosinophilic infiltrate. 
1.5.4 Heredity:   
There seems to be increasing evidence for a genetic role.  In a study of 224 patients with 
sinonasal polyposis 52% had a positive family history.(Rugina et al., 2002)  Greisner et 
al(Greisner and Settipane, 1996)  studied 50 patients with polyposis and found 14% had a 
positive family history with between 1-3 immediate family members having sinonasal 
polyposis.  This compared to a matched control group in which none had a family member 
with polyposis.  As well as shared environmental factors, the known heredity of polyp 
associated conditions, such as asthma and allergy, make it difficult to establish whether the 
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findings are more than this.  
 
1.5.5 Location:  
The majority of sinonasal polyps arise from the osteomeatal complex.  The reason for this is 
unknown but theories put forward include ‘touching mucous membranes’ resulting in the 
release of proinflammatory cytokines,  special air currents including the Bernoulli principle, in 
which there is internal pressure reduction with increased air stream velocity, or it may be 
neurogenic as nerve endings at the osteomeatal complex are thin(Cauna et al., 1972) and more 
susceptible to cytotoxic damage. 
1.5.6 Neurogenic:  
Sensory, autonomic secretory and vasomotor nerves cannot be identified within the stroma of 
polyps.(Cauna et al., 1972)  It is postulated that this denervation induces an abnormal vascular 
permeability leading to polyp formation.(Cauna et al., 1972)    
1.5.7 Histology and inflammation:  
At microscopy there is marked oedema of connective tissue with prominent lymphatic 
dilatation.(Michaels, 1987)  Different types of epithelium have been found, most typically 
respiratory pseudostratified epithelium with ciliary cells and goblet cells, but low cubic or 
cylindric, stratified squamous non-keratinized, and transitional epithelium can also be seen.  
The basement membrane is often thickened and the stroma is markedly oedematous with a 
myxomatous appearance and contains variable numbers of fibroblasts.  An associated 
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inflammatory infiltrate is predominantly composed of eosinophils in 80% of European 
polyps.(Stoop et al., 1993)  There are also increased numbers of mast cells and T lymphocytes 
with their humeral products, the cytokines.(Van Zele et al., 2006)    
1.5.8 Biofilms:   
CRS possesses all the hallmarks of biofilm mediated disease and there is good evidence of 
biofilm formation in CRS,(Harvey and Lund, 2007) however, little is known about its 
potential role in the pathogenesis of sinonasal diseases. 
1.5.9 Superantigens:   
Superantigens, predominantly derived from Staphylococcus aureus, are potent activators of T-
cells, induce the synthesis of IgE in B-cells and have many direct affects on pro-inflammatory 
cells, such as eosinophils.  IgE antibody to S.aureus enterotoxins have been described in polyp 
tissue, linked to both local IgE production and an aggravation of eosinophilic 
inflammation.(Bachert et al., 2003)  
1.5.10 Nitric oxide:  
 Epithelial cells in CRS show a stronger expression for inducible nitric oxide synthase (iNOS) 
than controls, iNOS being upregulated in nasal epithelium.(Wang et al., 2004a)  In a 
prospective randomised trial in patients with CRS who failed medical therapy with nasal 
corticosteroids, the rise in nasal NO seen on both medical and surgical treatments correlated 
with symptom score, saccharin clearance time, endoscopic changes and polyp size suggesting 
that nasal NO provides a non-invasive measure of the response for CRS to therapy.(Ragab et 
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al., 2006) 
1.5.11 Summary:  
In summary, sinonasal polyposis is a multifactorial disease process with local and general 
patient factors determining disease progression.  The precise cause and mechanism of 
polyposis in the majority of patients remains unknown. 
1.6 Treatment options 
Treatment depends upon patient symptomatology, which includes nasal blockage, nasal 
discharge, facial pain or pressure and hypo- or anosmia.   Loss of sense of smell with 
associated taste disturbance caused by polyp obstruction of the upper part of the nasal cavity is 
a common feature in many patients.  Treatment can either be medical and/ or surgical.  
Medical treatment consists of intranasal and/ or systemic corticosteroids.   
 
1.6.1 Intranasal corticosteroids:  
Topical intranasal corticosteroid sprays have a documented positive effect on bilateral 
sinonasal polyposis and on their associated symptoms.(Tos et al., 1998)  Nasal drops are more 
effective than nasal spray in symptom control and are more efficacious in improving the sense 
of smell.(Tos et al., 1998, Aukema et al., 2005) However, this is balanced with the slightly 
increased systemic absorption and potential side effects.   Intranasal corticosteroids have been 
extensively used for 30 years without any serious adverse event.(Mygind and Lund, 2006) 
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1.6.2 Systemic corticosteroids:  
Systemic corticosteroids should be used in patients with severe symptoms as a means of 
creating a medical polypectomy (Lildholdt et al., 1988) to create space for intranasal 
corticosteroid sprays or used when topical nasal sprays are ineffective.  They are also 
increasingly being used in the perioperative period to reduce intraoperative bleeding and 
improve longer term surgical outcomes in patients with CRS with polyposis undergoing 
endoscopic sinus surgery.(Wright and Agrawal, 2007) A short oral course is indeed as 
effective as a simple polypectomy with a snare(Lildholdt et al., 1988) and the therapeutic 
effect outlasts the medication for a variable period.  The beneficial effect on olfaction is also 
most pronounced with oral corticosteroids than nasal drops or topical nasal spray.  
 
1.6.3 Novel medical treatments: 
1.6.3.1 Capsaicin:   
Capsaicin is the active substance in hot chilli peppers. It is a neurotoxin leading to long term 
damage of axons when repeatedly applied to the nasal mucosa.  The neurogenic hypothesis in 
nasal polyp formation has lead to trials in capsaicin treatment for nasal polyposis that have 
shown potential benefit for this novel treatment.(Filiaci et al., 1996, Baudoin et al., 2000) The 
commonest side effect, if the nose is not topically anaesthetised, is a severe burning sensation.  
1.6.3.2 Antileukotrienes:   
Leukotrienes are upregulated in asthma and nasal polyposis especially in association with 
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aspirin sensitivity. Current evidence does not yet support the routine use of leukotriene 
antagonists for sinonasal polyposis.   
 
1.6.3.3 Aspirin desensitization: 
In CRS patients with sinonasal polyposis and aspirin intolerance, systemic aspirin 
desensitisation or topical lysine-aspirin treatment may protect against polyp 
recurrence.(Stevenson et al., 1996, Mardiney and Borish, 2001)  Aspirin desensitisation by 
graded oral doses can be effective, but must only be carried out by a specialist under 
controlled supervised conditions.   
 
1.6.4 Surgery 
Due to the inflammatory nature of mucous membranes in sinonasal polyposis, surgery cannot 
be expected to cure the disease.  In most patients sinonasal surgery is reserved for those who 
do not satisfactorily respond to medical treatment.  The aim is to reduce the amount of 
inflammatory tissue, open up the nasal airway and improve ventilation of the paranasal 
sinuses.  Although a simple intranasal polypectomy was performed repeatedly before, most 
patients should be referred to a rhinologist for endoscopic sinus surgery, preceded by a 
computed tomography (CT) scan.  Endoscopic sinus surgery is well established and there are 
many techniques (Fokkens et al., 2007). However, the risks of minor and major complications 
exist and this has to be balanced with the expected result of operative verses conservative 
treatment.  If surgery is chosen then the extent of surgery is up to the individual surgeon and 
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will also be determined by the extent of sinus disease as well as patient symptoms.  Surgery 
gives the greatest improvement in relieving nasal obstruction and the least improvement in 
sense of smell.  Surgery can range from simple intranasal polypectomy to nasalisation with 
removal of the middle turbinate and large antrostomies in all paranasal sinuses, including a 
median drainage procedure for the frontal sinuses.  There is as yet no convincing evidence that 
more radical surgery is more beneficial. 
 
1.7 Hypothesis and Aims 
Nasal polyposis is a common disease, whose aetiology is currently unknown. If further 
understanding of the driving force of nasal polyposis can be made, this opens the possibility of 
new treatment modalities never considered before for this clinically important disease process.  
Despite the prevailing opinion at the time of starting this research, we concluded that the 
evidence for polyposis being an angiogenesis-dependent pathology was poor. We therefore 
tested the null hypothesis, that the formation of nasal polyps is independent of angiogenesis 
(chapter 6). Subsequently, we attempted to derive evidence for the underlying stimuli with 
particular reference to vasoactive elements such as NO (chapters 7, 8). 
 
 
 
  
 
CHAPTER 2 
GENERAL METHODS 
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2 General Methods 
2.1 Human tissue  
All human tissue was obtained from patients undergoing routine surgery at University 
Hospitals Birmingham NHS Trust (numbers 0692 and 06/Q2702/15), following informed 
consent (appendix II and IV) under either local or general anaesthesia.  To date, no adverse 
effects from any biopsy has been detected or reported.  
2.2 Muscle Samples 
Local ethical committee approval was granted for the work and all patients gave informed 
consent for the biopsy to be taken. 
18 muscle biopsy samples were analysed, from 17 different subjects. 
4 samples demonstrated fibre hypertrophy in male quadriceps muscle and 2 samples 
demonstrated fibre atrophy in male quadriceps muscle.  These were obtained by needle biopsy 
in a Middlesex hospital to determine the cause of each patients muscle weakness.  The 
remaining 12 samples were obtained by open biopsy at either the Queen Elizabeth or Selly 
Oak hospitals in Birmingham.  All were carried out by the same surgeon (Mr Adrian Drake-
Lee) who took biopsies from the same part of each muscle, thus reducing variability.  6 
samples were of the Medial Gastrocnemius muscle from limb ischaemia patients taken during 
a femoral-distal artery bypass.  These were compared to age matched controls of the same 
muscle from varicose veins operation patients.  4 final samples of normal muscle were taken 
from varicose veins patients to compare fibre type distributions in the following normal 
muscles:  Sartorius, Medial Adductor Longus and Medial Gastrocnemius. 
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All 12 open biopsies were obtained under the local anaesthetic Prilocaine.  Potential muscle 
samples were sought on the basis of the types of operations at the various hospitals.  However, 
this was found to be very time consuming due to the serendipitous nature of the operating lists. 
After removal the samples were immediately mounted in an embedding medium (Tissue-tek, 
O.C.T. compound) with fibres orientated vertically, using fine tipped forceps, on a labelled 
cork disk.  A fine pin was also pushed into the cork to help support the vertical  fibres and to 
enable more even freezing, the pin acting as a thermal conduction shaft through the tissue.  
The mounted muscle block was then snap frozen in isopentane cooled in liquid nitrogen.  Thus 
a flask of liquid nitrogen and other apparatus were taken into theatre for every sample taken, 
reducing the loss of labile enzymes that occurs if the tissue is not frozen soon after removal 
(Loughlin, 1993).  The samples were transported from the hospital to be stored at   -70 0 C 
until analysis.  Serial transverse sections, 12um thick, were cut from the muscle blocks at -20 
oC using a Bright 5020 cryostat machine and mounted on slides for staining. 
 
2.3 Muscle fibre types  
The fibre types were identified by using differential sensitivity of the myofibrillar ATPase to 
inactivation after preincubation in acidic and alkali solutions.  The enzyme ATPase is 
responsible for catalysing the breakdown of ATP to ADP and inorganic phosphate.  Fast 
myosins, as in type II fibres, are inactivated at acid pH whereas slow myosins, as in type I 
fibres, are inactivated at alkaline pH.  Having preincubated the section and inactivated one set 
of fibres the myosin ATPase activity can be visualised in the other set.   The histochemical 
reaction depends upon a complex series of reactions for the production of its end product (see 
Loughlin, 1993). 
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Serial sections were also stained for fibres using succinate dehydrogenase (SDH), a 
mitochondrial enzyme, thereby ensuring unambiguous identification of fibres. 
 
2.4 Myosin ATPase Stain - Method (adapted from Brooke and Kaiser, 1970) 
1. fgb Air dry unfixed sections for 30 minutes. 
2. Pre-incubate sections at pH 4.35, 4.60 and 10.2 at room temperature for 8 minutes. 
3. Rinse in distilled water once. 
4. Rinse in glycine/ calcium buffer once. 
5. Incubate sections at pH 9.6 for 25 minutes at room temperature. 
6. Rinse in distilled water 3 times. 
7. Rinse in 3 changes of 2% CaCl2 . 
8. incubate in 1% CoCl2 for 3 minutes.   
9. Rinse in distilled water 5 times. 
10. Incubate in 1% Ammonium sulphide for 2 minutes. 
11. Rinse in distilled water. 
12. Mount in Aquamount. 
 
Solutions - for coplin jar (30ml, 6 - 8 slides) 
2% CaCl2  solution. 
1% CoCl2  solution. 
1% Ammonium sulphide solution (in fume cupboard). 
Glycine/ CaCl2  solution. 
3.0g glycine plus 2.94g Cl2 / l      200ml 
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Acid Pre-incubation solutions 
Sodium acetate, 3.282g/ 200ml     60ml 
Adjust to pH 4.35 and 4.60 with Acetic acid (1:1 dil. with water). 
 
Alkali 
Boric acid, 3.09g/ l       30ml 
Adjust to pH 10.2 with 1molar KOH 
Incubation solution  
Take 50ml Glycine/ Ca Cl2  solution and adjust pH to 9.60 with 0.1M KOH  
ATP (disodium salt).  To be measured out just before staining. 45mg 
Add this to 50ml of the glycine/ Cl2 solution and readjust the pH to 9.6 
2.5 Lectin staining 
Working Solution -For 1ml (covering 10 slides)  
10ul stock +990ul P.B.S.  (stock solution =2mg UEA-1 / ml) 
Vectastain ABC Kit  
Refer to kit’s instructions 
DAB substrate Kit 
Refer to kit’s instructions. 
Lectins are plant proteins that bind to specific sugar residues.  The lectin used here binds to 
galactose residues, which are found at a high concentration on the proteoglycans in the 
glycocalyx which lines blood vessels.  The sarcolemma of muscle fibres is also faintly stained, 
allowing quantification of fibres. 
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2.5.1.1 Method 
Air dry sections (30 min). 
Fix sections in pre-cooled acetone (4°C or less) for 5 sec. 
Apply rhodamine-conjugated Griffonia simplicifolia lectin – 1 (Vector Labs) or other lectin eg  
Ulex europaeus agglutin 1 (UEA-1) at a concentration of 20µg/ml (1:100 - 5µl lectin in 500µl 
PBS) for 30 min at RT.  Keep sections out of direct light. 
Rinse in PBS: 3 x 5 min washes. 
Rinse in distilled water (dH2O). 
2.6 Counting capillaries 
Place two to four sampling squares randomly on the slide and count the number of capillaries, 
fibres and larger vessels inside these squares.  The top and left sides of the square are 
designated ‘inclusion lines’ with the bottom and right sides designated ‘exclusion lines’.  Any 
capillary or fibre touching the exclusion lines is not counted, and capillaries or fibres 
exclusively touching the inclusion lines are counted along with those contained within the 
square (Gunderson, 1977, Egginton and Turek, 1990). 
Fibre boundaries can be visualised by the lectin slightly staining the sarcolemma of muscle 
fibres, which may be digitally enhanced on the computer to allow easy visualisation of fibres.  
Capillaries are defined as being stained objects of 12µm in diameter or less. 
A graticule is used to measure the sample area, and capillary density (CD, mm-2) and fibre size 
(a(f), µm2) can be calculated from this.  The capillary to fibre ratio (C:F) can then also be 
calculated. 
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2.7 Immunohistochemical Staining 
Samples taken for confocal analysis were immediately fixed in 4% buffered formalin and left 
for 24 hours. Samples were then washed in 3 changes of phosphate buffered saline (PBS) for a 
further 24 hours before being stained whole with dilutions of either fluorescein-conjugated 
Ulex europeaus lectin (Vector Labs), or a fluorescein-conjugated lectin mixture (1:1:1 Ulex 
europeaus, Griffonia simplicifolia, Euonymus europeaus, Vector Labs) to account for different 
affinities associated with blood groups (Capaldi et al., 1985).  Samples were then washed and 
stored in PBS until being viewed under a confocal  Leica DM IRE2 microscope.  A total of 60 
samples were stained with the single lectin protocol, and 50 different samples stained with the 
triple lectin protocol. 
 
Samples taken for immunostaining were snap frozen in liquid nitrogen-cooled isopentane 
immediately in theatre, and 8 µm sections were subsequently cut on a cryostat.  These were 
allowed to air dry before being fixed in 4% buffered formalin (for 1, 5, 10, 20 or 60 minutes) 
or ice-cold acetone (for 10, 30, 60 or 300 seconds).  Antigen retrieval was performed in citrate 
buffer (10 mM citric acid adjusted to pH 6.0 with NaOH, 0.05% Tween 20) heated to 95°C for 
5 min then allowed to cool to room temperature.  Slides were then blocked for 30 min at room 
temperature in wash buffer (either 5% foetal bovine serum (FBS) or 1.5% w/v BSA, 0.6% v/v 
Triton X-100 in PBS, or 5% FBS in PBS), then incubated for 2 hours with primary antibodies 
(Ki-67, Dako/PCNA, Santa Cruz) diluted in wash buffer to label proliferating nuclei.  Sections 
were then washed in PBS and incubated for 1 hour with secondary antibody (TRITC 
polyclonal rabbit anti-mouse, Dako) diluted in wash buffer.  Sections were rinsed in PBS and 
then incubated for 30 min with lectin to stain blood vessels.  Sections were washed in PBS, 
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rinsed with dH20 and mounted using Vectashield containing DAPI (4',6-diamidino-2-
phenylindole) to label all nuclei, and enable calculation of a proliferation index (Ki-67 count / 
DAPI count).  All counts were made on either the same section, or on a serial section from the 
same sample. 
 
2.8 PCNA/Capillary Dual Staining 
PCNA (proliferating cell nuclear antigen), also called cyclin, is a DNA polymerase co-factor 
expressed by cells undergoing mitosis, and so can act as a measure of cell proliferation.  Co-
localisation of PCNA with capillaries can give a measure of cell proliferation associated with 
the capillaries, and that associated with interstitial cells.  This can be performed using 
fluorescent filters that exite and observe at different wavelengths, allowing two different 
fluorophores to be observed separately on the same section. 
Solutions 
 
4% buffered formalin  
100ml 37% formaldehyde 
900ml distilled water (dH2O) 
 
Washing buffer 
1.5%  bovine serum albumin, 0.6% Triton X-100 
  500µl  6% Triton X-100 stock 
  666µl  7.5% BSA stock 
  3.83ml PBS 
  
 
 
 
51 
2.8.1.1 Method 
Air dry cryostat sections (30 min). 
Fix in 4% buffered formalin for 5 min. 
Wash in PBS for 5 min. 
Block with washing buffer at RT for 30 min. 
Incubate with primary antibody (rabbit anti-PCNA antibody, Santa Cruz) 1:100 for 1hr at RT 
(5µl antibody in 500µl washing buffer). 
Rinse in PBS: 3 x 7 min washes. 
Incubate with secondary antibody (CY2 conjugated donkey anti-rabbit, Jackson) 1:50, and 
1:100 rhodamine conjugated Ulex europeaus lectin (vector) for 1 hour at RT (10µl antibody, 
5µl lectin in 500µl washing buffer).  Keep sections covered and out of direct light. 
Rinse in PBS: 3 x 7 min washes. 
Rinse in distilled water. 
Mount with glycerol if required. 
 
 
2.9 Triple stain – Ki67/ Lectin/ DAPI 
Solutions: 
Citrate buffer 
 
2.94g  Tri-sodium citrate (dihydrate) 
Dissolve in 1L dH20, adjust to pH 6.0 with HCl, then add 0.5ml Tween 20 
or 
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1.92g  Citric acid (anhydrous) 
Dissolve in 1L dH20, adjust to pH 6.0 with NaOH, then add 0.5ml Tween 20 
Wash buffer 
 
 500µl  Normal rabbit serum 
 500µl  of 6% v/v Triton X-100 stock  
 4ml  PBS 
2.9.1.1 Method 
Air dry slides for 30 min at RT. 
Use wax pen now if slides are poly-lysine coated, otherwise wait until after heat treatment.  
Use at least two concentric elipses round the sections. 
Fix slides in 4% formalin solution (1 in 10 dilution of 37% formalin in PBS) for 20 min 
Wash 3 x 2 min in PBS. 
Heat citrate buffer to 90-95°C on heater (about 10 min at heat 10, then drop to 6.5) in a glass 
beaker (NOT slide jar, they break!), then add slides for 20 min (drop heat to about 3).  After 
20 min, remove beaker from heat and allow to stand for about 30-40 min until cooled to under 
35°C. 
Alternatively, put slides in plastic coplin jar, add buffer and microwave for 5 min at power 20, 
followed by 2 min at power 10. 
 
Remove slides from citrate buffer, rinse in PBS (add PBS to coplin jar, remove immediately), 
then wash for 5 min. 
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If using non-poly-lysine coated slides, wipe slides clean round the edges and reverse side, tilt 
slides and blot the bottom of the drop with a torn edge of a tissue (facilitating capillary action 
up the tissue) to allow slides to dry (wait about 30 min). Once sections are dry, apply wax pen 
or crayon round the sections. 
Block for 30 min by applying wash buffer.  Tip excess solution away, then blot the slides as 
previously described to minimise the amount of buffer on the slide. 
Incubate with primary antibody (Clone Ki67, Dako), diluted 1:100 in wash buffer (5µL 
antibody in 500µL wash buffer) for 2 hours at RT, (overnight in the fridge should work just as 
well, if not better). 
Wash 3 x 5 min in PBS, then wipe and blot slides. 
Incubate with secondary antibody (Polyclonal rabbit anti-mouse TRITC, Dako), diluted 1:100 
in wash buffer for 1 hr at RT. 
Rinse 3 times in PBS, then wipe and blot slides. 
Add lectin (normally Ulex europeaus lectin-1, fluorescein) diluted 1:250 in PBS (2µL lectin in 
500µL PBS). 
Wash 3 x 5 min in PBS. 
Rinse in dH20 and allow slides to dry (wiping and blotting the sections as previously 
described). 
Once slides are dry, coverslip with diluted DAPI solution (in fridge, made from 1ml 
Vectashield with DAPI with 2ml Vectashield). 
 
Slides are now ready for viewing.  If saving for future analysis, cover from light and leave in 
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the fridge (overnight, or one or two days), or seal with clear nail varnish, then cover and 
refrigerate (3-10 days). 
 
2.10 Succinate Dehydrogenase Staining 
Succinate dehydrogenase is a mitochondrial enzyme that catalyses the conversion of succinate 
to fumarate, reducing NAD+ to NADH in the process.  When used for staining, sodium 
metaborate is used as the electron acceptor, and the reduced form acts on nitro-blue 
tetrazolium to form a blue precipitate in areas with a high oxidative capacity.  In skeletal 
muscle, this can therefore be used to differentiate between muscle fibre types 
Solutions 
Stock buffer 
 
  0.29g  potassium dihydrogen orthophosphate (KH2PO4) 
  2.19g  di-sodium hydrogen orthophosphate (Na2HPO4) 
  4.50g sodium succinate 
  Up to 1L dH2O 
  Store at 4°C 
Sodium metaborate solution 
 
  6.89g  sodium metaborate (NaBO2) 
  Up to 1L dH2O 
Buffered sucrose formol 
 
  30g  sucrose 
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  50ml  37% formaldehyde 
  5g calcium nitrate [Ca(NO3)2] 
  Adjust to pH 7.2 with sodium metaborate solution 
  Store at 4°C 
Working buffer 
 
  50ml stock buffer solution 
  25mg NBT (nitro blue tetrazolium) 
  Store at 4°C.  Mix well and bring to RT before use 
2.10.1.1 Method 
Air dry fresh cryostat sections at RT for 30 min 
Incubate slides in working buffer for 30 min at about 37°C 
Rinse in distilled water 
Post-fix in sucrose-formol for 2 min 
Rinse in 3 changes of distilled water 
Mount with aquamount and cover slip 
2.11 Power calculations 
 
Based on the control values,  
Expect a 50% change from control, no change seen 
30% (conservative) change in Vv requires n=1 
15% change in Vv  requires a sample size of 3 for 80% power (sigma = 0.05) 
Expect a 50% change from control, no change seen 
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30% change in Sv requires n=1 for 80% power 
15% change requires n=3 
Expect a 30% change from control, no change seen 
30% change in cap density requires n=2 
15% change requires n=6 
As we mentioned, capillary density is dependent on interstitial volume 
Expect a 2-400% change from control, compared to 850% change seen in the interstitium of 
polpys 
100% increase in proliferation requires n=2 
50% increase in proliferation requires n=7 
All these calculations assume a normal distribution from the mean, which may not necessarily 
be the case with increases in Vv, Sv, or capillary density (these often increase in a single-tailed 
manner as is common in closed biological systems), but these errors should be minute 
compared to the error in estimating calculations. 
 
2.12 Sensiscript Reverse Transcription 
Solutions 
 
Master mix: 
  2.0µL  10x Buffer RT (Qiagen) 
  2.0µL  dNTP mix (Qiagen) 
  1.0µL  Primer (oligo dT 50µM or random hexamers)  
  1.0µL  RNase inhibitor (10 units/µl)  
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  1.0µL   Sensiscript reverse transcriptase (Qiagen) 
  ddH2O up to 20 µL with RNA template 
2.12.1.1 Methods 
Thaw solutions on ice. 
Prepare a fresh master mix on ice.  Mix by briefly vortexing solution, then centrifuge briefly to 
collect residual liquid. 
Distribute master mix into reaction tubes on ice. 
Add template RNA to the master mix.  Mix thoroughly. 
Incubate for 60 min at 37°C 
 
2.13 Gene expression in nasal polyps  
2.13.1 High Capacity cDNA extraction 
Solutions 
 
2x Master mix: 
  2.0µL  10x RT Buffer (Applied Biosystems) 
  0.8µL  25x dNTP mix (100mM, Applied Biosystems) 
  2.0µL  10x RT random hexamers or oligo dT  
  1.0µL  Multiscribe reverse transcriptase (Applied Biosystems) 
  1.0µL  RNase inhibitor (10 units/µl) (Qiagen) 
  3.2µL  nuclease free H2O (Sigma) 
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2.13.1.1 Method 
Thaw solutions on ice 
Prepare a fresh master mix on ice.  Mix by briefly vortexing solution, then centrifuge briefly to 
collect residual liquid. 
Distribute master mix into reaction tubes on ice. 
Add template RNA to the master mix.  Mix thoroughly. 
Incubate for 60 min at 37°C. 
2.14 Northern Blot 
Everything must be Thoroughly cleaned of RNAses, and gloves must be worn at all times. 
Use RNAse-ZAP or some other commercially available RNAse cleaner to clean the work area 
and all equipment that may come into contact, directly or indirectly, with the RNA.  
Clean everything with 95 % ethanol.  This will also help any residual RNAse-ZAP evaporate. 
 
Solutions 
10x TBE Buffer pH8.3 
  54g  Tris base 
  27.5g  Boric acid 
  4.65g  Sodium EDTA (NaEDTA.2H20) 
  ddH20   up to 500ml 
 
6x Loading buffer 
 
  10µM  Tris/HCl (pH7.5) 
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  50µM  EDTA 
  10%  Tricoll 400 
  0.25%  Xylene cyanol 
  0.25%  Bromophenol Blue 
  150µg/ml Ethidium Bromide 
2.14.1.1 Method 
Assemble the tray, combs and clamp according to the manufacturers’ instructions. 
Dissolve 1.5g of agarose in 100ml TBE buffer (for 300-500bp, 1g for longer, 2g for smaller), 
and pour gel into the tray to a depth of 5mm.  Remove any bubbles with a Pasteur pipette.   
Allow the gel to set for 1hr before placing the gel in the gel holder and removing the gel 
combs.  Cover with 2mm of TBE buffer. 
Prepare the samples with 2µl of loading buffer with 10µl of sample, and load the samples 
carefully into the wells, with a 100bp DNA ladder (100bp molecular ruler, BioRad).   
Attach the cover and run the gel at 75V until the dye front nearly reaches the bottom of the 
gel. 
Remove the gel into a tray filled with ddH20, and photograph gel with excitation at 254nm 
(Gel Logic, Kodak) and Photofinish software. 
2.15 Western Blotting Protocol 
Solutions 
 
0.5M TrisCl/SDS (pH 6.8):    
Dissolve 6.05g Trizma base (Sigma) in 40ml ddH20.  Adjust pH to 6.8 with 1M HCl, then add 
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ddH20 to 1000ml.  Filter through a 0.45µm filter, then add 0.4g SDS.  Store at 4˚C. 
 
1.5M TrisCl/SDS (pH 8.8):  
Dissolve 18.17g Trizma base (Sigma) in 40 ml ddH20.  Adjust pH to 8.8 with 1M HCl, then 
add ddH20 to 1000ml. Filter through a 0.45µm filter, then add 0.4g SDS.  Store at 4˚C. 
4x SDS sample buffer 
 
  0.5ml  0.5M TrisCl/SDS pH 6.8 
  0.4ml  100% glycerol 
  0.8ml 10%(w/v) SDS (in ddH20) 
  0.2ml bromophenol blue 
  1.9ml ddH20 
  0.2ml β-mercaptoethanol 
 
10x SDS electrophoresis buffer 
 
  30g tris base 
  144g glycine 
  10g SDS 
  ddH20 up to 1000ml 
Resolving Gel 
7.5%  /  10%  /  12% acrylamide 
 6.25ml/ 8.25ml/12.5ml 30% acrylamide/bis (Biorad) 
 12.1ml/ 10.1ml/ 6.0ml ddH20 
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 6.25ml   1.5M TrisCl/SDS pH 8.8 
 0.25ml   10% SDS 
 12.5µl   TEMED (N,N,N',N'-Tetramethyl-1-,2 diaminomethane) 
 125µl   APS (Ammonium persulphate) 
 
Stacking Gel 
  0.55ml 30% acrylamide/bis 
  1.04ml 0.5M TrisCL/SDS pH 6.8 
  50µl 10% SDS 
  2.5ml ddH20 
  4µl TEMED 
  21µl APS 
Blotting Transfer Buffer (pH 8.3) 
  3.03g Tris base (25mM) 
  14.4g Glycine (192mM) 
  150ml Methanol (15%) 
  ddH20 to 1000ml 
 Do not adjust the pH.  If pH is incorrect, prepare a new solution.  Store at 4˚C. 
 
Tris-buffered saline Tween (TTBS) pH 7.6 
  2.42g Tris base   (20mM) 
  8g Sodium Chloride (137mM) 
 Dissolve in 40ml ddH20.  Adjust pH to 6.8 with 1M HCl, then add ddH20 to 1000ml.  
Add 1ml Tween-20 (Sigma).   Store at 4˚C. 
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Stripping buffer 
  3.8ml β-mercaptoethanol     (100mM) 
  Tris base adjusted to pH 6.7 with 1M HCl  (62.5mM) 
  10g SDS      (2%) 
  ddH20 to 500ml 
2.15.1.1 Method 
Gel Preparation 
 
Assemble glass plates according to the manufacturers instructions (MiniProtean3, Biorad). 
Place the comb in the plates, and mark a level approximately 1cm below the bottom of the 
comb.  Fill to this mark with the resolving gel solution.  When preparing the gels, mix all the 
reagents except for the APS and TEMED, then allow the solution to de-gas for a few minutes 
before adding the final reagents and gently swirling to mix. 
Immediately overlay the solution with about 200µl of a 1:1 mixture of butanol/ddH20 to avoid 
evaporation and obtain a good border between the two gels. 
Leave the gel to polymerise for about 1hr. 
 
Drain the water/butanol mixture from the plates, and pour the stacking gel solution on top of 
the solid resolving gel.  Insert the comb, taking care to avoid air bubbles, and ensure that the 
gel level reaches the top of the comb teeth. 
Leave the gel to polymerise for about 45 min before carefully removing the gel and 
assembling in the electrophoresis cell as per the manufacturer’s instructions.  Fill the cell with 
1x SDS electrophoresis buffer, and fill the outside of the cell to a level where both the 
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electrodes are completely submerged. 
 
Sample preparation 
 
Dilute 50µg of sample (in a volume of 12µl) 4:1 with sample buffer and heat at 95˚C for 5 
min, then immediately place on ice for 5 min and briefly spin down. 
Load the samples into the wells created by the comb, then run the gel at a constant current of 
40mA for about 1hr, taking care to check the progress of the electrophoresis. 
 
Protein blotting 
 
Dismantle the gels from the gel holder and cut away the resolving gel with a clean scalpel 
blade and soaking the resolving gel in transfer buffer for 5 min. 
Cut a piece of Hybond-ECL polyvinyl diflouride (PVDF, Amersham) membrane to the size of 
the gel, wet fully with methanol, and soak for a few minutes in the transfer buffer. 
Place the gel on top of a piece of filter paper soaked in the transfer buffer, place the gel on the 
membrane and cover with another soaked filter paper.  Remove air bubbles by rolling a glass 
pipette over the paper.  Sandwich the filter papers between two fibre pads saturated in the 
transfer buffer, and place these in the blotting cassettes, loading the cassette so that the 
membrane is on the red (positive/anode) side of the blotting holder relative to the gel. 
Fill the apparatus with 1x blotting transfer buffer (pre-cooled in the fridge), and the proteins 
transferred to the membrane at 30V overnight or 80V for 3 hours, keeping the apparatus at 4˚C 
or less by immersing in ice-water. 
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Once the transfer is complete, remove the membrane from the cassette and rinse in TTBS. 
Stain with Ponceau S as per the manufacturer’s method. 
 
2.16 Protein Measurement 
Construct a set of dilutions using 1.37mg ml-1 bovine serum albumin (Biorad), using a 25µl 
sample volume with 0, 5, 10, 15, 20 and 25µl of the standard diluted in ddH20. 
Dilute the samples to roughly 1 mg ml-1 based on the amount of sample placed in the volume 
of extraction buffer, and ignoring the loss of material in the pellet.  Assay 25µl of these diluted 
samples. 
Using a detergent compatible protein assay kit (Biorad, based on the Lowry assay (Lowry et 
al. 1951)), add 1ml of reagent B (Folin phenol reagent) to each sample, followed by 125µl 
reagent A (alkaline copper tartrate), to which 10µl of reagent S (a surfactant) had been added 
per 1ml reagent A. 
Transfer the samples to cuvettes and leave to incubate for 15 min before assaying the 
absorbance at 650nm.  Take two absorbance readings for each sample, running through the 
samples in order, then in reverse order. 
 
2.16.1 Detergent Protein Extraction 
Solutions 
 
Detergent solution:  
    50µl 20% NP-40 stock (Sigma) 
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    50µl 10% sodium deoxycholate (NaDOC, Sigma) stock 
    5µl 20% sodium dodecyl sulphate (SDS, Sigma) stock 
 
2.16.1.1 Method 
Cool mortar and pestle in dry ice with Eppendorf tubes. 
Cool PBS and proteinase inhibitor cocktail (PIC, Sigma) on ice. 
Crush 25mg muscle in the mortar, transfer to an Eppendorf and homogenise in 137.5µl 1:1 
PIC in PBS using a hand homogeniser. 
Add 15.75µl detergent solution to give final concentrations of 1% NP-40, 0.5% NaDOC, 0.1% 
SDS. 
Re-homogenise, then leave on ice for 20 min. 
Centrifuge at 12,000g at 4˚C for 20 min to pellet. 
Remove supernatant, assay for protein levels, freeze in liquid nitrogen and store at -80˚C. 
 
2.16.2 Cryosectioning 
Take excised biopsies and place on a cork disc. Coat the muscle with OCT Tissue Tek 
compound (Leica Instruments) for structural support and cryoprotection.    
Orientate the muscle perpendicular to the cork by leaning the muscle against a pin, then 
carefully drop the disc into liquid nitrogen-cooled isopentane.  The isopentane should be at its 
freezing point, which can be ascertained through an increase in the viscosity and clouding 
whilst stirring. 
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Place discs in the liquid nitrogen for short-term storage before sectioning.  Long-term storage 
is at -80˚C. 
Cut 10µm sections on a cryostat at -20 ± 3˚C, depending on the rigidity of the sections 
obtained, which varies from patient to patient.  Pick up slides on poly-L-lysine coated slides 
for better adhesion on subsequent immunohistochemistry.  Allow sections to air-dry for 30-
60min before staining or re-freezing and storage at -20˚C. 
2.16.3 Endpoint cDNA method: 
End-point primer amplification 
Solutions 
Reaction mix: 
  12.5µL Taqman Universal PCR Master Mix (Applied Biosystems) 
  2.5µL TGF-β forward primer (Binding Site) 
  2.5µL TGF-β backwards primer (Binding Site) 
  1µL cDNA sample 
  6.5µL ddH2O 
Methods 
Thaw solutions on ice 
Make up the reaction mix, then transfer to thermal cycler. 
Run thermal cycler using the following program: 
 
Step 1:  95°C 10 min  AmpliTaq Gold Amplification (Applied Biosystems)  
Step 2:  95°C 15 sec  Denature 
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Step 3:  60°C 1 min  Extend 
Step 4:  Repeat steps 2 and 3 for 40 cycles 
 
2.16.4 TRIZOL method 
2.16.4.1 Equipment treatment 
 
To reduce the effect of environmental RNAases on the samples, all plasticware that came into 
contact with the samples or solutions use either RNAase free disposable plasticware, or soak 
in 0.5 M NaOH for 1 hour, then rinse with reverse-osmosis filtered water and autoclave.  Bake 
glass homogenisers at 150°C for 4 hours.  Clean disposable gloves and forceps with RNAZap 
(Ambion). 
2.16.4.2 Sample treatment 
Pre-cool glass homogenisers and TRIZOL reagent (Life Sciences) on ice.  Pre-weigh tissue 
samples and homogenise in 1ml of ice-cold TRIZOL, transfer to a labelled eppendorf tube, 
then incubate for 10 min at RT.  Add 0.2ml of chloroform to each tube, then shake the tubes 
vigorously by hand for 15 sec, and incubate at RT for 3 min.  Centrifuge tubes at 12,000g for 
15 min at 4°C.  This gives a colourless aqueous phase containing RNA, an interphase and a 
lower red, phenol-chloroform phase. 
2.16.4.3 RNA extraction 
Remove the aqueous phase carefully and transfer to a fresh labelled eppendorf, keeping 
phenolic phase at -20°C for subsequent DNA and protein extraction.  Precipitate RNA by 
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addition of 0.5ml isopropyl alcohol and incubate for 10 min at RT.  Centrifuge samples at 
12,000g for 10 min at 4°C to pellet the RNA.  Discard the supernatent, and wash the pellet 
with 1 ml of 75% ethanol in RNAase free water.  Vortex the pellet off the bottom of the 
eppendorf, then centrifuge at 7,500g for 5 min at 4°C.  Store sample at -80°C until used.  
Before use, discard the supernatent, and allow the RNA pellet to air-dry for 15 min before 
resuspending in 25µl of RNAase free water. 
2.16.4.4 DNA extraction 
Remove the remaining traces of aqueous phase from the phenolic phase and discarde, then add 
0.3ml of 100% ethanol to precipitate the DNA.  Invert samples several times to mix, and 
incubate for 3 min at RT.  Sediment DNA by centrifugation at 2,000g for 5 min at 4°C.  Split 
the phenolic supernatent equally into three labelled eppendorfs for protein extraction. 
2.16.4.5 Protein extraction 
Add 1 ml of acetone to each eppendorf containing approximately 250 ml phenolic supernatant.  
Incubate samples for 10 min at RT, then sediment protein by centrifuging at 12,000g fot 10 
min at 4°C.  Remove the supernatant and wash each protein pellet three times in 800 ml of 
0.3M guanidine hydrochloride in 95% ethanol.  During each wash, store the protein pellet in 
the wash solution for 20 min at RT and centrifuge at 7,500g for 5 min at 4°C.  After the final 
wash, vortex the protein pellets in 700ml ethanol.  Store in ethanol at -20°C until use.  To use, 
centrifuge pellet at 7,500g for 5 min at 4°C, remove supernatent and air dry the pellet for 15-
20 min.  Dissolve in 9.5M Urea/2% CHAPS and measure concentration. 
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2.16.4.6 Gene array 
Gene arrays consist of DNA fragments spotted onto a substrate.  When a cDNA sample is 
added to the array, complimentary sample strands will specifically bind to the immobilised 
ligand.  Non-binding strands will be washed away, and non-specific fragments on the array 
will remain unbound.  If the cDNA sample is labelled with a reporter, such as Cy3 in this case, 
the presence of the reporter will give the position and intensity of bound cDNA fragments.  As 
the efficiency of binding will vary between sequences (both due to A-T/C-G binding 
differences and shape), and differences in spotting efficiency between arrays, a reference 
sample containing cDNA for every DNA sequence on the array is added.  This reference uses 
a Cy5 reporter dye, and allows differences to be controlled for by measuring the Cy3 signal 
against the Cy5 signal.  The reference sample was constructed from RNA extracted from the 
buffy coat of healthy donors (non-red cell fraction in centrifuged blood), Epstein-Barr virus 
transformed B lymphocytes, human fibroblasts, and peripheral blood mononuclear cells.  This 
combination of cell types gave >95% positive signals on the array used, which was a 
customised array (Corning) with 850 genes made from 70-mer oligonucleotides (Qiagen). 
 
Protocol for Microarrays (No Amplification). 
 
1. Sample Collection. 
 
2. Ambion RNA Extraction. 
 
3. Dnase I Treatment. 
  
 
 
 
70 
 
4. RT-PCR. 
 
5.  Dye Labelling. 
 
6.  Probe Quantitation.   
 
7.   Probe Hybridisation. 
 
8.   Post-Hybridisation Washes. 
 
9.   Scanning. 
 
 
Step 1 – Sample Collection. 
 
• Sample cells taken. 
• Cells spun down 1200 rpm 8 mins. 
• Pellet resuspended in 200µl lysis buffer. 
• Sample frozen at –700C and transported in dry ice. 
 
(Samples can be stored at –700C for 3 months ) 
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Step 2 - Ambion RNA Extraction. 
 
• Sample defrosted at room temperature. 
• 200µl 64% ethanol added and mixed in by pipetting. 
• Mix applied to filter cartridge. 
• Spun for 1 min at 13000 rpm. 
• Filter washed with 700µl wash solution 1. 
• Spun for 1 min at 13000 rpm. 
• Filter washed with 500µl wash solution 2/3. 
• Spun for 15 secs at 13000 rpm. 
• Filter washed with 500µl wash solution 2/3. 
• Spun for 2 mins at 13000 rpm. 
• Filter cartridges transferred to clean microfuge tubes. 
• 35µl elution solution added to each filter cartridge. 
• Filters incubated at 700C (on heat-block) for 5 mins. 
• Spun for 1 min at 13000 rpm. 
• RNA used in Dnase I treatment. 
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Step 3 – Dnase I Treatment. 
 
• 3.5µl 10x Dnase I buffer added to RNA samples. 
• 1µl Dnase I added. 
• Samples kept at 370C for 30 mins. 
• 5µl Dnase inactivation reagent added to each RNA sample. 
• Samples kept at room temperature for 2 mins. 
• Spun for 1 min at 13000 rpm. 
 
The RNA is then quantitated by use of a spectrophotometer. 
 
 
Step 4 – RT-PCR. 
 
At this point it is important that the same quantity of RNA from each sample is used in the 
labelling reaction. It is hence best to measure the sample with the lowest concentration of 
RNA, and then use a quantity of RNA from every other sample to match this. The lowest 
RNA concentration will probably be attained from the –ve control samples, as there should 
only be “housekeeping” quantities of RNA produced in these. 
 
• Make following reaction mix: 
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5µg RNA 
1µl oligo(dT)12-18 primer (1µg/µl) 
Up to 17ul H2O 
 
• Heat to 650C for 10mins. 
• Cool on ice. 
• Add the following to each tube - 
 
8µl 5x first-strand buffer 
4µl 0.1M DTT 
2µl dATP (10mM)  
2µl dCTP (10mM) 
2µl dGTP (10mM) 
2µl dTTP (10mM) 
2µl Superscript II (200U/µl) 
1µl H2O 
 
• Keep at 420C for 2 hours. 
 
• Add 200µl PB buffer to sample. 
• Add sample to Qiagen PCR purification column. 
• Spin for 1 mins. 
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• Wash filter twice through with 700µl PE buffer. 
• Spin for 1 min extra. 
• Place filter into clean tube. 
• Add 50µl H2O to column. 
• Spin for 1 min. 
 
 
Step 5 – Dye Labelling. 
 
• Make following reaction mix: 
 
500ng cDNA 
20µl Random primer mix 
Up to 43ul H2O 
 
• Heat to 940C for 5mins. 
• Cool on ice. 
• Add the following to each tube - 
 
1.2µl dATP (10mM) 
1.2µl dTTP (10mM) 
1.2µl dGTP (10mM) 
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0.72µl dCTP (10mM) 
1µl Klenow Enzyme (40U/µl) 
0.68µl H2O 
1µl Cy3 or Cy5 
 
• Keep at 370C for 2 hours. 
 
• Add 250µl buffer PB to sample. 
• Add probe to Qiagen PCR purification column. 
• Spin for 1 mins. 
• Wash filter twice through with 700µl buffer PE. 
• Spin column for extra minute. 
• Place filter into clean tube. 
• Add 50µl H2O to column. 
• Spin for 1 min. 
 
 
Step 6 – Probe Quantitation. 
 
• Measure probe concentration by taking measurements at 550nm and 650nm. 
 
Cy3 (550nm) = (Absorbance Measurement x Dilution Factor)/ 0.15 
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Cy5 (650nm) = (Absorbance Measurement x Dilution Factor)/ 0.25 
 
• Use 40 pmole of each dye. 
 
• Add required volume of each probe to microcon column. 
• Spin for 10 mins. 
• Invert column into fresh tube. 
• Add 30µl H2O. 
• Spin for 1 min. 
 
 
Step 7 – Probe Hybridisation. 
 
• Pre-hybridise slides in pre-hybridisation solution for 2 hours at 420C. 
 
Pre-hybridisation solution. 
12.5ml formamide 
12.5ml 20 x SSC 
0.25ml 20% SDS 
50µl 100mg/µl Fraction V BSA 
Up to 50ml H2O 
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• Mix 80µl of hybridisation solution for each slide. 
 
Hybridisation Solution. 
20µl formamide 
20µl 20 x SSC 
0.4µl 20% SDS 
2.5µl 2mg/ml PolyA DNA 
4µl 2mg/ml Cot1 DNA 
30µl Cy3 and Cy5 labelled probe 
Up to 80µl H2O 
 
• Denature hybridisation solution at 950C for 5 mins, then keep on ice. 
• Add hybridisation solution to each slide and apply cover-slips. 
• Place slides in hybridisation chambers. 
• Add 10µl H2O to each hybridisation chamber and moisten seal. 
• Seal hybridisation chambers and wrap in dampened paper towels. 
• Wrap slide chambers in tinfoil, and keep at 420C overnight. 
 
 
Step 8 – Post-Hybridisation Washes. 
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• Remove slides from hybridisation chambers. 
• Dip slides in 2 x SSC, 0.1% SDS until cover-slip falls off. 
• Wash slides in 2 x SSC, 0.1% SDS at 420C for 2 mins. 
• Wash slides in 0.2 x SSC for 2 mins at room temperature. 
• Wash slides in 0.05 x SSC for 2 mins at room temperature. 
• Wash slides in 0.05 x SSC for 2 mins at room temperature.  
• Wash slides in 0.05 x SSC for 2 mins at room temperature. 
• Wash slides in 0.05 x SSC for 2 mins at room temperature. 
• Dip slides in H2O. 
• Dip slides in 100% ethanol. 
• Dry slides by spinning briefly in 50ml falcon tube. 
 
 
Step 9 – Scanning. 
 
• Scan slides on Axon scanner 4100B scanner and Genepix Pro v5.0 using PMT Power of 
600V 
Upload files into GEPAS for normalisation 
Perform print-tip normalisation (normalising to overall intensities in different regions to 
account for spotting differences) with background subtraction 
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2.16.5 TUNEL staining 
 
During apoptosis, endonucleases digest DNA to form short double stranded DNA fragments.  
These fragments can be detected by attaching biotinylated nucleotides to the 3’-OH ends using 
a terminal deoxynucleotidyl tranferase (TdT) enzyme.  These can then be visualised using a 
streptavidin-horseradish peroxidase conjugate followed by the substrate diaminobenzidine 
(DAB) which forms a brown precipitate when broken down by peroxidase.  Apoptotic cells 
must be distinguished from necrotic cells morphologically. 
 
 
Solutions: 
 
3.7% buffered formalin:  5 ml 37% formaldehyde 
45 ml PBS 
 
Quenching solution:   5 ml 30% H2O2  
     45 ml methanol 
 
Labelling reaction mix:  1 µl TdT-dNTP kit solution (R&D Systems)  
     1 µl Co2+ kit solution 
     1 µl TdT enzyme kit solution    
50 µl TdT labelling buffer (kit solution diluted 1:9 in dH2O)  
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DAB solution:   50 ml PBS 
     250 µl DAB 
     50 µl 30% H2O2 
2.16.5.1 Method 
 
Air dry cryostat sections fully (30 min if fresh or taken from freezer). 
Draw round sections with a wax pen, and allow to dry fully (15 min). 
Fix in 3.7% buffered formalin for 10 min. 
Wash slides for 2 x 5 min in PBS. 
Blot slides dry, then immediately add 50 µl proteinase K solution (1 µl kit solution in 50 µl 
dH2O per slide) and cover with a coverslip. 
Incubate for 15 min at RT, then wash 2 x 2 min in dH2O. 
Place slides into 50 ml of quenching solution for 5 min, then wash 2 x 1 min in PBS. 
Incubate slides in 50 ml TdT labelling buffer for 5 min. 
Blot slides dry, then immediately add 50 µl labelling reaction mix and cover with a coverslip. 
Incubate slides in a 37°C incubator in a humidity chamber for 2 hours. 
Transfer slides into 50 ml TdT stop buffer (kit solution diluted 1:9 in dH2O) and incubate for 5 
min. 
Wash slides 2 x 2 min in PBS. 
Blot slides dry, then add 50 µl streptavidin-HRP detection solution onto each sample (1 µl kit 
solution in 50 µl dH2O per slide) and cover with a coverslip.  Incubate at RT for 10 min. 
Wash slides 2 x 2 min in PBS. 
  
 
 
 
81 
Incubate slides in 50 ml DAB solution for 5 min. 
Rinse slides in dH2O, then transfer to fresh water. 
Counterstain by transferring slides to 50 ml methyl green solution for 3 min. 
Wash slides by sequentially dipping 10 times each in: 
     dH2O 
     70% ethanol (2 changes) 
     90% ethanol (2 changes) 
     100% ethanol (2 changes) 
     xylenes (2 changes) 
 
Dry xylenes from the back of the slide.  Leave xylenes on the surface of the slide to aid the 
mounting process. 
Place two drops of Histomount (Sigma) on the samples and coverslip. 
Leave to harden overnight.  Store out of direct light. 
 
Notes: 
 
Do not allow samples to dry at any point after they have been fixed. 
Use fresh solutions for large numbers of slides (max. 4 slides per 50 ml coplin jar) 
Keep TdT enzyme in the freezer – only remove it for long enough to pipette the amounts 
required, and do this immediately before use. 
Empty pipette tip racks with water in the bottom work very well as humidity chambers. 
Any flaws in the section will show up brown as they have exposed DNA fragments.  This is 
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not apoptosis, but can be a useful positive control. 
If staining mouse tissue, the above protocol overexposes the background.  I would suggest 
using the Mg2+ kit solution in the labelling buffer, and incubating for 1 hour instead of 2. 
Additionally, the methyl green protocol listed above does not work on mouse muscle.  These 
must be counterstained by incubating in the methyl green solution for 5 min, then dipping in 
1-butanol until the sample turns from blue to mainly green, dipping once more in fresh 
butanol, then dipping 10 times in 2 changes of xylenes and mounting as before. 
2.16.6 Dye labelling cDNA 
This procedure uses a polymerase reaction to create copies of cDNA that incorporate a 
cyanine dye into the new copies.  This procedure uses Cy3 (green fluorescent; excited at 
550nm, emits at 570nm) and Cy5 (red fluorescent; excited at 649nm, emits at 670nm) dyes 
conjugated to dCTP monomers.  As the Cy dyes are quite bulky, they sterically hinder CTP 
incorporation, so some unlabelled dCTP is added to the reaction mix. 
 
 
 
 
 
Solutions 
 
Primer mix: 
  500ng cDNA 
  20µl Random primer mix (Bioprime labeling kit, Invitrogen) 
  Up to 43µl H2O 
 
  
 
 
 
83 
Reaction mix (per sample): 
 
1.2µl dATP (10mM) 
1.2µl dTTP (10mM) 
1.2µl dGTP (10mM) 
0.72µl dCTP (10mM) (all from Invitrogen) 
1µl Klenow Enzyme (40U/µl) (Invitrogen) 
2µl Cy3 (samples) or Cy5 (cDNA reference) (Amersham Biosciences) 
 
2.16.6.1 Method 
Heat to 94°C for 5 min to denature dsDNA 
Cool on ice 
Add 7.3µl reaction mix to each tube 
Incubate at 37°C for 2 hours 
Add 50µl H2O to each sample 
Add 100µl PB buffer (QIAquick PCR Purification Kit, Qiagen) to sample 
Add probe mix to Qiagen PCR purification column 
Spin at 13000 rpm for 1 min 
Empty collection tube and discard flow-through 
Add 700µl PE (QIAquick PCR Purification Kit, Qiagen) buffer to column 
Spin at 13000 rpm for 1 min 
Empty collection tube and discard flow-through 
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Spin at 13000 rpm for 2 min 
Transfer insert to a fresh 1.5ml microfuge tube 
Add 50µl H2O 
Leave at RT for 2 min to allow cDNA to dissolve 
Spin at 13000 rpm for 1 min to collect cDNA 
 
Measure probe concentration by taking measurements at 260nm, 535nm and 635nm: 
 Cy3 pmol/µl = Absorbance (535nm )/ 0.15 
 Cy5 pmol/µl = Absorbance (650nm) / 0.25 
 cDNA yield ng/µl = Absorbance (260nm) x 50 
Calculate dye concentration per ng cDNA to check efficiency of labelling: 
 CyX pmol/ng = CyX concentration / cDNA yield 
Ensure at least 50 pmol/ng, otherwise relabel 
Add 100 pmol of each dye to a microcon column (Qiagen) 
Spin at 13000 rpm for 5 min 
Add 10µl H2O 
Invert column into a fresh tube 
Spin at 13000 rpm for 3 min 
2.16.7 iNOS staining 
Optimisation of the iNOS antibody was performed as follows:  First, sections were stained 
according to the previously established protocol for Ki67, but comparing BSA/Triton X-100 
wash buffer with normal sheep serum (NSS) with and without antigen retrieval as previously 
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described. Wash buffer without either the primary or the secondary antibody as controls.  No 
specific staining was seen in either of the antigen retrieval techniques, and little was seen with 
NSS without antigen retrieval.  BSA/Triton without antigen retrieval gave punctate staining, 
although background was far too high, so the secondary antibody concentration was tested in 
5x dilutions from 1:100 to 1:25,000.  The optimum secondary concentration was 1:5,000, so 
the primary concentrations were titrated against this in 5x dilutions from 1:25 to 1:2,500.  This 
gave clear, punctate staining with all concentrations, including the control without any 
primary.  As this is artefact, the protocol was amended to look at different fixation procedures 
(cold methanol, ethanol and acetone) with no change. 
Total protein extracted from polyps and ITs 
Protein measured and loaded equally into ELISA 
Samples run in duplicate with A450 background correction, quantified against ladder of 
known concentrations 
Diluted protein re-assayed and A650 absorbances corrected for small protein loading 
differences 
 
 
2.16.8 RT-PCR 
Reverse transcription polymerase chain reaction (RT-PCR, not to be confused with real-time 
PCR, rtPCR) is a method for creating cDNA chains for analysis.  RNA is fairly labile, and the 
ubiquitous presence of environmental RNases means that it not easy to work with.  DNA is 
much more stable, and is thus used for most analysis. 
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Solutions 
 
Primer mix: 
  5µg RNA 
  1µl oligo (dT)12-18 primer 1µg/µl (Invitrogen) 
  Up to 17µl H2O 
Reaction mix (per sample): 
 
  8µl 5x first-strand buffer 
  4µl 0.1M DTT 
  2µl dATP (10mM) 
2µl dCTP (10mM) 
2µl dGTP (10mM) 
2µl dTTP (10mM)  
2µl Superscript II (200U/µl) (all from Superscript II RNase H Reverse 
Transcriptase kit, Invitrogen) 
1µl H2O 
2.16.8.1 Method 
Isolate RNA from the samples. 
Add 3.5µl DNase I buffer. 
Add 1µl DNase I 
Incubate samples at 37°C for 30 min 
Add 5µl DNase inactivation reagent 
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Incubate at RT for 2 min 
Spin for 1 min at 13000 rpm on a bench centrifuge 
Quantify RNA using a spectrophotometer 
Use 5µg RNA in the primer mix 
Heat to 65°C for 10 min to unfold RNA 
Cool on ice 
Add 23µl reaction mix to each tube 
Incubate at 42°C for 2 hours 
Add 200µl PB buffer (QIAquick PCR Purification Kit, Qiagen) to each sample.   
Mix well 
Make spin column by adding semi-permeable membrane insert (Qiagen) to collection tube 
Add sample to spin column 
Spin at 13000 rpm for 1 min 
Empty collection tube and discard flow-through 
Add 700µl PE buffer (QIAquick PCR Purification Kit, Qiagen) to column 
Spin at 13000 rpm for 1 min 
Empty collection tube and discard flow-through 
Spin at 13000 rpm for 2 min 
Transfer insert to a fresh 1.5ml microfuge tube 
Add 50µl H2O 
Leave at RT for 2 min to allow cDNA to dissolve 
Spin at 13000 rpm for 1 min to collect cDNA 
Quantify DNA yield via spectrophotometry (Eppendorf Biophotometer)
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CHAPTER 3 
MEASURING CAPILLARY SUPPLY 
PHYSIOLOGICAL ADAPTATION 
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3 Measuring capillary supply - Physiological adaptation 
To understand and refine staining techniques to measure capillarity for use in human tissue, 
initial experiments were carried out on human skeletal muscle looking at physiological 
adaptation; how capillary supply is linked to metabolic demand and muscle fibre size and 
type. We used human muscle biopsies, as these were readily available whilst we awaited 
ethical committee approval to allow us take human nasal biopsies.  We refined the established 
mouse lectin protocol and tried different lectins to increase the yield.  We then compared this 
physiological adaptation of capillarity to pathological human muscle states. 
 
3.1 Introduction  
 
An accurate quantitative analysis of capillary supply to skeletal muscle is an essential 
prerequisite for understanding the limits to peripheral oxygen transport. The capillary supply 
to skeletal muscle is influenced by its metabolic profile, oxidative capacity and fibre size 
(Hudlicka et al., 1992). Quantitative differences in gross capillary supply are normally 
expressed as the ratio of capillary number to fibre number (capillary to fibre ratio, C: F) or to 
fibre area (capillary density, CD). Given that these indices are scale dependent, there is a need 
for a more discriminatory analysis that takes account of fibre size (Figure 3.1).  
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Figure 3.1: Allometry of muscle capillary supply 
 
Changes in muscle capillary supply as a function of fibre cross-sectional area, illustrating the 
linear positive relationship with capillary to fibre ratio (C:F), and the non- linear negative 
relationship with capillary density (CD) (Egginton, 2002). 
 
The global analysis was first brought down to a local analysis by Plyley and Groom (1975) 
when they quantified the mean number of capillaries around a fibre (CAF) for individual 
categories of fibre type.  However, this method does not render information regarding 
diffusion distances and does not take into account fibre size.  This drawback was overcome by 
relating CAF to fibre area for each category.  CAF relative to fibre area gives a slight 
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overestimate of diffusion capacities of large fibres as a proportionally higher number of 
capillaries around a fibre cannot compensate for larger diffusion distances.  In mixed muscle 
the influence of neighbouring fibres also needs to be considered and oxygen supply scaled 
accordingly (Egginton, 1990a).  Thus each capillary needs to be weighted according to the 
metabolic character of its neighbours (Gray and Renkin, 1978; Flood, 1979).  Plyley and 
Groom (1975) also calculated the sharing factor (SF) which is the number of fibres 
surrounding a capillary.  It attempts to focus on the individual capillaries’ contributions to the 
microvascular supply. With both CAF and SF, influence of fibre size, adjacent fibres and 
proximity of  neighbouring capillaries limit their capacity  to directly reflect oxygen demand.  
Gray and Renkin (1978) took this into consideration and used a mean numerical fraction of SF 
to give a specific capillary to fibre ratio (SCF) and a specific capillary density (SCD) for each 
fibre group. 
 
Using mathematical models such as Voroni tessellations (Voroni, 1908) it is possible to 
calculate the domain of influence or area of tissue supplied by individual capillaries (Hoofd et 
al, 1985; Egginton et al, 1988; Egginton and Ross, 1989; Egginton, 1990).  The interaction of 
capillary domains and individual fibres may be quantified as the sum of partial domains 
overlapping a fibre profile (local capillary to fibre ratio), being the real equivalent of Gray and 
Renkin’s numerical fraction of SF (Egginton and Ross, 1989)(Figure 3.2) 
By calculating the area of muscle tissue supplied by, or the domain of influence of, individual 
capillaries an unbiased measure of the local capillary to fibre ratio (LCFR) and local capillary 
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density (LCD) may be derived (Egginton and Ross, 1989)). This novel approach was used to 
investigate whether the local capillary supply was modelled according to the size or type of 
individual human skeletal muscle fibres. 
 
           
Figure 3.2 Comparison of scoring methods based on the numerical method or areal 
(Domain method) fraction of a capillary to be ascribed to different fibre types.   
 
Above, the central capillary [ ] serves two large glycolytic fibres and a smaller oxidative 
fibre.  The numerical fraction of this capillary serving glycolytic fibres is therefore 0.66 
whereas the areal fraction is much greater, around 0.80.  In addition to this discrepancy the 
numerical method only allows for a distribution analysis on the basis of capillary fractions per 
fibre type while the Domain method provides an additional level of resolution by summing 
capillary fractions per individual fibre (Egginton and Ross, 1989). 
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3.2 Methods   
With the approval of the Local Ethics Committee and written informed consent, samples from 
the lateral portion of the quadriceps femoris muscle were obtained by percutaneous needle 
biopsy from fifteen active young subjects (10 male and 5 female): mean age, 23.3 ± 1.38 years 
(males) and 21.0 ± 1.73years (females); height, 1.80 ± 0.02m (males) and 1.66 ± 0.04m 
(females); and body mass, 83.3 ± 3.70kg (males) and 60.7 ± 1.56 kg (females).  
          
Figure 3.3 Percutaneous needle biopsy from lateral quadriceps femoris muscle 
 
Serial sections (10 um thick) were prepared for quantitative analysis by histochemical staining 
of fibre types (Brooke and Kaiser, 1970)) and capillaries (Holthofer et al., 1982) and Ulex 
europaeus Agglutin-1 (UEA-1), a lectin for capillaries. 
 
 
Muscle composition was determined by stereological analysis of fibre area and proportion of 
fibre types (Egginton, 1990). Digitized images of stained sections were used to determine the 
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x, y co-ordinates for muscle fibres and associated capillaries. From these data the LCFR and 
LCD, indices of fibre-specific capillary supply, were calculated (Egginton and Ross, 1989). 
Briefly, this involves calculating the geometric supply area (‘domain’) of each capillary, 
defined as that portion of tissue cross-section closer to one capillary than any other, and the 
summed fraction of different domains overlapping each muscle fibre (figure 3.1). Under 
conditions of maximal flow, assuming supply capacity to be similar for all capillaries, the 
domain size will be inversely proportional to the metabolic demand. Thus, LCFR represents 
supply capacity in ‘capillary equivalents’, which may be normalized for the effects of 
individual fibre size to give the LCD. For comparison, the equivalent number-based indices of 
local capillary supply, number of capillaries around each fibre (CAF) and its normalized 
derivative (i.e. CAF per fibre area, CPA), were also calculated. Data were analysed by 
ANOVA and results expressed as mean values ± S.E.M. 
 
3.3 Results  
The use of Ulex europaeus Agglutin-1 (UEA-1) for the identification and computerised 
quantification of capillaries was not found to be a reliable marker.  We found that UEA-1 does 
not stain all human capillary endothelium equally and differential staining was seen. Kirkeby 
et al. (Kirkeby et al., 1993), while investigating blood group specific lectins, discovered that 
UEA-1 does not stain strongly in patients with blood group A.  This finding could not be 
verified by our data as blood group information was not available from patients whose 
capillary endothelium did not stain strongly, although this was suspected.  Previous work 
using Ulex europaeus has only tested the Agglutin-1 (Holthofer et al., 1982, Alroy et al., 
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1987).  However, data from this investigation suggests that the lectin UEA-II is a more 
reliable marker for capillary endothelium than the agglutin-1, staining capillaries more densely 
especially in sections from patients of blood group A. 
 
Numerical muscle fibre composition was found to be 47.9 ± 4.2% type I, 31.3 ± 4.4% type IIa 
and 21.6 ± 5.1% type II b fibre types. In relation to muscle area the values were 51.8 ± 3.3, 
27.7 ± 4.4 and 15.7 ± 4.1%, respectively. Mean fibre cross-sectional areas were 4538 ± 240, 
4005 ± 390 and 3957 ± 814µm2 respectively.  Mean C:F was 1.3 ± 0.42, while CD was 442 ± 
52 mm-2. These values are comparable with those obtained previously for vastus lateralis 
biopsies from untrained individuals giving a C:F of 1.39-1.79 and a CD of 348-438 mm-2 
(Ingjer, 1979).  A total of 1741 muscle fibres (n=709, 520 and 512 for type I, IIa and IIb, 
respectively) from these individuals were also matched across serial sections for fibre type, 
fibre area and capillarity. Capillary supply (domain) area showed a logarithmic-normal 
distribution. Domain area (µm2) and log10 (domain area) were 2831 ± 150 and 3.41 ± 0.024, 
respectively (n= 6 biopsies and 944 domains). LCFR showed a positive correlation with fibre 
area (LCFR = 0.075 + 0.0015 x area; r2 = 0.47) that was independent of fibre type (Figure 3.1 
A). Slopes for the regression with fibre type were very close (0.0012-0.0016; r2= 0.40-0.45), 
although mean values scale with oxidative capacity i.e. type I > IIa> IIb. Normalizing the local 
capillary supply to give LCD produces a slope very close to zero (LCD = 186.8 + 0.0042 x 
area; r2= 0.009), effectively removing the scaling effect of fibre size for both slope and mean 
values, which is consistent with the observed lack of any significant difference among fibre 
types (Figure 3.1 B). 
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Figure 3.4: Local capillary indices in the lateral quadriceps, split according to fibre type: 
type I (triangle), type IIa(square) and type IIb(circle). A, local capillary to fibre ratio 
(LCFR); B, local capillary density (LCD).  232 S. K. AH-NILEDI)(N) IT EIRERS
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Fibre 
type 
LCFR LCD 
(µm-2) 
CAF 
(µm-2) 
CPA Fibre Area 
(µm2) 
Type I 
 
0.723 ± 0.084 174.1 ± 10.71 1.323 ± 0.168 329.7 ± 34.9 4176 ± 340 
Type II a 
 
0.569 ± 0.056 172.1 ± 13.30 1.027 ± 0.120 338.2 ± 50.8 3399 ± 366 
Type I  b  
 
0.532 ± 0.047 169.8 ± 8.34 0.912 ± 0.076 311.6 ± 23.7 3216 ± 366 
 
Table 3.1: Fibre type specificity of local capillary supply in the lateral quadriceps  
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Figure 3.5: Muscle stained to show capillaries (lectin) and sequential section stained to co-
localise muscle fibre types (Myosin ATPase) x 20 magnification.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Capillary 
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Figure 3.6:  Digitised images of lectin localised capillaries and mATPase localised muscle 
fibres using Image J for domain analysis.     
 
 
 
 
  Green = type I;   Blue = type IIa;    Red = type IIb  
 
    
3.4 Discussion  
Ulex europeaus agglutin I is not a valid marker of human capillary endothelium, as differential 
staining due to blood group specificity was found.  The agglutin II did not show any 
differential staining and is therefore superior to the agglutin I.  However, more investigation 
needs to carried out using UEA II in muscle from humans with different blood groups. 
Many studies have sought to determine whether the capillary bed of skeletal muscle is limiting 
for aerobic capacity via its role in setting the level of functional hyperaemia. While capillarity 
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is increased following a period of training, a number of variables may complicate the implicit 
relationship between supply and demand. For example, in a longitudinal training study 
Andersen & Henriksson (Andersen and Henriksson, 1977) showed that an expansion of the 
capillary bed was accompanied by fibre type transformation in vastus lateralis. Both the 
duration of training and size of fibres were also important factors, with C:F increasing 
significantly after 5 weeks, but CD only after 8 weeks due to the accompanying fibre 
hypertrophy. From biopsies taken before and following 24 weeks of endurance training, Ingjer 
(Ingjer, 1979) found a significant increase in C:F, with the CAF for slow oxidative fibres 
increasing more than that for fast glycolytic fibres. Indeed, Saltin& Gollnick (Saltin and 
Gollnick, 1983) suggested that the supply area for capillaries would be 20-30% (type Ib) or 
10-20% (type Ia) greater than that for type I fibres, which is similar to the differences shown 
by our measured values of local capillary supply (LCFR; Table 3.1). These and other studies 
are in agreement with the more extensive literature from animal experiments showing that 
local demand (in terms of fibre type) may influence capillary growth, and that CD often varies 
inversely with fibre size (Hudlicka et al., 1992). Such considerations may explain reported 
discrepancies in CD among human training studies. 
Using a specific marker for capillaries and a discriminatory analysis of local capillary supply, 
we have examined over 1700 human muscle fibres. By comparison with the discontinuous 
distribution of values from any of the integer-based indices of capillary supply, which convey 
little information regarding muscle composition, the continuous indices can be used to 
describe the local capillary supply and have the potential to discriminate between more subtle 
changes in fibre composition and/ or size. This may be of particular benefit where fibre size 
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changes between samples, e.g. hypertrophy following high resistance exercise (Abernethy et 
al., 1994), or where an increase in CD does not reflect capillary growth, but rather the atrophy 
of muscle fibres (Hoppeler and Desplanches, 1992). In particular, while both fibre size and 
capillary supply are reduced with age, the apparent specificity of training-induced increases in 
capillary supply to type I fibres in elderly subjects (Proctor et al., 1995) deserves closer 
attention. Indeed, in a pilot study we showed a regression of LCFR against fibre area in trained 
muscle which was merely offset from that of controls (LCFR= 0798 + 00017 x area; r2 = 
0.17), with a similar slope and clustering for fibre types, although LCD showed a slight 
negative slope against fibre size (LCD = 501.2 - 0031 x area; r2 = 0.15), suggesting that 
additional factors have some influence on local capillary supply (Ahmed et al., 1995) . We 
therefore conclude that the capillary supply to human skeletal muscle is scaled according to 
fibre size and is relatively independent of fibre type. The method of capillary domains offers a 
reproducible technique, with the potential to discriminate between subtle adjustments in local 
capillary supply at the level of individual human muscle fibres. 
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CHAPTER 4 
MEASURING CAPILLARY SUPPLY 
PATHOLOGICAL ADAPTATION 
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4 Measuring capillary supply - Pathological adaptation 
Skeletal muscle readily undergoes adaptive remodelling, and its capillary supply responds to 
metabolic demand but scales primarily according to fibre size not fibre type (Chapter 3) 
(Ahmed et al., 1997b). More than 70 diseases may have an angiogenic component, with either 
excessive or insufficient capillary supply (Egginton, 2010). Pathological conditions, such as 
diabetic retinopathy or psoriasis, are classed as angiogenic disorders as they uncouple the 
capillary supply of a tissue from its metabolic needs.  Uncoupling of capillary supply from 
metabolism can also be performed experimentally with in vivo models, through increasing 
shear stress (by vasodilators) and passive stretch (by overload)(Egginton, 2009). We examined 
how different pathologies affect the capillary supply of human skeletal muscle by a process of 
adaptive remodelling through: 1) examination of biopsies from patients with muscular 
atrophy, hypertrophy or peripheral vascular disease; 2) a meta-analysis of the available 
literature. 
 
4.1 Methods  
Percutaneous needle biopsies of vastus lateralis were taken from control volunteers (n=5), and 
patients with muscle fibre atrophy (n=2), fibre hypertrophy (n=4) or peripheral vascular 
disease (n=7) with informed consent and local Ethical Committee approval. Biopsies were 
snap-frozen in liquid nitrogen-cooled isopentane, and capillaries stained using Ulex europeaus 
lectin-1 on 10µm cryostat sections.  Capillaries were counted and fibre areas measured by 
stereology of digitised images, using 2-4 fields of view from random sections (Fig. 4.1).  A 
graticule was used to measure the sample area, and capillary density (CD, mm-2), fibre size 
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(a(f), µm2)  and the capillary to fibre ratio (C:F) was then calculated from this. 
 
For meta-analysis, literature searches using combinations of relevant terms (muscle, capillary, 
vasculature, fibre, human) were supplemented by reference mining all papers found.  Only 
adult human studies were used.  304 papers were checked to find those containing data on 
capillary density and mean fibre size, or data from which capillary density and fibre size could 
be calculated. Data from 44 papers was collated and analysed using C:F, CD, fibre size, 
methodology, muscle type and experimental protocols as separate variables. 
 
Formalin/ gluteraldehyde fixed samples had their average fibre size increased by 30% to 
correct for muscle shrinkage (Goldspink, 1961). 
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4.2 Results 
Figure 4.1 Muscle biopsies stained for capillaries and muscle fibre types  
Photographs taken at x 10 magnification of 10µm sections of muscle biopsies taken from 
patients with idiopathic muscle atrophy (top) and hypertrophy (bottom) stained with Ulex 
europeaus lectin-1 (left), showing the position of capillaries (black arrows) and mATPase to 
stain muscle fibre types (right). 
              
           
The top panels demonstrate smaller muscle fibres in keeping with muscle atrophy and the 
bottom panels larger fibres as seen in muscle hypertrophy. 
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Table 4.1:   Stereological analysis 
Capillary to fibre ratio (C:F), mean fibre area (ā(f)), and capillary density (CD) shown for 
control volunteers, patients with muscle hypertrophy, muscle atrophy, or peripheral vascular 
disease (PVD).  Mean ± SEM. 
 C:F ā(f) µm2 CD mm-2 
Control 1.64 ± 0.21 6040 ± 870 293 ± 15 
Hypertrophy 2.01 ± 0.03* 6630 ± 570 319 ± 30 
Atrophy 1.68 ± 0.41 3440 ± 1160* 434 ± 34 
PVD 1.29 ± 0.09* 4040 ± 730 323 ± 19 
*P <0.05 vs. control 
 
Figure 4.2  Regression analysis of experimental data 
  
  
 
 
 
 
 
 
Linear regression of capillary to fibre ratio (C:F) vs. mean fibre area (ā(f) µm2) for control 
volunteers, patients with muscle hypertrophy or atrophy, of peripheral vascular disease 
demonstrates that scaling of capillarity is independent of the magnitude of capillary supply. 
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The overall R2 increased from 4.05 to 4.43 when formalin/ gluteraldehyde fixed samples had 
their average fibre size increased by 30% to correct for muscle shrinkage (Goldspink, 1961).   
 
Figure 4.3  Regression of meta-analysis data 
 
Linear regression of capillary to fibre ratio (C:F) vs. mean fibre area (ā(f) µm2) for all control, 
experimental and pathological conditions. 
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Figure 4.4  Regression of grouped meta-analysis data 
Linear regression of capillary to fibre ratio (C:F) vs. mean fibre area (ā(f) µm2) for controls, 
endurance trained muscles, acute muscle atrophy and chronic muscle atrophy. 
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4.3 Discussion 
 
Mean fibre area confirmed the clinical diagnoses of atrophy and hypertrophy.  Hypertrophy 
maintained capillary density (CD), but increased capillary to fibre ratio (C:F), whereas atrophy 
maintained C:F but increased CD (Table 3.1).  Regression analysis of C:F vs. mean fibre size 
showed a single line for controls, hypertrophy and peripheral vascular disease, with a trend for 
idiopathic muscle atrophy to lie above this line (Fig. 3.2). This suggests active remodelling of 
the capillary bed by feedback control.  Evidence form this comes from analysis of distribution 
with similar geometric patterns seen across muscle with 2 orders of magnitude difference in 
CD (Egginton and Gaffney, 2010), suggesting that the growth process is a fixed genetic 
program. This may be driven by oxygen consumption via some feedback control mechanism 
however we have shown in chapter three that muscle fibre size is the key determinant to 
capillarity (Ahmed et al., 1997a).  This has significant clinical implications and may mean a 
different approach to therapy. Of this were the case then we would see a similar trend in other 
published studies in the literature. We then undertook a meta-analysis approach to investigate 
this. 
 
Following meta-analysis, there was no significant difference in the regression lines when 
studies were split into groups for gender, age, or muscle type (Fig. 4.3).  There was a 
significant difference in data points for muscles that had undergone significant endurance 
training, which had a higher C:F for a given fibre size than other muscles (Fig. 4.4).  The 
regression for atrophic muscles was only slightly above that for control muscles, unless the 
  
 
 
 
110 
atrophy was split into chronic (>6 weeks) and acute atrophy (<6 weeks).  Chronic atrophy has 
a regression line similar to controls, whereas acute atrophy showed vascular maintenance. 
 
4.4 Conclusions 
 
Capillary supply to human skeletal muscle is primarily determined by muscle fibre size, with 
adaptive remodelling occurring in response to resistance training or chronic muscle atrophies.  
Endurance training leads to a higher C:F than would be predicted by fibre size, showing 
angiogenesis in response to increased metabolic demand, and acute atrophy shows a 
maintenance of the vascular supply that is not seen in chronic atrophy, indicating that vascular 
regression occurs subsequent to the atrophy.  In pathological processes there appears to be a 
decoupling of angiogenesis from metabolic demand, for example capillarity is mainly 
dependant on fibre size not fibre type, suggesting that the preponderance of angiogenesis-
based diseases may be dependent on the tissue involved.  
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CHAPTER 5 
MEASURING HUMAN NASAL CAPILLARY SUPPLY 
METHOD DEVELOPMENT 
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5 Measuring Human Nasal Capillary Supply - Method development 
5.1 Staining of nasal mucosa to examine remodelling 
5.1.1 Introduction 
Immunohistochemical examination of nasal mucosal tissue is essential for studying the 
aetiology of conditions such as chronic sinusitis, polyposis or airway remodelling.  Multiple 
labelling of different molecules on the same section is highly desirable as it allows co-
localisation of different factors, however, most established protocols use paraffin-embedded 
human tissue (Mumbuc et al., 2007), which limits the available tissue markers, as many 
antibodies will not recognise epitopes after paraffin embedding.  Using fresh tissue allows 
whole mount staining (using relatively large tissue samples); the sample can then be examined 
with confocal microscopy and analysed in three dimensions.  This approach could yield a 
wider range of information, avoiding problems with heterogeneity of structure by examining a 
larger mass of tissue, and correcting for the large changes in tissue volume typically seen in 
the nasal mucosa due to the nasal cycle.  This has been successfully applied to the examination 
of blood vessels with fluorescent lectins in animal models (Williams et al., 2006b), and we 
have demonstrated in chapters 3 and 4 the staining of capillaries in human muscle.  Hamid et 
al., has also demonstrated the use of lectins in a proof-of-principle human study (Hamid et al., 
2003), but the use of lectins can be problematic in large human studies as no single lectin will 
stain a population with heterogeneous blood groups (Capaldi et al., 1985).  
 
As different lectins bind to different sugar moieties, we reasoned that a mixture of the three 
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different lectins reported to stain human blood vessels (Capaldi et al., 1985) would 
successfully stain a far greater proportion of patient samples, and would therefore provide a 
more robust staining protocol for visualising capillary beds in three dimensions, allowing 
further investigation of vasculature changes during tissue remodelling in patients. 
 
5.2 Methods 
Subjects 
Patients were recruited from University Hospitals Birmingham NHS Trust, UK, with local 
ethical committee approval (numbers 0692 and 06/Q2702/15). Patients’ informed consent was 
obtained. Polyp and ipsilateral inferior turbinate specimens, 1 cm back from the anterior edge, 
were obtained from patients undergoing routine polypectomy. Previous studies have found no 
difference in vascularity between the different areas of the lateral nasal wall (Philpott et al., 
2005).  Inferior turbinate specimens from the same anatomical site were also taken from 
patients undergoing routine septoplasty or septorhinoplasty. 
 
Fixation 
First, 16 µm sections were observed under fluorescent illumination for red, green and blue 
filters to check for autofluorescence after different fixation methods.  4% buffered formalin 
(20 min), cold acetone (2 min), and 100% ethanol (5 min) were used, then washed in PBS for 
3 x 5 min, and mounted.  Dry sections and sections left in PBS for 5 min were also examined.  
Acetone and ethanol fixation resulted in substantial autofluorescence under green illumination 
and a small, but observable, amount of autofluorescence was seen under all channels for all 
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fixation methods.  Formalin fixation resulted in the lowest autofluorescence under all channels 
and was therefore chosen for subsequent optimisation. 
 
Immunohistochemical staining 
The different stains were tested separately, both for efficacy of staining and for checking non-
specific fluorescence in other channels.  DAPI staining was performed using Vectashield + 
DAPI.  This successfully stained cell nuclei with no fluorescence in the other two channels, 
but the 16 µm sections contained too many nuclei in different layers to allow quantification. 
Different thicknesses of sections were cut and stained, with 10 µm sections being the thinnest 
that good quality sections could be reproducibly obtained. 
Staining for capillaries was attempted with flourescein-conjugated lectins, with a comparison 
made between Ulex europeaus, Euonymus europeaus and Griffonia simplicifolia lectins.  All 
three lectins gave a similar pattern of staining on test sections, however as individual lectins 
can fail to stain individuals with different blood groups (Capaldi et al., 1985), a 1:1:1 
combination of the lectins was used at a concentration of 10 µl/ml for 60 min.  This gave good 
staining with a lower background than the individual stains at that concentration.  Proliferation 
staining was performed using a stain for PCNA that is well established in the mouse.   
 
Due to the problems with PCNA (Table 5.2) staining, Ki67 was chosen as a proliferation 
marker instead (Mumbuc et al., 2007), using the same protocol, but changing to the primary 
(Ki-67, Dako) and secondary (clone, Dako).  This gave some staining, but with a very poor 
signal-to-noise ratio, and after consultation with the manufacturers, an antigen retrieval 
procedure was performed.  This uses citrate and heat to break down the protein cross-links 
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caused by formalin fixation.  The standard protocol uses buffered citrate heated to 95°C, then 
the slides are kept at 95°C for 20 min and allowed to cool in the buffer for another 20 min.  An 
alternative protocol suggests that a microwave is used to simmer the citrate buffer for 5 min 
before allowing the slides to cool for 20 min.  A comparison of these two procedures showed 
no difference between them, so the microwave procedure was chosen for subsequent use due 
to its shorter duration.  Antigen retrieval gave good staining for Ki67, and had no effect on 
either lectin or DAPI staining.  The stains were then combined in pairs and all three together to 
check for any unforeseen interactions.  The lectin stain was found to show some fluorescence 
in the blue channel, so the dilution was lowered to 5 µl/ml.  The order of staining was checked 
with the lectin being applied before and after the Ki67 stain, and with the secondary antibody.  
Whichever stain was applied first lost signal intensity, so simultaneous application of the 
secondary antibody with the lectin gave best results.  Signal intensity for the DAPI stain was 
much higher than the other stains, necessitating changes in camera exposure times, so this was 
rectified by diluting the Vectashield + DAPI 1:1 in Vectashield. 
 
5.2.1 Results  
Samples from a total of 60 patients were stained using Ulex europeaus lectin, and compared to 
samples from 50 patients stained with a combination of Ulex europeaus, Griffonia 
simplicifolia and Euonymus europeaus. Samples that showed stained blood vessels were 
designated as positive, and samples in which blood vessels were not visualised were restained. 
Repeated failure to stain capillaries was seen in 23 of the single-lectin samples and in eight of 
the triple-stained samples (p <0.005; Pearson’s chi-square test), representing a significant 
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difference between single and triple lectin methods 
 Our method of using a mixture of three lectins stained a significantly higher proportion of 
samples than using Ulex europeaus lectin alone (84% vs 62%, P<0.005 Student's t-test).  
Comparison of different proliferation markers showed that Ki67 is a more suitable marker 
than PCNA for use in frozen sections. 
 
 Single Triple 
+ve 37 42 
-ve 23 8 
% +ve 62% 84% 
 
Table 5.1:  Comparison of single Ulex europeaus lectin staining vs triple lectin protocol.  
Data are shown for samples that stained well after up to three attempts (+ve) and for those 
that repeatedly failed to stain (-ve). 
 
Samples from a total of sixty patients were stained using Ulex europeaus lectin, and compared 
to samples from fifty patients stained with a combination of Ulex europeaus, Griffonia 
simplicifolia and Euonymus europeaus.  Samples that stained blood vessels clearly were 
designated as positive, samples that did not show any blood vessels were redone.  Repeated 
failure to stain capillaries was seen in 23 of the single-lectin samples and 8 of the triple-stained 
samples (P<0.005, Pearson’s chi squared test), representing a significant difference between 
single and triple lectin methods (Table 5.1, Figure 5.1). 
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Figure 5.1  Inferior turbinate mucosa stained with whole mount protocol using three 
lectins.  
Both PCNA and Ki67 staining gave best results using poly-L-lysine coated slides, and fixing in 
4% buffered formalin for 20 minutes.  Both stains gave best results with a wash buffer 
containing Triton X-100.  Ki67 staining required antigen retrieval, and optimal antibody 
concentrations were 1:100 for both the primary and secondary antibodies.  PCNA staining 
required antibody concentrations of 1:50 for primary and 1:100 for secondary. 
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Figure 5.2:  Triple stain of a single section of inferior turbinate mucosa under different 
fluorescent illuminations. e: epithelial layer.  A: Rhodamine-conjugated Ki67 stain.  B: 
Fluoroscein-conjugated lectin stain.  C: DAPI stain for nuclei. 
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 PCNA Ki67 
Proliferation Count/mm2 1127 ± 201 39 ± 9* 
Proliferation Index 34.3 ± 5.6 1.4 ± 0.3* 
 
Table 5.2:    Comparison of PCNA and Ki67 as measures of proliferation.   
Data are shown for the total proliferation count (expressed as positive counts per mm2) and 
proliferation index (expressed as percentage of total nuclei.  Mean ± SEM, n=12 *P<0.05 
Student’s t-test). 
 
A significant difference was seen in the level of proliferation marked by PCNA and Ki67 
staining (Table 5.2).  Both the proliferation count per mm2 and proliferation index was 
significantly higher when measured using PCNA staining compared to Ki67. 
5.2.2 Discussion 
The objective of these experiments was to provide a robust multiple staining protocol using 
samples that have not been embedded in paraffin, so that a broader range of antibodies can be 
used.  The use of lectins to stain blood vessels is well established in animal models, but is less 
widely used in humans due to variability in staining between individuals with different blood 
groups (Capaldi et al., 1985). Our data show a marked improvement when using a mixture of 
the three most commonly used human-specific lectins (which bind to different sugar moieties 
present on the endothelium), compared with use of a single lectin. Lectins were also seen to 
bind to nasal mucosa epithelium (figure 5.2), as previously described; (Hassid et al., 1997, 
Huang et al., 1993) however, as this layer is avascular, it does not interfere with capillary 
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visualisation. Lectins have several advantages over other immunohistochemical methods in 
the staining of blood vessels. They can be readily conjugated to several fluorophores, allowing 
multiple stains to be used on the same section. The one-step protocol reduces the signal 
degradation associated with other multiple labelling methods, as well as saving time. Lectins 
are relatively inexpensive, allowing whole-mount stains to be performed economically. 
Finally, using lectins avoids the problems commonly associated with the use of two primary 
antibodies raised in the same host species. 
 
Proliferating cell nuclear antigen (PCNA, also termed cyclin) is a protein that acts as a 
processivity factor for deoxyribonucleic acid polymerase delta in eukaryotic cells, and the 
staining of this antigen is well documented for paraffin-embedded sections. However, we have 
demonstrated that staining for PCNA is not appropriate for frozen sections, as the calculated 
proliferation index is unreasonably high. Normal mucosal tissue is highly unlikely to have 34 
per cent of total nuclei undergoing mitosis at any one time (Table 5.2).  It is likely that this 
antibody stains proliferating cell nuclear antigen epitopes in fresh human cells that are not in 
their biologically active form, as we have also seen unrealistically high labelling indices in 
serum-starved Human Umbilical Vein Endothelial Cell (HUVEC) monolayers where mitosis 
is arrested (J. Williams, S. Egginton, G. Nash, unpublished observations). Staining for Ki67 is 
far more successful after a brief formalin fixation with subsequent antigen retrieval. Results 
for proliferation indices for fresh tissue using this method broadly agree with those published 
for tissue prepared with paraffin-embedding (Hiroshima et al., 2002). 
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5.3 Conclusion 
This is a novel and robust method for analysing the capillary bed and the extent of cellular 
proliferation in unfixed samples of human respiratory mucosa. This method will allow further 
investigation into the vascular response during tissue remodelling in human biopsies, and 
could thus help elucidate the aetiology and pathogenesis of chronic sinusitis, nasal polyposis, 
allergic rhinitis and asthma.  
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 CHAPTER 6 
ANGIOGENESIS IN NASAL POLYPOSIS  
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6 Angiogenesis in Nasal Polyposis  
6.1 Introduction 
Nasal polyps are oedematous, semi translucent, benign masses that develop from the mucosal 
linings of the paranasal cavity, usually originating from the mucosa in the osteomeatal 
complex.(Larsen and Tos, 2004)  The aetiology and pathogenesis of nasal polyposis are far 
from clear, with suggestions of them being adenoma formations,(Billroth, 1885) arising from 
inflammation,(Bachert et al., 2000a, Jenkins, 1932) oedema,(Krajina, 1963) or epithelial 
rupture.(Tos, 1990)  Recently, a number of studies have proposed a role for angiogenesis, 
based on upregulation of pro-angiogenic factors in polyps.(Caye-Thomasen et al., 2004, Ito et 
al., 1995b, Coste et al., 2000a) 
 
The vascular endothelial growth factors (VEGFs) are a family of glycoproteins that are 
constitutively expressed in tissue and have an essential involvement in angiogenesis.(Ferrara, 
1999)  Five members have been identified so far, of which VEGF-A is the predominant 
angiogenic factor through binding to VEGFR2.  VEGFR-2 binding initiates a large number of 
signalling pathways that stimulate endothelial cells to proliferate, migrate and/or survive, as 
well as leading to an increase in vascular permeability.(Gerber et al., 1998, Bates and Curry, 
1997a, Rousseau et al., 2000, Takahashi et al., 1999)  VEGF mRNA(Ito et al., 1995b) and 
protein(Yang et al., 2002) are up-regulated in nasal polyps compared to inferior turbinates, and 
localised to both epithelial and inflammatory cells, while primary cultures of epithelial cells 
from nasal polyps secrete VEGF.(Coste et al., 2000a)  Other researchers have reported VEGF 
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expression in vascular endothelium and glandular cells in nasal polyps,(Guo et al., 2001b) so 
the expression and role of VEGF in polyposis is unclear, with both paracrine and autocrine 
functions a possibility. 
 
In order for angiogenesis to occur, endothelial cells need to migrate, an action that is 
dependent on up-regulation of matrix metalloproteinases (MMPs).(Rundhaug, 2005)  MMP 
expression is involved in many forms of angiogenesis,(Rundhaug, 2005, Haas et al., 2000)  
MMP expression has been observed in nasal polyps,(Lechapt-Zalcman et al., 2001, Watelet et 
al., 2004) and it has been suggested that the success of treatment with macrolide antibiotics is 
mediated by suppression of MMP activity, and hence angiogenesis.(Kanai et al., 2004)  
 
All this evidence is circumstantial, and the presence of pro-angiogenic molecules does not 
automatically lead to angiogenesis(Milkiewicz et al., 2004).  Angiogenesis is controlled by the 
balance of pro- and anti- angiogenic factors,(Folkman, 1995) so measurement of angiogenesis 
has to examine actual capillary growth.  Angiogenesis is uniquely difficult to study in the 
nose, as the cycle of congestion and decongestion leads to large changes in tissue volume, 
which makes normal measures of capillary density meaningless without confirmation by other 
methods.  In addition, polyposis frequently occurs alongside other airway diseases, such as 
asthma or chronic sinusitis, which often cause tissue remodelling.  Any tissue remodelling will 
cause a restructuring of the vascular supply for that tissue, which would confound attempts to 
measure any angiogenesis associated with polyp formation alone.  
  
Based on the current literature if polyposis is indeed driven by angiogenesis, there should be 
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changes in the morphology and architecture of the capillary bed, alongside proliferation of 
endothelial cells, similar to that seen in bowel polyps.(Balazs, 1990)  If angiogenesis is not a 
major factor in the aetiology of polyp formation, then the capillary bed should expand in line 
with the metabolic needs of the tissue, and be morphologically similar to non-diseased 
tissue.(Papetti and Herman, 2002)   The architecture and proliferation of the capillary bed was 
analysed, as well as capillary density, to provide unambiguous measures of the extent of 
angiogenesis in nasal polyposis. 
 
6.2 Subjects 
This study involved patients recruited from University Hospitals Birmingham NHS Trust, UK.  
Following local ethical committee approval (Numbers 0692 and 06/Q2702/15) and informed 
consent, polyp (P) and ipsilateral inferior turbinate specimens (PIT), 1cm back from the 
anterior edge, were obtained from patients undergoing routine polypectomy (n=5, allowing at 
least 80% power for 95% confidence intervals in half the biological effect we would expect to 
see(Pritchard et al., 1995, Li and Wilson, 1997),  based on power calculations of pilot data).  
Previous studies have shown there is no difference in vascularity in different areas of the 
lateral nasal wall(Philpott et al., 2005).  Control inferior turbinate specimens (CIT) were taken 
from patients undergoing routine septoplasty or septorhinoplasty (n=5).  Neither the control 
nor the polyp group had asthma, aspirin sensitivity or diagnosed allergies.  All polyp patients 
had been previously given oral or nasal corticosteroids in accordance with best clinical 
practice. None were on oral corticosteroids within two weeks of surgery. 
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6.2.1 Tissue Preparation 
Samples taken for confocal analysis were immediately fixed in 4% buffered formalin and left 
for 24 hours. Samples were then washed in 3 changes of phosphate buffered saline (PBS) for a 
further 24 hours before staining with 1:100 dilution of a fluorescein-conjugated lectin mixture 
(1:1:1 Ulex europeaus, Griffonia simplicifolia, Euonymus europeaus, Vector Labs) to account 
for different affinities associated with blood groups.(Capaldi et al., 1985)  Samples were then 
washed and stored in PBS until being viewed under a confocal  Leica DM IRE2 microscope.  
Vertical stacks of images (Z-stacks) were taken from multiple orientations, and single images 
measuring 1300 x 880 µm were taken from the same Z-stack separated by 50 µm.  These were 
analysed by standard point and intercept counts(Egginton et al., 1993) with a stereological grid 
using squares of 64 µm2.  Sample area, microvascular surface density (SV, the surface area of 
capillaries compared to volume of the sample) or volume density (VV, the total volume of 
capillaries compared to volume of the sample)  were calculated using standard stereological 
counting procedures (Egginton et al., 1993).  These were averaged for multiple levels in each 
Z stack and then averaged for different orientations of the same sample. 
6.2.2 Immunohistochemical Staining 
Samples taken for immunostaining were immediately snap frozen in liquid nitrogen-cooled 
isopentane (in theatre) and 8 µm sections cut on a cryostat.  Sections were allowed to air dry 
before being fixed in 4% buffered formalin for 20 min.  Antigen retrieval was performed in 
citrate buffer (10 mM citric acid adjusted to pH 6.0 with NaOH, 0.05% Tween 20) heated to 
95°C for 5 min then allowed to cool to room temperature.  Slides were then blocked for 30 
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min at room temperature in wash buffer (1.5% w/v BSA, 0.6% v/v Triton X-100 in PBS), then 
incubated for 2 hours with primary antibody (Ki-67, Dako) diluted 1:100 in wash buffer to 
label proliferating nuclei.  Sections were then washed in PBS and incubated for 1 hour with 
secondary antibody (TRITC polyclonal rabbit anti-mouse, Dako) diluted 1:100 in wash buffer.  
Sections were rinsed in PBS and then incubated for 30 min with the lectin mixture to stain 
blood vessels.  Sections were washed in PBS, rinsed with dH20 and mounted using 
Vectashield containing DAPI (4',6-diamidino-2-phenylindole) to label all nuclei, and a 
proliferation index calculated as (Ki-67 count / DAPI count) for capillaries, interstitium and 
the epithelial layer. 
 
Stained sections were viewed under fluorescent microscopy, with the number of blood vessels 
and nuclei in a 500 x 500 µm sample recorded.  Two samples were taken randomly from each 
patient.  Ki-67 staining was recorded as being either associated with blood vessels, or the 
interstitial space. 
 
6.2.3 Statistical analysis 
All data are presented as mean ± S.E.M. Statistical significance between groups was 
performed using factorial ANOVA with post-hoc comparisons among groups using a 5% 
significance level. A self-blinded researcher took all measurements. 
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6.3 Results 
6.3.1 Inferior turbinate samples 
Histological sections showed no overt differences in inferior turbinate samples from patients 
with polyposis (PIT) to those from control patients (CIT) (Figure 6.1).  Vessel density was not 
significantly different from control values of 35.2 ± 4.4 mm-2 (Figure 6.2).  Proliferation 
indices for capillaries (1.8 ± 0.4 x 10-3), the epithelium (9.9 ± 3.2 x 10-3) and the interstitium 
(76.3 ± 26.4 x 10-3) also showed no significant differences between inferior turbinate samples 
from the two groups (Figure 6.2, Table 6.I).  Confocal microscopy showed no differences in 
the morphology of the capillary bed (Figure 6.3, Table 6.2). 
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Figure 6.1 Lectin, Ki-67 and DAPI staining showing capillary density and sites of 
proliferation 
Panels show sections stained with a fluorescein-labelled lectin staining capillaries (A), 
rhodamine-labelled Ki-67 antibody staining proliferating nuclei (B), DAPI staining all nuclei 
(C), and an overlaid composite image (D) 
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Figure 6.2  Capillary Density and Proliferation Index  
Capillary density (Cap, black bars) and proliferation index (PI, white bars) are shown for 
inferior turbinates from control patients (CIT) and inferior turbinates (PIT) and polyps (P) 
from patients with nasal polyposis. Mean ± SEM (n=4). *P<0.05 vs. control 
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Figure 6.3 Morphological features of the capillary bed 
Extended focus (30µm), colour inverted images of the capillary bed from inferior turbinates 
from control patients (CIT) and inferior turbinates (PIT) and polyps (P) from patients with 
nasal polyposis stained with fluorescein-conjugated lectin. 
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Figure 6.4    
Comparison of mean 
capillary surface density vs  
 
 
 
 
 
 
Figure 6.5:  Comparison of mean capillary surface density vs capillary volume density 
Regression of vascular surface and volume densities across groups. SV = 0.006 + 0.177 * VV; 
R2 = 0.811 
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Table 6.1:    Proliferation indices for the epithelial and interstitial compartments 
 
Interstitial and epithelial proliferation indices are shown for inferior turbinates from control 
patients (CIT) and inferior turbinates (PIT) and polyps (P) from patients with nasal polyposis. 
Mean ± SEM (n=4). *P<0.05 vs. control 
 Interstitial proliferation 
index (x 103) 
Epithelial proliferation 
index (x 103) 
CIT 9.9 ± 3.2 76.3 ± 26.4 
PIT 13.9 ± 5.2 73.2 ± 31.3 
P 86.8 ± 20.8* 84.3 ± 22.2 
 
Table 6.2 : Stereological analysis of the capillary bed 
 
Capillary diameter, volume density (volume of capillaries per unit area of sample) and surface 
density (surface area of capillaries per unit area of sample) are shown for control patients 
(CIT) and inferior turbinates (PIT) and polyps (P) from patients with nasal polyposis. Mean ± 
SEM (n=4). *P<0.05 vs. control 
 
 Capillary Diameter 
(µm) 
Surface density (SV) 
(µm-1) 
Volume density (VV) 
CIT 12.4 ± 0.3 0.042 ± 0.003 0.184 ± 0.016 
PIT 13.0 ± 0.5 0.052 ± 0.014 0.243 ± 0.038 
P 16.5 ± 0.6 * 0.037 ± 0.010 0.189 ± 0.019 
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6.3.2 Polyp samples 
The vascular bed of the polyp was grossly different from the matched inferior turbinate 
sample, having distended vessels (Figure 6.1, Figure 6.3) with a greater mean diameter: 16.5 ± 
0.6 vs 12.4 ± 0.3µm in P vs CIT, respectively; P<0.05 (Table 6.2).  However, vessel density 
and capillary associated cellular proliferation, commonly accepted measures of angiogenesis 
(Hudlicka et al., 1992), showed no change from the levels seen in the inferior turbinate (Figure 
6.2), despite an increase in interstitial proliferation [86 ± 21 x 10-3 vs 99 ± 32 x 10-3 (Table 
6.1).  Proliferation in the epithelial layer was unchanged from controls (Table 6.1).  There was 
no significant difference in the polyp or matched inferior turbinate compared to control 
patients in either microvascular surface density (SV) or volume density (VV), although 
capillaries within polyps were dilated (Table 6.2). Importantly, the regression of volume 
density against surface density lies on the same line as that for the inferior turbinate samples, 
indicating no change in the architecture of the capillary bed (Figure 6.4). 
 
6.4 Discussion  
Angiogenesis is a complex process relying on a balance between pro- and anti- angiogenic 
factors, and can manifest in different ways in the same tissue.(Williams et al., 2006c)  As 
angiogenesis can be a heterogeneous process, any assay of angiogenesis in vivo must rely on 
the final outcome of angiogenesis, namely an expansion of the vascular bed.  This is uniquely 
difficult to perform in the nose, as the continuous cycle of congestion and decongestion makes 
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standard measures of capillary density difficult to interpret. 
 
Consequently, this study used polyp samples (P) with matched inferior turbinate (PIT) 
samples from the same side of the same patient, at the same time point.  These samples were 
also compared with inferior turbinate biopsies taken from healthy control patients (CIT), 
allowing comparison of polyps with both internal and external controls.  None of the patients 
included in this study suffered from asthma, allergies or aspirin sensitivity.  Airway 
remodelling in response to asthma and allergy may have angiogenesis or mucosal layer 
proliferation that is completely unrelated to the process of polyp formation (Watelet et al., 
2006, Homer and Elias, 2005), which would have potentially confounded our results.  Using a 
‘clean’ patient group without these conditions allows us to examine whether angiogenesis is 
part of the aetiology of polyposis, or merely occurring as part of a separate pathology.  
Multiple measures of angiogenesis (capillary density, capillary-associated cell proliferation, 
capillary surface- and volume density) were averaged from multiple images, taken from 
multiple orientations (for parameters measured by confocal microscopy) in order to overcome 
any potential analytical bias, and provide a definitive measurement of angiogenesis in nasal 
polyps. 
 
None of these parameters suggested that there was any abnormal or pathogenically active 
angiogenesis occurring in nasal polyps compared with either matched IT or healthy IT.  
Capillary density was almost constant between the three groups of samples, suggesting that 
whilst angiogenesis must be taking place to allow growth of the polyp, the angiogenesis is 
only sufficient to maintain the capillary density required for nasal mucosal integrity and 
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function. 
 
Capillary surface and volume density were similarly unchanged in the three groups, again 
showing that the angiogenesis seen in nasal polyposis results in a capillary bed with the same 
surface area and percentage volume as the normal mucosal network.  Moreover, the regression 
of individual surface densities versus volume densities (Figure 6.4) is adequately described by 
a single line for all groups.  Such a plot provides a way of measuring the overall architecture 
of the capillary bed.  If nasal polyposis were a condition dependent upon active angiogenesis, 
the capillary sprouts and smaller daughter capillaries would give the sample higher surface 
density for a given volume density, resulting in a steeper regression line for the polyp samples.  
In addition, a single sample exhibiting a change in capillary bed architecture would show as an 
outlier, which would obviously show any heterogeneity in angiogenic response.   
 
Sprouting angiogenesis requires proliferation of endothelial and perivascular cells to form new 
capillaries, therefore measurements of capillary-associated proliferation signals are often taken 
as an indirect measure of angiogenesis.  In this study, capillaries from nasal polyps showed no 
increase in proliferation from the very low values seen in either matched IT or healthy 
controls.  As mucosal epithelium has a high cell turnover rate this was used as a positive 
control, and also showed no significant change between our study groups (Table 6.1).  
Interestingly, interstitial proliferation (not associated with capillaries) was greatly increased in 
certain polyps, showing heterogeneity of cell division among samples. However, these highly 
proliferative polyps showed no increase in capillary-associated proliferation compared to other 
polyps (data not shown). 
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The initial hypothesis that angiogenesis is important in nasal polyposis was derived mainly 
from semi-quantitative immunohistochemical studies showing upregulation of VEGF,(Yang et 
al., 2002) MMPs,(Lechapt-Zalcman et al., 2001) bFGF (FGF-2),(Powers et al., 1998) and 
TGF-β(Elovic et al., 1994a) in nasal polyps compared to controls, with elevated bFGF also 
seen with a quantitative ELISA.(Norlander et al., 2001)  Whilst this evidence supports a role 
for angiogenesis, it is far from conclusive, especially as upregulation of different factors is 
only seen in a proportion of cases.  MMPs, bFGF and TGF-β have pleiotropic effects on 
various cell types,(Okada-Ban et al., 2000, Mott and Werb, 2004, Kim et al., 2005) and may 
well be important in the growth of the polyp itself.  Indeed, our results show a significant level 
of proliferation in the polyp.  However, the lack of active angiogenesis seen in this study 
suggests they are not acting to promote vessel growth over that required to support tissue 
expansion.  VEGF is far more specific for endothelial cells, however it is constitutively 
expressed and changes in VEGF levels do not necessarily correspond to changes in 
capillarity,(Gavin et al., 2005, Milkiewicz et al., 2004) given that angiogenesis is a regulated, 
multifactorial phenomenon.  VEGF can also have other effects: it was originally described as 
vascular permeability factor (VPF), and is 50 times more effective than histamine at dilating 
vessels.(Bates and Curry, 1997b)  The 33% increase in capillary diameter seen in this study, 
and the oedematous nature of polyps is likely to be at least partially a response to the observed 
levels of VEGF. However, a threshold level of VEGF is required to initiate 
angiogenesis,(Williams et al., 2006a) and the semi-quantitative measures used to examine 
VEGF expression in polyposis give no indication that this threshold has been reached. 
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The maintenance of a normal vascular density and shape in a growing structure clearly 
requires some degree of angiogenensis.  This, along with the angiogenesis seen in response to 
airway remodelling, may have lead to the hypothesis that angiogenesis is part of the 
pathogenesis of polyoposis. In nasal polyposis the rate of angiogenesis required to meet the 
physiological needs of the tissue is low and can be driven by metabolic or mechanical 
factors,(Hudlicka et al., 1992) rather than being an integral part of the pathology as it is in 
solid tumours, bowel polyps, psoriasis or retinopathy.  Therefore, treatment of nasal polyps 
with anti-angiogenic therapies may reduce symptoms, but will not provide an effective 
treatment for polyposis. 
 
6.5 Conclusion 
 No significant differences in capillary density, capillary-associated proliferation, capillary 
surface density or capillary volume density were seen between the three study groups, and the 
regression of surface density versus volume density described a linear relationship.  Polyp 
samples showed increases in capillary diameter and interstitial proliferation. 
These results show no active angiogenesis occurring in the polyp, or changes in capillary bed 
architecture, although capillaries seem more oedematous in the polyp.  As the capillary supply 
increases in line with the physiological needs of the growing polyp, we conclude that 
angiogenesis is not a driving force in the aetiology of nasal polyposis. 
 
This study examined capillary density, capillary-associated proliferation, and capillary bed 
morphology in nasal polyps and control tissue.  None of these common measures of 
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angiogenesis have shown any difference between nasal polyps, matched inferior turbinate or 
control inferior turbinate samples.  Thus, we conclude that angiogenesis is not a driving force 
in the aetiology of nasal polyposis, and research for an effective treatment should focus 
elsewhere. 
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CHAPTER 7 
GENE EXPRESSION IN NASAL POLYPS 
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7 Gene expression in nasal polyps 
In the work described in chapter 6 it became evident that angiogenesis is not the driving force 
in the aetiology of nasal polyposis.  However, there remains a body of evidence that supports 
high levels of pro-angiogenic factors in nasal polyps with other authors having specifically 
identified higher levels of vascular endothelial growth factor (VEGF) – commonly thought to 
be the most important growth factor in angiogenesis  (Ferrara, 2002, Ito et al., 1995b, Yang et 
al., 1998a, Coste et al., 2000a).  However, this compound has multiple roles such as increasing 
vessel permeability (originally called Vascular Permeability Factor (Senger et al., 1983); and 
vasodilatation (Georgi et al., 2011).  To investigate further the evidence for angiogenesis in 
nasal polyposis experiments were designed to look at gene expression, specifically 
investigating for known inflammatory and pro and anti angiogenic genes.  There are different 
methods for screening for unknown genes that change their expression pattern, such as 2D 
protein gels, multiplex beads and mass spectrometry.  They all have their own advantages but 
the simplest and fastest method is using gene microarrays, allowing insight into the potential 
biological response available by transcriptional regulation.  A targeted microarray gene chip 
system was used containing 850 of the most common inflammatory, angiogenic and neoplastic 
genes.  The study design was meticulous in having carefully selected internally matched 
samples with polyp and inferior turbinate specimens from the same patient from the ipsilateral 
nasal cavity compared with control inferior turbinate mucosa from patients without polyposis.  
None of the patients had a history of asthma or aspirin sensitivity as both are known to affect 
polyposis (Drake-Lee, 1987, Parikh et al., 2002).  RNA was extracted from the tissue and 
converted to cDNA which was then used for the analysis.   
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7.1 Study Design  
Nasal polyp and inferior turbinate biopsies were taken from each side of patients with bilateral 
polyposis, with the ipsilateral inferior turbinate acting as an internal control. Inferior turbinate 
samples were also taken from patients with no asthma or allergy undergoing routine 
septorhinoplasty, as an external control.  Polyp patients with a history of asthma and/or 
allergy, or Samter’s triad were excluded.  These same groups were used for the microarray, 
microfluidics and the luminex experiments. N=5 in each of the 3 groups. 
 
 
  
 
 
 
143 
7.2 cDNA production 
 
A large polyp and control inferior turbinate biopsy was homogenised and RNA extracted by 
TRIzol (see Methods).  The purity of the RNA was confirmed using Beta actin on an agarose 
gel  (Figure 7.1) The quality of the cDNA was analysed by Northern blot after end-point 
primer amplification Figure 7.1 
 
A variety of methods were attempted to get good-quality cDNA for analysis.  Three different 
kits were used:  Sensiscript reverse transcription (Sens), High capacity cDNA reverse 
transcriptase(HC) and Superscript reverse transcription as a control (Sup). 
Sens and HC were tested with random hexamers (H) and oligo d(T) primers and a 
combination of the two (HT).   
 
RNA was redissolved in 25 µl ddH2O, the RNA concentration was measured using a 
biophotometer (Eppendorf) and was found to be 1147µg/ml, which is 1147ng/µl. 
2µl (2294ng) of this RNA solution was used in each RT reaction.  Amplification of cDNA 
(see Methods) was performed on 1µl aliquots of Sens/HT, HC/HT and Sup (Sens/HT/Amp, 
HC/HT/Amp, Sup/Amp). 
 
RT reaction products were purified using Qiaquick PCR purification kit before having their 
concentration measured using a biophotometer (eppendorf) (Table 7.1).  5µl aliquots were 
then run on a denaturing agarose gel (see Methods) and densitometrically analysed.   
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Figure 7.1 Agarose gel for Beta actin  
 
     
        Reference band   Control     Polyp 
 
 
      
 
Beta Actin 
(284 bps) 
150 bps 
500 bps 
750 bps 
300 bps 
1000 bps 
1500 bps 
2000 bps 
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Table 7.1: cDNA Production 
Sensiscript reverse transcription (Sens), High capacity cDNA reverse transcriptase(HC) and 
Superscript reverse transcription as a control (Sup). 
Sens and HC were tested with random hexamers (H) and oligo d(T) primers and a 
combination of the two (HT).   
(Amp) is amplification using the Qiagen amplification kit. 
 
Sample ssDNA (µl/ml) 
Sens/T 26.6 
Sens/H 22.4 
Sens/HT 15.6 
HC/T 36.8 
HC/H 38.8 
HC/HT 23.9 
Sup 15.6 
Sens/HT/Amp 3.9 
HC/HT/Amp 4.7 
Sup/HT/Amp 76.4 
 
As cDNA concentration gives a crude measure of how much PCR product has been obtained, 
the size and purity of the PCR products were assessed by running 5µl aliquots on a denaturing 
agarose gel (see Methods) and densitometrically analysing the results. 
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Figure 7.2 Native electrophoresis gel – Total cDNA from primer amplification in Table 7.1 
 
 
All the different methods of reverse transcription yielded bands at roughly the same point on 
the agarose gel, indicating that the PCR products obtained were of similar size, so there was 
little difference in cDNA fragment length with the different methods of cDNA synthesis.  
There was a good correlation between relative cDNA concentration measured 
densitometrically from the gel, and cDNA concentration measured photometrically. 
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Figure 7.3: Comparison of cDNA concentration  
 
Figure 7.4: Gel densitometry vs. Photometry  
 
Gel densitometry is a way of measuring the relative density of the electrophoresis bands.   
Photometry is from cDNA samples loaded giving a measure of sample concentration before 
electrophoresis.  The graph confirms fairly good correlation. 
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7.2.1 Primer efficiency test 
The quality of cDNA was assessed by measuring how well the samples amplified TGF-beta 
primers (known to be found in nasal polyps (Guo et al., 2001a, Ahn, 2001, Elovic et al., 
1994b)).  This was done using end-point primer amplification (see Methods), with PCR 
products purified using the Qiaquick PCR purification kit.  Samples were run on a denaturing 
electrophoresis gel to check product size and band integrity. 
 
 
Figure 7.5: Denaturing electrophoresis gel – TGF beta 
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Table 7.2:  TGF-Beta densitometry yield 
Sensiscript reverse transcription (Sens), High capacity cDNA reverse transcriptase(HC) and 
Superscript reverse transcription as a control (Sup). 
Sens and HC were tested with random hexamers (H) and oligo d(T) primers and a 
combination of the two (HT).   
(Amp) is amplification using the Qiagen amplification kit. 
 
 
 
 
On the basis of these results Sens/HT, HC/T, HC/HT and Sup/HT/Amp were run on a 
microfluidics card.   
 
 
Sample 
TGF-beta 
Densitometry 
Sens/T 6403 
Sens/H 6940 
Sens/HT 8201 
HC/T 4927 
HC/H 847 
HC/HT 5260 
Sup 4240 
Sens/HT/Amp 6982 
HC/HT/Amp 4830 
Sup/HT/Amp 7023 
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7.3 Gene Microarray  
Gene microarrays: 
RNA was extracted from samples using the TRIZOL method.  1st strand synthesis was 
performed using the SMART system kit with PCR product clean up.  For the gene arrays, 
DNA was dye-labelled using a cyanine dye and spotted on the arrays.  Positive control gene 
values were obtained from human buffy coat fraction.  
 
Raw data is in 1 vs 1 list.  Primary component analysis (PCA) plots are measures of similarity 
to the overall mean of all the samples.  The groups are different colours with CIT blue, PIT 
green and P red.  The x-axis represents 90% of the variability, with the y-axis showing 90% of 
the remaining, and the z the final.  This is basically to give a visual separation akin to a 
logarithmic scale. 
 
We used Significance of Analysis of Microarrays (SAM, Stanford) and Prediction Analysis of 
Microarrays (PAM, Stanford) statistical analysis software packages.  PAM is a technique for 
class prediction from gene expression data using nearest shrunken centroids (Tibshirani et al., 
2002).  The method of nearest shrunken centroids identifies subsets of genes that best 
characterise each class.  
 
From the data we produced Lorenz plots and cluster heatmaps of the data.  
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Figure 7.6: Primary Component Analysis plots angle 1.  The groups are different colours 
with CIT blue, PIT green and P red 
  
 
 
 
152 
 
 
Figure 7.7: Primary Component Analysis plots angle 2.  The groups are different colours 
with CIT blue, PIT green and P red 
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Figure 7.8:  Primary Component Analysis plots angle 3.  The groups are different colours 
with CIT blue, PIT green and P red 
 
 
Approximate clustering hints that they are fairly distinct, but there is a definite inter-patient 
variability, as one would expect.  A Lorenz plot was drawn to analyse how the samples 
grouped together.  
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Figure 7.9: Lorenz plot – measure of cluster 
 
 
 
The peak in delta area at 3 clusters confirms that the samples group into 3 and confirms 
quality of the samples used in the gene array.  
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Figure 7.10: Cluster heatmap of predictive analysis of the gene array data. 
 
 
 
This demonstrates that the samples from the 3 groups in the gene array (P, PIT and CIT) all 
cluster separately confirming the quality of our samples and data suggesting a single 
mechanism for polyposis as the clusters are fairly tight.  
It is not possible to determine which group is which.  
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Table 7.3:  PAM analysis showing genes above threshold in order of the highest 
magnitude of change in the three groups from microarray data. 
 
 
P vs PIT 
 
P vs CIT CIT vs PIT 
iNOS 
 
iNOS TACSTD2 
iNOS 
 
IRS2 TACSTD2 
iNOS 
 
PARC TRA1 
PARC 
 
EMP3 RPS3A 
TACSTD2 
 
TNFRSF21 HSPCA 
TP53 
  
VDAC1 
VDAC1 
 
Beta-
2_Microglobulin VDAC2 
IFNAR1 
 
PRKCA CYC1 
TNFRSF14 PARC HLA-A_0201 
TERF2IP 
 
EP300 FKSG2 
RBL2 
 
IAP-1 GALECTIN_3 
IL-1_R_antagonist CLU HLA-A_0201 
PDCD6 
 
L19 NSMAF 
Transferin_R CBLB TRANK 
PARC 
 
CLU RbAp48 
IAP-1 
 
FRACTALKINE PIG7 
TACSTD2 
 
IGF1 TRA1 
 
 
 
 
 
 
 
 
The repeats are different spots and should be seen several times above our (arbitrary and 
semi-quantitative) threshold level 
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Figure 7.11: 
Stanfords’s 
standard analysis of 
microarrays (SAM) 
and predictive 
analysis of 
microarrays (PAM) 
of  
CIT v PIT 
Key to gene colours 
 
Black = unchanged  
Red = PIT downregulated  
Green = PIT upregulated 
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Figure 7.12: 
Stanfords’s 
standard analysis of 
microarrays (SAM) 
and predictive 
analysis of 
microarrays (PAM) 
of  
PIT v Polyp 
Key to gene colours 
 
Black = unchanged  
Red = Polyp downregulated  
Green = Polyp upregulated 
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Figures 7.11 and 7.12 are graphical representations of changes in gene expression between 
inferior turbinates from control patients (CIT) and inferior turbinates (PIT) with matched 
polyps from patients with nasal polyposis. Genes are shown more green where the expression 
is higher in the second named group, more red where the expression is lower, and black where 
no change is detected. 
 
There were significant differences between all sample groups, however there was a greater 
difference between the control and polyp patient inferior turbinate tissue than there was 
between the polyp patient inferior turbinate and the matched polyps. The greatest changes 
were seen in genes associated with cell cycle control, apoptosis, cell signalling, inflammation, 
and tissue remodelling. The greatest change between the polyp tissue and matched inferior 
turbinate tissue was in the level of inducible nitric oxide synthase (iNOS, NOS2) (See Tables 
7.4 and 7.5). 
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Table 7.4: From the PAM  analysis (Table 7.3) we identified genes that showed the most 
change, listed in order of magnitude - PIT v Polyp group.  
 
Changed in  
Polyp Name Other Names 
    
iNOS   iNOS/NOS2 
PARC   
CKb7; PARC; AMAC1; DCCK1; MIP-4; 
AMAC-1; DC-CK1; SCYA18 
PDCD6  Programmed cell death 6 ALG-2; MGC9123 
TNFRSF14   LTg; TR2; HVEML; LIGHT 
SREBF2  
Sterol regulatory element binding 
transcription factor 2 SREBP2 
TP53   P53; p53; TRP53 
MadCAM-1   CD34 
REELIN    
AKT3     
AKT3    
CAD-8   CDH8 
CXCR-4   
HM89; LAP3; NPYR; WHIM; LESTR; 
NPY3R; fusin; HSY3RR; NPYY3R; 
D2S201E 
HCC-4   
LEC; LMC; NCC4; CKb12; HCC-4; 
LCC-1; Mtn-1; NCC-4; SCYL4; 
ILINCK; SCYA16; CCL16 
IGFBP4  
Insulin-like growth factor binding 
protein 4  
ILF1  Interleukin enhancer binding factor 1 FOXK 
TNFRSF21   DR6; BM-018 
BAK1  BCL2-antagonist/killer 1 BAK; CDN1; BCL2L7 
BNIP2  
BCL2/adenovirus E1B 19kD 
interacting protein 2 NIP2; BNIP-2 
CDC2   CDK1 
C-MET    HGFR; RCCP2 
C-MYC    
EphA_4    
EphrinB_2    
IRS2     
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Table 7.5: From the PAM  analysis (table 7.3) we identified genes that showed the most 
change, listed in order of magnitude – CIT v PIT group. 
    
Changed in PIT  Name Other Names 
   
EMP3  Epithelial membrane protein 3 YMP 
HLA-A_0201   HLA-A 
MPL_R   MPLV; TPOR; C-MPL; CD110 
PRKCA   PKCA 
PTPN13  
Protein tyrosine phosphatase, non-
receptor type 13 (APO-1/CD95 (Fas)-
associated phosphatase) 
PNP1; FAP-1; PTP1E; PTPL1; PTPLE; 
PTP-BL; PTP-BAS 
Beta-2_Microglobulin B2M 
FRACTALKIN
E   
NTN; NTT; CXC3; CXC3C; SCYD1; 
ABCD-3; C3Xkine 
GMF-beta  Glia maturation factor beta  
TRANK  ?see PRDX4 AOE37-2 
CLU  
Clusterin (complement lysis inhibitor, 
SP-40,40, sulfated glycoprotein 2, 
testosterone-repressed pro 
CLI; APOJ; SGP2; SGP-2; SP-40; 
TRPM2; TRPM-2 
ENA-78   ENA78; SCYB5; ENA-78; CXCL5 
NAIP   BIRC1 
TNFSF6   FAS; APT1; CD95; APO-1; FASTM 
GALECTIN_3   
GAL3; MAC2; CBP35; GALBP; 
LGALS2; LGALS3 
HSPCA   
HSPN; LAP2; HSP86; HSPC1; 
Hsp89Hsp90; HSP90A; HSPCAL1; 
FLJ31884 
L19   RPL19 
PRDX4   AOE37-2 
RPL7   RPL7 
SRP72  Signal recognition particle 72kD  
TRA1  Tumor rejection antigen (gp96) 1 ECGP; GP96; GRP94 
BAG5  BCL2-associated athanogene 5 BAG-5; KIAA0873 
BECN1  Beclin 1 (coiled-coil, myosin-like BCL2 interacting protein) 
Cyclophilin_A   CYPA; CYPH 
DAP13  
13kDa differentiation-associated 
protein NDUFA12 
DAP3  Death associated protein 3 DAP-3; MRPS29; MRP-S29; bMRP-10 
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7.4 Microfluidics 
 
Multiplex, real-time PCR (RT-PCR) is a powerful tool that enables simultaneous 
quantification of control and target genes in the same reaction. The technique not only allows 
reliable normalization of target gene levels, but also conserves sample material.  
 
In real-time PCR, labelled nucleotides are attached to a quenching molecule that gets detached 
when the nucleotide is incorporated into RNA, releasing the fluorescent label.  Thus, the more 
RNA there is in a sample, the greater the fluorescence in the well.  This initially increases 
exponentially as each new copy gets replicated along with the existing copies.  A threshold 
value is either manually chosen, or generated by the software, and the cycle number where the 
curve crosses this value is called the threshold cycle, or CT.  Comparison of expression 
profiles of genes passing CT allows quantitation relative to an endogenous control.  The 
difference between the CT value of the sample, and that of the reference is called the Δ CT.  Δ 
CT is directly proportional to number of copies of mRNA in the original sample. 
 
The first analysis used computer-generated CT values, compared to CT for the 18S RNA 
control on the array.  This was cleaned up with all blank values deleted, then put into Statview.  
Unfortunately, Statview was unable to handle this much data, so genes were split into 6 
families, and an ANOVA performed using a Bonferroni correction with an alpha value 
calculated from the Bonferroni equation.  There were no statistically significant results.  Other 
post-hoc ANOVA tests, such as Scheffe’s also gave no significant result.  
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Figure 7.13: Curves of fluorescence vs cycle number – RT- PCR 
 
Real-time quantitative PCR data from microfluidics 
Panel shows the raw data from a 96-gene custom-made microfluidics card, showing PCR 
cycle number (x-axis) vs fluorescence intensity (y-axis). The copy number of each gene 
increases with each PCR cycle, and this increases the fluorescence in the corresponding well. 
The earlier the cycle at which the fluorescence hits a threshold level, the greater the number 
of copies of the gene in the original sample. 
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The genes with the greatest magnitude of change in the gene array (iNOS, TNF, IL-5) were 
given manual CT thresholds and reanalysed using t-tests.  This confirmed a trend with a P 
value of < 0.1 but again not being statistically significant. 
 
The software supplied with the PCR machine can also generate “Average Δ CT values” which 
can calculate a Δ CT value by extrapolating curves, and thus generate information where a 
clear curve crossing a threshold value is difficult to obtain. 
 
The data was analysed using both techniques described above, with very similar non-
significant results. 
 
As the 18S RNA results could have been the problem, all the CT values were taken, and the 
data for each plate averaged, and this was used as the control (centroids technique).  Data was 
analysed as before, with much the same results. 
 
Finally, the data was put through Stanford’s significance of microarrays software (SAM), 
which we used for the gene arrays.  These gave similar non-significant results despite the 
samples all being paired with the microarrays. 
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7.5 Discussion  
The gene array SAM and PAM analysis (Figures 7.11 and 7.12) showed more green coloured 
squares in figure 7.11 (CIT vs. PIT) than Figure 7.12 (PIT vs. Polyp), indicating that polyposis 
is a more global phenomenon affecting the mucosa with some additional changes causing 
polyposis. This in part is expected, as the PIT and CIT are different patients whereas the gene 
changes detected between PIT and Polyp are within the same patient with the gene changes 
representing the change mucosa over the inferior turbinate to nasal polyp just a centimetre or 
so away in the ipsilateral nasal cavity.  The CIT vs. PIT analysis showed changes with greatest 
magnitude in genes associated with cell cycle control, apoptosis, cell signalling, inflammation 
and tissue remodelling.  The PIT vs. Polyp analysis showed changes in similar families of 
genes, however, the largest change seen was in the gene for iNOS.   
 
This changes the view that nasal polyposis is an angiogenic driven disease.  
 
This data were then used to design a microfluidics array to measure the changes in gene 
expression, in order to quantitatively validate the broader perspective given by the 
microarrays. 
 
The lack of significance of any difference in the common angiogenesis genes in the 
microarray may be due to biological variability (inter-patient variance) or confounding issues: 
age, gender, other morbidities.
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CHAPTER 8 
 
PROTEOMICS 
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8 Proteomics  
8.1 Method development:  TRIZOL protocol 
 
TRIZOL reagent allows simultaneous extraction of RNA, DNA and protein from the same 
samples, however the traditional method (recommended by the manufacturer) of extracting 
protein then redissolving with 1% SDS is very inefficient, and leaves traces of SDS that may 
interfere with subsequent analysis.  Redissolving proteins with 9.5M Urea with 2% CHAPS 
([3-[(3-cholamidepropyl)-dimethylammonio] propane sulfonate]) has been reported to greatly 
improve the both quantity of protein recovered and number of proteins detectable by SELDI 
(Surface Enhanced Laser Desorption/ Ionization) analysis, compared to 1% SDS, 10% 
acetonitrile, and 1% Triton X-100 (Man et al., 2006).  Precipitating the protein using acetone 
rather than isopropyl alcohol increases protein recovery by about 15% according to the 
manufacturer of a similar product (http://www.mrcgene.com/tri.htm), however this has not 
been shown with TRIZOL reagent.  A comparison of acetone and isopropyl alcohol was 
therefore performed on 2 equal aliquots (100µl) of the same sample with resuspension in 
urea/CHAPS, repeated once.   
 
    1st Sample  2nd Sample 
Isopropyl alcohol  0.341   0.354 
Acetone   0.385   0.367 
Table 8.1:  Comparison of acetone and isopropyl alcohol    
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After resuspension, protein content was measured using the DC compatible protein 
measurement kit, which is based on the Lowry protein assay (Lowry et al., 1951) and is not 
affected by low concentrations of SDS.   
 
Absorbances were higher for acetone extraction, indicating that a greater quantity of protein 
was extracted by this method, although if we assume a linear relationship between absorbance 
and protein concentration, the protein recovery is only increased by 8%. 
 
8.2 ELISA 
In preparation for proteomic studies I have extracted protein and created a VEGF ELISA 
standard curve.   
ELISA STANDARD CURVE
y = 0.1226x + 0.2227
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8.3 Luminex 
Gene expression data will provide a snapshot of the pathological response, identifying 
pathways with potentially altered activity. However, there may be post-transcriptional 
modification of signalling pathways that may not be adequately identified using just this 
approach. We therefore also needed to examine the gene product, i.e. quantify protein levels 
within biopsies. The Luminex system measures water-soluble proteins, typically cytokines and 
growth factors.  We used a custom array with 34 cytokines: 
 
8.3.1 Results: 
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Statistically significant results:  
(i) IP-10 (CXCL10) upregulated in both polyps and PIT  
(ii) MCP-1 
(iii) Eotaxin & RANTES  
(iv) IL-2R – 
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8.4 iNOS Enzyme Linked Immunosorbent Assay (ELISA) 
The gene array analysis demonstrated that the greatest magnitude of change between Polyp 
and inferior turbinate from the same patient was in the gene for iNOS which is upregulated in 
polyps.   This was not commercially available in a microfluidics card so we used an iNOS 
ELISA  (see methods chapter).   Total protein was extracted from polyps and inferior 
turbinates.  The protein was measured and loaded equally into ELISA.  The samples were run 
in duplicate with A450 background correction, quantified against a ladder of known 
concentrations.  Diluted protein was re-assayed and A650 background was used.   
Absorbances were corrected diluted for small protein loading differences.   
 
 
Figure 8.1   Inducible Nitric Oxide Synthase ELISA 
Units of iNOS per mg of protein are shown for inferior turbinates from control patients (CIT) 
and inferior turbinates (PIT) and polyps (P) from patients with nasal polyposis. Mean ± SEM 
(n=4). *P<0.05 vs. control 
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8.5 Discussion 
Quantitative PCR broadly confimed the results of the gene array, with changes in genes 
involved in cell cycle control, apoptosis, cell signalling and inflammation, although greater 
patient numbers are needed for good statistical significance. Examination of protein 
concentration of iNOS with ELISA confirmed a clear and significant upregulation of iNOS in 
polyp tissue.  Gene microarrays show differences in a number of genes involved in cell cycle   
progression and apoptosis.  We have previously shown an increase in cell proliferation in 
nasal polyps (Chapter 6 (Ahmed et al., 2008)), but the slow, chronic growth of nasal polyps 
suggests that this growth must be tempered by other factors. The luminex data shows 
significantly higher levels of genes involved in chemoattraction of eosinophils and 
macrophages.  Specific cytokines identified incude Eotaxin and RANTES, which are both 
chemoattractant cytokines for macrophages and eosinophils.  Both have been identified in 
higher concentration in nasal polyps (Chao et al., 2012, Shin et al., 2000) with a suggestion of 
a possible involvement in eosinophil activation.  Similarly, IP-10 (CXCL10) is also 
upregulated in both polyps and PIT.  This is a chemoattractant for macrophages & monocytes, 
and reported to be pro-angiogenic (Morelli et al., 2011).  MCP-1 is a macrophage 
chemoattractant and IL-2R – Inerleukin 2 receptor is involved in signalling and T cell 
proliferation.  
 
Growth factors (HGF, VEGF) appear to be upregulated, but these results are non-significant. 
iNOS protein is highly upregulated in polyps. 
These changes between the polyp and PIT may point to the mechanism by which polyps are 
formed.
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CHAPTER 9 
APOPTOSIS IN NASAL POLYPS 
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9 Apoptosis in nasal polyps 
9.1.1 Introduction: 
Nasal polyps are oedematous, semi translucent, benign masses that develop from the mucosal 
linings of the paranasal cavity, usually originating from the mucosa in the osteomeatal 
complex(Larsen and Tos, 2004).  Nasal polyposis is a heterogenous condition associated with 
chronic sinus inflammation, allergy and asthma.  A proportion of patients with asthma have 
Samter’s triad where they have aspirin (or salicylate) hypersensitivity as well as asthma and 
nasal polyps(Samter and Beers, 1968, Bateman et al., 2003, Caplin et al., 1971a).  The 
aetiology and pathogenesis of nasal polyposis are far from clear, with suggestions of them 
being adenoma formations(Billroth, 1885), arising from inflammation(Bachert et al., 2000a, 
Jenkins, 1932), oedema(Krajina, 1963) or epithelial rupture(Tos, 1990).  Recently, a number 
of studies have proposed a role for angiogenesis(Caye-Thomasen et al., 2004, Ito et al., 1995a, 
Yang et al., 1998b, Coste et al., 2000b) with polyps having a higher rate of cell proliferation 
and tissue remodelling than normal nasal tissue.  We have previously shown an increase in cell 
proliferation in nasal polyps (Chapter 6 (Ahmed et al., 2008)) and the aim of this study was to 
examine whether the conditions of asthma, allergy or aspirin sensitivity cause more active 
nasal polyposis and to what extent.   
 
9.1.2 Methods: 
Nasal polyp and inferior turbinate biopsies were taken from each side of patients with bilateral 
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polyposis. Inferior turbinate samples were also taken from patients with no asthma or allergy 
undergoing routine septorhinoplasty, as an external control.  Polyp patients with a history of 
asthma and/or allergy, or Samter’s triad were grouped accordingly.  Frozen sections were 
TUNEL stained to label apoptotic cells, and parallel sections stained for Ki-67 to label 
proliferating nuclei. 
 
         
Sample Groups 
P+ 
Polyp 
      Patients with  nasal 
allergies and/ or 
asthma, and/ or 
aspirin sensitivity  
 
PIT+ 
Inferior Turbinate  
from Polyp Pt 
 
Patients with no asthma,  
aspirin sensitivity  
or history of  allergy 
P 
Polyp 
PIT 
Inferior Turbinate  
from Polyp Pt 
CIT 
Control Inferior Turbinate 
 
Table 9.1: experimental design (n=5 per group). 
 
9.1.3 Results:  
Patients with a history of allergy and/or asthma had significantly higher apoptotic indices than 
patients with neither.  There appeared to be an additive effect of asthma and allergy with more 
apoptosis occurring in patients with both or Samter’s triad compared to patients with one 
condition only.  Proliferation was higher in patients with asthma and/or allergy than in patients 
with neither. 
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Figure 9.1: Apoptosis ratio in different patient groups.  
 
 
Patient Group Apoptosis Ratio +/- SD 
CIT 0.0094 0.0060 
PIT 0.0213 0.0179 
PIT+ 0.0733  0.0488 
P 0.1698  0.0422 
P+ 03086 0.0954 
Table 9.2: Apoptosis ratios  
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9.1.4 Discussion: 
Patient recruitment for this study was over slow, over an eighteen-month period, due to the 
serendipitous nature of the operating lists and the individual numbers of patients in each 
subgroup was low.  The degree of apoptosis was greatest in polyps of patients with Samters 
triad and or allergy, and then in patients with polyps but no allergy, asthma or aspirin 
sensitivity.  In the inferior turbinate group the apoptosis ratio was highest in the group with 
aspirin sensitivity, asthma and or allergy and lowest in the control.  The standard deviations 
are wide but there is a definite trend.  If one tried to quantify the degree of inflammation 
present in each of the tissue groups tit is likely that they would be ordered in the same manor 
from the least inflammation in the control inferior turbinate (CIT) then in the PIT.  A patient 
with nasal polyposis with allergy, asthma or aspirin sensitivity would be expected to have 
more inflammation than the PIT but less than a frank nasal polyp.  Finally a polyp from a 
patient with Samter’s triad would have the greatest degree of inflammation so the results seem 
to agree with the clinical and histopathological findings. 
 
This study shows that having a history of asthma, allergy or aspirin sensitivity leads to more 
cell proliferation and apoptosis in nasal polyposis, and thus greater cell turnover. Both asthma 
and allergy increase the cell turnover, and the effect is additive, suggesting different 
mechanisms.  Further studies will ascertain to what extent apoptosis and cell turnover occurs 
with asthma, allergy and aspirin sensitivity. 
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10 General Discussion 
As with many clinical trials there are issues with Ethical Approval, patient recruitment, 
funding and disease prevalence.  We also relied on the serendipity of operating theatre lists 
containing the patient groups that we were investing.  This led to severe delays in gathering 
data for the proposed initial studies for a number of years. Given the additional complications 
of conducting research on a part-time basis whilst also handing a full clinical workload, and 
moving jobs every six months, it was thought to be pragmatic to refine the analytical 
techniques using material previously collected and immediately available.  Although on 
skeletal muscle, this allowed me to develop proficiency with histochemical procedures and 
analytical approaches. In the first experimental chapter (Chapter 3) we measured capillarity in 
physiological adaptation.  We refined the lectin staining technique to using Ulex europeaus 
agglutin II instead of UEA-I as it seemed to give greater staining and we used a novel 
technique of capillary domains to calculate capillarity.  We conclude that the capillary supply 
to human skeletal muscle is scaled according to fibre size and is relatively independent of fibre 
type.   
 
The second experimental chapter looked at measuring capillary supply in pathological 
adaptation in muscle atrophy hypertrophy and we also conducted a meta-analysis of the 
available literature.  We reaffirmed our previous experiments but this time in pathological 
muscle hypertrophy and atrophy with what seems to be a decoupling of angiogenesis from 
metabolic demand, so capillarity is mainly dependant on fibre size not fibre type, suggesting 
that the preponderance of angiogenesis-based diseases may be dependent on the tissue 
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involved. 
 
When sufficient clinical samples were available we were able to begin refining the 
immunohistochemical techniques.  In chapter 5 we developed a novel triple stain to examine 
remodelling using a 1:1:1 mixture of 3 lectins with Ki67 and DAPI, to assess the endothelium, 
degree of proliferation and nuclei all within the same section.  This novel and robust method 
for analysing the capillary bed and the extent of cellular proliferation in unfixed samples of 
human respiratory mucosa enabled us to further assess vascular remodeling the nose.  
  
The literature on the aetiology of nasal polyposis was lacking with many studies having poor 
patient selection or being inadequately designed. Our study was the first to robustly assess the 
condition, and specifically answer the question as to whether angiogenesis was the driving 
force behind nasal polyposis.  For the first time we were able to categorically refute the 
common belief of angiogenesis-driven polyposis. 
 
There was still a large body of evidence that supported high levels of pro-angiogenic factors 
so we carried out a gene array.  Gene microarray analysis shows upregulation of genes 
controlling the cell cycle and apoptosis, suggesting cell turnover is an important part of the 
pathogenesis of nasal polyps. This gene expression data was confirmed by TUNEL staining of 
cryosections, indicating an increased level of apoptosis in nasal polyp tissue, counterbalancing 
the increased cell proliferation.  Inflammatory genes are also upregulated, however the data 
collected so far cannot distinguish between different types of inflammatory response, which 
means further research is necessary to elucidate the causal agents of nasal polyposis.  A broad-
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spectrum analysis of gene expression shows that there are greater differences between the 
inferior turbinate of the polyp patients and controls than between inferior turbinates and 
polyps of the same patients, implying that polyposis is primarily a disease of the whole nose 
rather than a local phenomenon. Both mRNA and protein expression of iNOS show a clear 
increase in nasal polyps, suggesting that iNOS has an important role in changing the whole 
nose disease into growing polyps. 
 
We carried out proteiomic studies using the luminex system but this did not clarify the 
situation despite using matched samples that were used in the gene array.  They highlight the 
protein differences occurring in the polyps themselves.  We have shown chemoattractants for 
eosinophils & macrophages (which are found in polyps), and significantly in iNOS, which is 
novel. 
 
We have not shown significant results in the growth factors, specifically VEGF, sseen by other 
researchers, although the trends seem to be in the same direction.  We have also seen an 
increase in apoptosis, indicating that cell turnover in the polyps is high, and the impact of 
growth factors reported by other researchers may be less important than has been suggested. 
 
Future directions would be to carry out similar genomic and proteomic analyses on further 
subgroups of patients; not only patients with nasal polyposis but also with asthma and allergic 
rhinitis, to further unravel the complex mechanisms that contribute to these common clinical 
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conditions.  Nitric Oxide levels in the nose have been correlated with a number of nasal 
conditions and are currently used clinically in some tertiary hospital departments.  Further 
investigation into our finding of high levels of iNOS is also very worthy of further research.  
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11 Abbreviations  
APS Ammonium persulphate 
bFGF Basic fibroblast growth factor 
BSA Bovine serum albumin 
CAF Capillary around fibre 
CPA CAF per fibre area, normalized derivative of CAF 
C:F Capillary to fibre ratio 
Ca(NO3)2 Calcium nitrate 
CD Capillary density 
CF Cystic fibrosis 
CHAPS [3-[(3-cholamidepropyl)-dimethylammonio] propane sulfonate 
CIT Control inferior turbinate 
CRS Chronic rhinosinusitis 
CT Computed tomography 
DAB Diaminobenzidine 
DAPI 4',6-diamidino-2-phenylindole 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
ECM Extra cellular matrix  
EPC Endothelial precursor cells 
eNOS/NOS3 Endothelial nitric oxide synthases 
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FGF Fibroblast growth factor 
FBS Fetal bovine serum 
iNOS/ NOS2 Inducible nitric oxide synthase 
IT Inferior turbinate 
KH2PO4 Potassium dihydrogen orthophosphate  
LCD Local capillary density 
LCFR Local capillary to fibre ratio 
MAP Mitogen-activated protein 
MCP-1 Macrophage chemoattractant  
MMPs Matrix metalloproteinases 
Na2HPO4 Di-sodium hydrogen orthophosphate 
NaBO2 Sodium metaborate 
NaDOC, Sodium deoxycholate 
NBT Nitro blue tetrazolium 
nNOS/ NOS1 Neuronal nitric oxide synthases 
NO Nitric Oxide  
NOS Nitric oxide synthases 
NSAID Non steroidal inflammatory drug 
NSS Normal sheep serum 
P Polyp 
PAM Predictive  analysis of microarrays 
PBS Phosphate buffered saline 
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PCA Primary component analysis 
PCD Primary ciliary dyskinesia 
PCNA Proliferating cell nuclear antigen 
PDGF Platelet derived growth factor 
PIC Proteinase inhibitor cocktail 
PIT Ipsilateral inferior turbinate 
PVD Peripheral vascular disease 
PVDF Polyvinyl diflouride 
RNA Ribonucleic acid 
RSV Respiratory syncytial virus 
RT Room temperature  
RT-PCR Reverse transcription polymerase chain reaction 
SAM Standard analysis of microarrays 
SDS Sodium dodecyl sulphate  
SELDI Surface Enhanced Laser Desorption/ Ionization 
TdT Terminal deoxynucleotidyl tranferase 
TBE Tris-borate- EDTA 
TEMED Tetramethylethylenediamine 
TIMPs Issue inhibitors of metalloproteinases  
TNF Tumour necrosis factors 
TRIZOL Phenol & guanidine isothiocyanate reagent 
TTBS Tris-buffered saline  
  
 
 
 
195 
VEGF Vascular endothelial growth factor 
VPF Vascular permeability factor 
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 Short Communication
Staining of nasal mucosa to examine remodelling
S K AHMED, J L WILLIAMS*, A DRAKE-LEE, S EGGINTON*
Abstract
Background and objective: The process of embedding tissue in paraffin degrades many important molecules
involved in respiratory epithelial remodelling. We therefore examined alternative methods.
Methods: Inferior turbinate and nasal polyp biopsies were either placed in formalin or immediately
snap-frozen in the operating theatre. Novel protocols for staining remodelling markers were compared with
current methods.
Results: Our method, using a mixture of three lectins, stained a significantly greater proportion of samples,
compared with using Ulex europeaus lectin alone (84 vs 62 per cent; p , 0.005). Comparison of different
proliferation markers showed that Ki67 was more suitable than proliferating cell nuclear antigen for frozen
sections.
Conclusions: This study indicates that our robust, repeatable methods for examining whole mounts and for
staining capillaries, cell proliferation and nuclei on the same section of nasal mucosa are superior to current
methods. The use of fresh tissue that has not been paraffin-embedded would allow a greater suite of epitopes
to be examined in the future.
Key words: Remodelling; Nasal Mucosa; Polyp; Turbinates; Histology
Introduction
Histological examination of nasal mucosal tissue is essen-
tial when studying the aetiology of conditions such as
chronic sinusitis, polyposis, allergic rhinitis and asthma.
Tissue remodelling is an important feature of these dis-
eases, often being associated with increased severity or
chronicity, although the mechanisms involved are unclear
and require investigation.1 Multiple labelling of different
molecules on the same section is highly desirable, as it
allows co-localisation of different factors involved in
remodelling. However, most established protocols use
paraffin-embedded human tissue.2 This restricts the tissue
markers available, as many antibodies will not recognise
epitopes after paraffin-embedding. Thus, research into
airway remodelling is currently limited to studying a rela-
tively small set of proteins.
Using fresh tissue allows whole mount staining (using
relatively large tissue samples); the sample can then be
examined with confocal microscopy and analysed in three
dimensions. This approach could yield a wider range of
information, avoiding problems with heterogeneity of
structure by examining a larger mass of tissue, and correct-
ing for the large changes in tissue volume typically seen in
the nasal mucosa due to the nasal cycle. This approach has
been successfully applied to the examination of blood
vessels with fluorescent lectins in animal models3 and in a
proof-of-principle human study.4 However, the use of
lectins can be problematic in large human studies, as no
single lectin will stain a population with heterogeneous
blood groups.5 Antibody staining, such as cluster of differ-
entiation (CD) 31 or CD34, is poor at consistently staining
contiguous structures such as blood vessels.
As different lectins bind to different sugar moieties, we
reasoned that a mixture of the three different lectins
reported to stain human blood vessels5 would successfully
stain a far greater proportion of patient samples, and
would therefore provide a more robust staining protocol
for visualising capillary beds in three dimensions, allowing
further investigation of vasculature changes during tissue
remodelling in patients.
Materials and methods
Subjects
Patients were recruited from University Hospitals
Birmingham NHS Trust, UK, with local ethical committee
approval (numbers 0692 and 06/Q2702/15). Patients’
informed consent was obtained. Polyp and ipsilateral
inferior turbinate specimens, 1 cm back from the anterior
edge, were obtained from patients undergoing routine
polypectomy. Previous studies have found no difference
in vascularity between the different areas of the lateral
nasal wall.6 Inferior turbinate specimens from the same
anatomical site were also taken from patients undergoing
routine septoplasty or septorhinoplasty.
Immunohistochemical staining
Samples taken for confocal analysis were immediately fixed
in 4 per cent buffered formalin and left for 24 hours.
Samples were then washed in three changes of phosphate-
buffered saline for a further 24 hours, before being stained
whole with dilutions of either fluorescein-conjugated
Ulex europeaus lectin (Vector Labs, Peterborough, U.K.)
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or a fluorescein-conjugated lectin mixture (1:1:1 Ulex eur-
opeaus, Griffonia simplicifolia and Euonymus europeaus;
Vector Labs), in order to account for different affinities
associated with different blood groups.5 Samples were
then washed and stored in phosphate-buffered saline until
viewed under a confocal microscope (DM IRE2; Leica,
Milton Keynes). A total of 60 samples were stained with
the single lectin protocol, and 50 different samples were
stained with the triple lectin protocol.
Samples taken for immunostaining were immediately
snap-frozen in liquid nitrogen cooled isopentane in the
operating theatre, and 8 mm sections were subsequently
cut on a cryostat. These were allowed to air-dry before
being fixed in 4 per cent buffered formalin ( for 1, 5, 10,
20 or 60 minutes) or ice-cold acetone ( for 10, 30, 60 or
300 seconds). Antigen retrieval was performed in citrate
buffer (10 mM citric acid adjusted to pH 6.0 with NaOH,
0.05 per cent Tweenw 20) heated to 958C for 5 minutes
then allowed to cool to room temperature. Slides were
blocked for 30 minutes at room temperature in wash
buffer (either 5 per cent fetal bovine serum or 1.5 per
cent weight/volume bovine serum albumin, 0.6 per cent
volume/volume Tritonw X-100 in phosphate-buffered
saline, or 5 per cent fetal bovine serum in phosphate-
buffered saline), then incubated for 2 hours with primary
antibodies (Ki-67 and proliferating cell nuclear antigen;
Dako, Santa Cruz, California U.S.A.) diluted in wash
buffer to label proliferating nuclei. Sections were then
washed in phosphate-buffered saline and incubated for 1
hour with secondary antibody (Tetramethyl Rhodamine
Iso-Thiocyanate polyclonal rabbit anti-mouse; Dako)
diluted in wash buffer. Sections were rinsed in phosphate-
buffered saline and then incubated for 30 minutes with
lectin to stain blood vessels. Sections were washed in
phosphate-buffered saline, rinsed with dH20 and mounted
using Vectashield containing 40,6-diamidino-
2-phenylindole, in order to label all nuclei and enable cal-
culation of a proliferation index (Ki67 count/
40,6-diamidino-2-phenylindole count), based on counts of
four 500 mm ! 500 mm sampling squares, using inclusion/
exclusion lines. All counts were made either on the same
section or on a serial section from the same sample.
Results and analysis
Samples from a total of 60 patients were stained using
Ulex europeaus lectin, and compared to samples from
50 patients stained with a combination of Ulex europeaus,
Griffonia simplicifolia and Euonymus europeaus. Samples
that showed stained blood vessels were designated as posi-
tive, and samples in which blood vessels were not visualised
were restained. Repeated failure to stain capillaries was
seen in 23 of the single-lectin samples and in eight of the
triple-stained samples (p, 0.005; Pearson’s chi-square
test), representing a significant difference between single
and triple lectin methods (see Table I and Figure 1).
Both proliferating cell nuclear antigen and Ki67 staining
gave the most consistent results when sections were
attached to poly-L-lysine coated slides and fixed in 4 per
cent buffered formalin for 20 minutes. Both stains gave
best results with a wash buffer containing Triton X-100.
Staining with Ki67 required antigen retrieval, and the
optimal antibody concentration was 1:100 for both the
primary and secondary antibodies. Staining with proliferat-
ing cell nuclear antigen required antibody concentrations
of 1:50 for primary and 1:100 for secondary antibodies. A
significant difference was seen in the level of proliferation
marked by proliferating cell nuclear antigen and Ki67
staining (p , 0.05), with both the count per mm2 and the
proliferation index being significantly higher when
measured using proliferating cell nuclear antigen staining
compared with Ki67 (Table II).
Discussion
The objective of this study was to develop a robust
multiple staining protocol using samples that had not
been embedded in paraffin, so that a broader range of anti-
bodies could be used. The use of lectins to stain blood
vessels is well established in animal models, but it is less
widely used in humans due to variability in staining
between individuals with different blood groups.5 This
study found a marked improvement when using a mixture
of the three most commonly used human-specific lectins
TABLE I
COMPARISON OF SINGLE ULEX EUROPEAUS LECTIN STAINING VS
TRIPLE LECTIN PROTOCOL
Result Single Triple
þve (n) 37 42
2ve (n) 23 8
þve (%) 62 84#
#Staining was interpreted as þve ¼ samples stained well after
up to 3 attempts; 2ve ¼ samples repeatedly failed to stain
FIG. 1
Inferior turbinate mucosa stained with whole mount protocol
using three lectins.
TABLE II
COMPARISON OF PCNA AND KI67 AS MEASURES OF PROLIFERATION
Parameter PCNA Ki67
Proliferation (þve
counts/mm2)
1127+201 39+ 9†
Proliferation index# 34.3+5.6 1.4+ 0.3†
Data are expressed as mean+ standard error of the mean.
#Proliferation index expressed as percentage of total nuclei;
n ¼ 12. †p , 0.05; Student’s t-test. PCNA ¼ proliferating cell
nuclear antigen; þve ¼ positive
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(which bind to different sugar moieties present on the
endothelium), compared with use of a single lectin.
Lectins were also seen to bind to nasal mucosa epithelium
(Figure 2), as previously described;7,8 however, as this layer
is avascular, it does not interfere with capillary visualisa-
tion. Lectins have several advantages over other immuno-
histochemical methods in the staining of blood vessels.
They can be readily conjugated to several fluorophores,
allowing multiple stains to be used on the same section.
The one-step protocol reduces the signal degradation
associated with other multiple labelling methods, as well
as saving time. Lectins are relatively inexpensive, allowing
whole-mount stains to be performed economically. Finally,
using lectins avoids the problems commonly associated
with the use of two primary antibodies raised in the same
host species.
Proliferating cell nuclear antigen (also termed cyclin) is a
protein that acts as a processivity factor for deoxyribonu-
cleic acid polymerase delta in eukaryotic cells, and
the staining of this antigen is well documented for
paraffin-embedded sections. However, this study shows
that staining for proliferating cell nuclear antigen is not
appropriate for frozen sections, as the calculated prolifer-
ation index is unreasonably high. Normal mucosal tissue
is highly unlikely to have 34 per cent of total nuclei under-
going mitosis at any one time (Table II). We surmise that
this antibody stains proliferating cell nuclear antigen epi-
topes in fresh human cells that are not in their biologically
active form, as we have also seen unrealistically high label-
ling indices in serum-starved Human Umbilical Vein
Endothelial Cells monolayers where mitosis is arrested
(J Williams et al., unpublished data). Staining for Ki67 is
far more successful after a brief formalin fixation with
subsequent antigen retrieval. Results for proliferation
indices for fresh tissue using this method broadly
agree with those published for tissue prepared with
paraffin-embedding.9
Conclusions
This study demonstrates a novel and robust method for
analysing the capillary bed and the extent of cellular pro-
liferation in unfixed samples of respiratory mucosa. This
method will allow further investigation into the vascular
response during tissue remodelling in human biopsies,
and could thus help elucidate the aetiology and pathogen-
esis of tumours, chronic sinusitis, nasal polyposis, allergic
rhinitis and asthma. The protocols used are detailed below.
Protocols
Lectin staining protocol. Place samples in standard hospital
pathology formalin pots for 24 hours at 48C. Stain with a
1:100 dilution, in phosphate-buffered saline, of a 1:1:1
stock of fluorescein-conjugated Ulex europeaus, Griffonia
simplicifolia and Euonymus europeaus lectins for
24 hours at 48C. Wash three times with phosphate-buffered
saline for 1 hour each wash, before examining under confo-
cal microscopy.
Triple staining protocol. Snap-freeze samples in liquid
nitrogen cooled isopentane and store at 2808C, before
cutting 8 mm sections on a cryostat. Air-dry the sections,
perform an antigen retrieval with citrate buffer (10 mM
citric acid adjusted to pH 6.0 with NaOH, 0.05 per cent
Tween 20) heated to 958C for 5 minutes then allowed to
cool to room temperature. Fix for 20 minutes in 4 per
cent buffered formalin, then block for 30 minutes using a
wash buffer consisting of 1.5 per cent weight/volume
bovine serum albumin and 0.6 per cent volume/volume
Triton X-100 in phosphate-buffered saline. Incubate for
2 hours with primary antibody (Ki-67, Dako) diluted 1:100
in wash buffer. Wash with three changes of phosphate-
buffered saline for 5 minutes each, then incubate for
FIG. 2
Triple stain of a single section of inferior turbinate
mucosa under different fluorescent illuminations.
(a) Rhodamine-conjugated Ki67 stain; (b) fluorescein-
conjugated lectin stain; (c) 40,6-diamidino-2-phenylindole
stain for nuclei. e ¼ epithelial layer.
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1 hour with secondary antibody (Tetramethyl Rhodamine
Iso-Thiocyanate polyclonal rabbit anti-mouse; Dako)
diluted 1:100 in wash buffer. Rinse with phosphate-
buffered saline, then incubate for 30 minutes with 1:100
of stock 1:1:1 fluorescein-conjugated Ulex europeaus, Grif-
fonia simplicifolia and Euonymus europeaus lectins. Wash
with three changes of phosphate-buffered saline for
5 minutes each, rinse with dH20 and mount with Vecta-
Shield containing 40,6-diamidino-2-phenylindole.
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IS HUMAN SKELETAL MUSCLE CAPILLARY SUPPLY
MODELLED ACCORDING TO FIBRE SIZE OR FIBRE
TYPE?
S. K. AHMED, S. EGGINTON", P. M. JAKEMAN-t-t, A. F. MANNIONt§
AND H. F. ROSS
Department of Physiology and t School of Sport and Exercise Sciences, University of Birmingham, PO Box 363,
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SUMMARY
Analysis of muscle capillary supply usually relies on estimating either the numerical capillary to
fibre ratio or capillary density. Both indices are scale dependent, i.e. they vary with fibre size. We
have examined the use of an alternative approach based on the anatomical supply area of individual
capillaries, which allows the calculation of a local capillary to fibre ratio or density based on area,
rather than number of fibres. The results suggest that, in human skeletal muscle, capillary supply is
primarily scaled according to fibre size, and is relatively independent of fibre type.
INTRODUCTION
An accurate quantitative analysis of capillary supply to skeletal muscle is an essential
prerequisite for understanding the limits to peripheral oxygen transport. The capillary supply
to skeletal muscle is influenced by its metabolic profile, oxidative capacity and fibre size
(Hudlicka, Brown & Egginton, 1992). Quantitative differences in gross capillary supply are
normally expressed as the ratio of capillary number to fibre number (capillary to fibre ratio,
C: F) or to fibre area (capillary density, CD). Given that these indices are scale dependent, there
is a need for a more discriminatory analysis that takes account of fibre size. By calculating the
area of muscle tissue supplied by, or the domain of influence of, individual capillaries an
unbiased measure of the local capillary to fibre ratio (LCFR) and local capillary density (LCD)
may be derived (Egginton & Ross, 1989). This novel approach was used to investigate whether
the local capillary supply was modelled according to the size or type of individual human
skeletal muscle fibres.
METHODS
With the approval of the Local Ethics Committee and written informed consent, samples from the lateral
portion of the quadriceps femoris muscle were obtained by percutaneous needle biopsy from fifteen active
young subjects (10 male and 5 female): mean age, 23.3 + 1 38 years (males) and 21.0 + 1-73 years
(females); height, 1 80 + 0-02 m (males) and 1 66 + 0 04 m (females); and body mass, 83-3 + 3-70 kg
(males) and 60 7 + 1-56 kg (femrales). Serial sections (10 um thick) were prepared for quantitative
analysis by histochemical staining of fibre types (myosin ATPase; Brooke & Kaiser, 1970) and capillaries
(Ulex eutopaceus lectin, UEA-I; Holthofer, Virtanen, Kariniemi, Hormia, Linder & Miettineu, 1982).
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MUSCLE CAPILLARY SUPPLY AND FIBRE SIZE
Table 1. Fibre type specificity of local capillary supply in the lateral quadriceps
Fibre type LCFR LCD CAF CPA Fibre area
(#um-2) (Am-2) (#m2)
Type 1 0723 + 0-084 174.1 ± 10.71 1.323 + 0.168 3297 + 34.9 4176 + 340
Type Ila 0.569 + 0.056 172.1 + 13.30 1 027 + 0.120 338.2 + 50.8 3399 + 366
TypelIb 0532+0047 169.8+8.34 0912+0076 311 6+237 3216+366
DISCUSSION
Many studies have sought to determine whether the capillary bed of skeletal muscle is limiting
for aerobic capacity via its role in setting the level of functional hyperaemia. While capillarity
is increased following a period of training, a number of variables may complicate the implicit
relationship between supply and demand. For example, in a longitudinal training study
Andersen & Henriksson (1977) showed that an expansion of the capillary bed was accompanied
by fibre type transformation in vastus lateralis. Both the duration of training and size of fibres
were also important factors, with C: F increasing significantly after 5 weeks, but CD only
after 8 weeks due to the accompanying fibre hypertrophy. From biopsies taken before and
following 24 weeks of endurance training, Ingjer (1979) found a significant increase in C: F,
with the CAF for slow oxidative fibres increasing more than that for fast glycolytic fibres. Indeed,
Saltin & Gollnick (1983) suggested that the supply area for capillaries would be 20-30 %
(type II b) or 10-20 % (type II a) greater than that for type I fibres, which is similar to the
differences shown by our measured values of local capillary supply (LCFR; Table 1). These
and other studies are in agreement with the more extensive literature from animal experiments
showing that local demand (in terms of fibre type) may influence capillary growth, and that
CD often varies inversely with fibre size (Hudlicka et al. 1992). Such considerations may
explain reported discrepancies in CD among human training studies.
Using a specific marker for capillaries and a discriminatory analysis of local capillary supply,
we have examined over 1700 human muscle fibres. By comparison with the discontinuous
distribution of values from any of the integer-based indices of capillary supply, which convey
little information regarding muscle composition, the continuous indices can be used to
describe the local capillary supply and have the potential to discriminate between more subtle
changes in fibre composition and/or size. This may be of particular benefit where fibre size
changes between samples, e.g. hypertrophy following high resistance exercise (Abernethy,
Jurimae, Logan, Taylor & Thayer, 1994), or where an increase in CD does not reflect
capillary growth, but rather the atrophy of muscle fibres (Hoppeler & Desplanches, 1992). In
particular, while both fibre size and capillary supply are reduced with age, the apparent
specificity of training-induced increases in capillary supply to type II fibres in elderly subjects
(Proctor, Sinning, Wairo, Sieck & Lemon, 1995) deserves closer attention. Indeed, in a pilot
study we showed a regression of LCFR against fibre area in trained muscle which was merely
offset from that of controls (LCFR = 0 798 + 0 0017 x area; r2 = 0. 17), with a similar slope
and clustering for fibre types, although LCD showed a slight negative slope against fibre size
(LCD = 501.2- 0031 x area; r2 = 0. 15), suggesting that additional factors have some
influence on local capillary supply (Ahmed, Egginton, Ross, Mannion & Jakeman, 1995). We
therefore conclude that the capillary supply to human skeletal muscle is scaled according to
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fibre size and is relatively independent of fibre type. The method of capillary domains offers a
reproducible technique, with the potential to discriminate between subtle adjustments in local
capillary supply at the level of individual human muscle fibres.
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Effect of asthma and allergy on nasal polyp cell turnover 
 
Nasal polyps have a higher rate of cell proliferation and apoptosis than normal 
nasal tissue.  Polyposis is often linked to asthma, nasal allergies and aspirin 
sensitivity, which also increase tissue remodelling.  The aim of the study was to 
examine whether the conditions of asthma, allergy or aspirin sensitivity cause 
more active nasal polyposis and to what extent.   
Polyp and inferior turbinate biopsies were taken from each side of patients with 
bilateral polyposis. Inferior turbinate samples were also taken from patients with no 
asthma or allergy undergoing routine septorhinoplasty, as an external control.  
Polyp patients with a history of asthma and/or allergy, or Samter’s triad were 
grouped accordingly.  Frozen sections were TUNEL stained to label apoptotic 
cells, and parallel sections stained for Ki-67 to label proliferating nuclei. 
Patients with a history of allergy and/or asthma had significantly higher apoptotic 
indices than patients with neither.  There appeared to be an additive effect of 
asthma and allergy with more apoptosis occurring in patients with both or Samter’s 
triad compared to patients with one condition only.  Proliferation was higher in 
patients with asthma and/or allergy than in patients with neither. 
This study shows that having a history of asthma, allergy or aspirin sensitivity 
leads to more cell proliferation and apoptosis in nasal polyposis, and thus greater 
cell turnover. Both asthma and allergy increase the cell turnover, and the effect is 
additive, suggesting different mechanisms.  Further studies will ascertain to what 
extent apoptosis and cell turnover occurs with asthma, allergy and aspirin 
sensitivity. 
 
      
 
 
 
 
 
 
VEGF165b or bevacizumab (a monoclonal antibody against
VEGF-A). Hypoxic cells were cultured in a hypoxia chamber
to which 5%CO2/95% N2 was connected.% Cell viability
(alive cells/alive!dead cellsX100) was determined by Try-
pan blue staining, and cytotoxicity by lactate dehydrogenase
release. VEGF165b increased trophoblast survival in nor-
moxic (7592.8% VEGF165b, 5498.1% control) and hy-
poxic (6291.8% VEGF165b, 4093.8% control) conditions
(One-way ANOVA, p"0.0079, n"16). In hypoxia, bevaci-
zumab increased trophoblast cytotoxicity, and VEGF165b
addition to cells cultured in sodium butyrate (a cytotoxic
agent) reduced trophoblast death (Unpaired t tests, pB0.02
and pB0.01 respectively, n"14). VEGF165b is a survival
factor for 1st trimester trophoblasts. A lack of VEGF165b may
prevent adequate trophoblast invasion into the myometrium,
promoting pre-eclampsia development.
PC77
SCALING OF CAPILLARY SUPPLY IN HUMAN
MYOPATHIES
SK. Ahmed, J. Williams, J. Round, S. Egginton
Angiogenesis Research Group, Medical School, University of
B’ham, B15 2TT, UK - s.ahmed@doctors.org.uk
In skeletal muscle ontogenetic growth and adaptive remodel-
ling result in a capillary supply scaled according to fibre size
[1,2]; whether this holds when remodelling is pathological is
unknown. Biopsies were taken from control patients, and
patients with idiopathic clinical muscle atrophy or fibre
hypertrophy. Biopsies were snap-frozen and capillaries
stained using Ulex europeaus lectin-1. Mean fibre area
showed a 2-fold range among groups (!2800, 4500 and
6300 mm2). Capillary density (CD) of hypertrophic myopa-
thies showed no significant difference from controls, but
capillary to fibre ratio (C:F) increased in response to the
greater fibre size (2.05 vs. 1.25), suggesting scaling effects
similar to non-pathogenic stimuli. Atrophic myopathies
showed no difference in C:F from controls, but an increase
in CD (430 vs. 310 mm#2), suggesting maintenance of the
vasculature independent of intramuscular scaling. These data
are consistent with larger fibres being more susceptible to
metabolic error signals, with reduced intracellular PO2 acting
as an angiogenic signal [3]. A meta-analysis of 44 human
studies examined C:F, CD, fibre size, methodology, muscle
type and experimental protocols as separate variables.
Resistance training and chronic atrophies result in adaptive
remodelling of the capillary bed, whereas acute atrophy
shows vascular maintenance, and endurance training leads to
a higher C:F than predicted by fibre size. [1] Egginton S.
(1990). Adv Comp Environ Physiol 6:73$141 ; [2] Ahmed
et al. (1997). Exp Physiol 82:231$4 ; [3] Deveci et al.
(2001). Am J Physiol 281:H241$H252.
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USING HUMAN ORTHOLOG RELATIONSHIPS AS A
STRATEGY TO EXAMINE THE ORIGIN OF COLD-
INDUCED ANGIOGENESIS IN A NON-MODEL SPECIES
JMJ. Herbert, F. Buffa, H. Vorschmitt, S. Egginton,
R. Bicknell
Cancer Research UK Angiogenesis Group, IBR, Birmingham
Uni, Med. Schoo - j.m.herbert@bham.ac.uk
Some species increase their cardiovascular network to reduce
the effects of reduced oxygen diffusion and increased blood
viscosity associated with cold temperatures. Since many
angiogenic and endothelial genes have been discovered in
human, ortholog relationships between carp, zebrafish and
human were used to predict the identity of genes responsible
for cold induced angiogenesis. Carp sequences were collected
and human-carp ortholog relationships derived, via zebra-
fish, using a new Conditional Stepped Reciprocal Best Hit
(CSRBH) protocol. Then published articles, Gene Ontology
and cDNA libraries were used to predict the identity of
known or potential angiogenic genes. Finally, meta-analyses
of cold carp microarray data identified carp genes up-
regulated in response to cold temperatures. Using the CSRBH
approach, 3,752 human-carp ortholog relationships (none
redundant) were attained. 866 of these genes were predicted
to have a potential role in angiogenesis. The total number of
differentially expressed cDNAs in the carp data was 3603
and 1824 of these were up-regulated, representing 608 genes.
The angiogenic prediction found 150 from the 608 genes to
be angiogenic. Of these, 5 genes representing the orthologs
NCL, RHOA, NFKBIA, GAPDH and MAPK1 are expressed
in response to cold. Here we show that CSRBH ortholog
relationships and meta-analyses can be combined in a none
model species to predict genes of biological interest before a
genome sequence is fully available.
PC79
VEGF165B REDUCES HUMAN NEUROBLASTOMA
GROWTH RATE IN VIVO
1M. Peiris,
¯
2SJ. Harper, 2DO. Bates, 1P. Ramani
1University of Bristol, Department of Cellular and Molecular
Medicine, 2University of Bristol, Department of Physiology,
Microvascular Research Laboratories, UK - Pramila.
Ramani@bristol.ac.uk
Vascular endothelial growth factor (VEGF) has an essential
role in angiogenesis and is up-regulated by a variety
of tumours. An endogenous family of anti-angiogenic
isoforms termed VEGFxxxb has been identified in many
normal, non-angiogenic tissues, and, in contrast with the
angiogenic VEGFxxx isoforms, is down-regulated in several
Abstracts:59thMeetingofTheBritishMicrocirculationSociety
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THE FORMATION OF NASAL POLYPS IS INDEPENDENT OF ANGIOGENESIS 
 
S. K. Ahmed, J. L. Williams, A. Drake-Lee, S. Egginton 
Angiogenesis Research Group, Department of Physiology, University of Birmingham, 
Medical School, Birmingham B15 2TT, UK 
 
Nasal polyposis is a common disease, the aetiology of which is currently unknown. 
Several mechanisms have been proposed, and recent studies have shown up-
regulation of several pro-angiogenic factors [1,2]. The aim of this study was to assess 
and quantify the degree of angiogenesis in nasal polyps, and therefore whether 
angiogenesis is important in initiating polyposis. Biopsies of (1) polyp tissue and (2) 
nasal mucosa were taken from patients undergoing polypectomy, and compared with 
(3) nasal mucosal samples from control patients (n=5). Biopsies were either stained 
with fluorescent lectins for confocal microscopy or snap frozen and sectioned for 
histology for the examination of multiple measures of angiogenesis. 
No significant differences in capillary density, capillary-associated proliferation, 
capillary surface density or capillary volume density were seen between the three 
study groups. The regression of surface density vs. volume density described the 
same linear relationship in all three groups, indicating no gross differences in 
architecture of the capillary bed. Polyp samples showed increased capillary diameter 
and interstitial proliferation. These results show no active angiogenesis or changes in 
capillary bed architecture in the polyp, although polyp capillaries appear more 
oedematous. As the capillary supply increases in line with the physiological needs of 
growing polyps, we conclude that angiogenesis is not a driving force in the aetiology of 
nasal polyposis, but is recruited in a feedback manner to support tissue expansion. 
[1] Coste A et al. (2000). Eur Resp J. 15:367-372; [2] Norlander T et al. (2001). 
Rhinology. 29:88-92 
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Scaling of muscle capillary supply in humans:
effect of strength training
S.K. Ahmed, S. Egginton, H.F. Ross, A.F. Mannion* and
P.M. Jakeman*
Department of Physiology and *School of Sport & Exercise
Sciences, University of Birmingham, Birmingham
B15 2TT
An accurate quantitative analysis of capillary supply to
skeletal muscle is an essential prerequisite for
understanding the limits to peripheral oxygen transport.
Exercise-induced changes in the metabolic profile,
oxidative capacity and fibre size are known to produce
changes in muscle capillary supply, usually quantified as
the ratio of capillary number to tissue area (capillary
density, CD) or to fibre number (capillary to fibre ratio,
C: F). Calculating the area of muscle tissue supplied by, or
domain of influence of, an individual capillary provides a
measure (by summing the fraction of all domains
overlapping a fibre) of the local capillary to fibre ratio
(LCFR) and local capillary density (LCD) (Egginton & Ross,
1989). The aim of this study was to utilize this approach to
investigate whether the capillary supply to skeletal muscle
was modelled according to fibre size or fibre type, in normal
and post-training subjects.
With the approval of the local ethics committee and
informed consent, muscle samples from the lateral portion
of the quadriceps femoris muscle were obtained via
percutaneous needle biopsy from twenty-one healthy,
active young subjects (fifteen males and six females). Serial
sections (10 ,um) of muscle were prepared for histochemical
analysis of fibre type (ATPase) and capillary visualization
(Ulex Europaeus lectin, UEA-I). Digitized images of each
stained section were used to determine the fibre area and
the x, y co-ordinates for all fibres and associated
capillaries. From these data the LCFR and LCD indices of
capillary supply were calculated according to the
procedures described previously (Egginton & Ross, 1989).
Fibre type composition (mean + S.D.) by number for the
subjects were: type J 47*4 + 13-2, type IIa 39-8 + 12-2 and
type IIb 13-0 + 9-2%; and by area occupied by type I
41-8 + 14-4%, type IIa 41-7 + 14-4 and type IIb
11 0 + 7 7%. Mean fibre area was: type I 4224 + 1006,
type IIa 5245 + 1480 and type IIb 4293 + 1194 ,sm2. A
total of 960 fibres were matched across serial sections for
fibre type, fibre area and capillarity. Mean capillary supply
was 310 + 71P6 mm-2 and 1-77 + 0 34 (CD and C: F,
respectively). The LCFR analysis showed a significant
positive correlation with fibre area (r = 0-71, P < 0.0001,
ANOVA) that was independent of fibre type, while LCD
showed no significant relationship to fibre area and no
significant difference between LCD and fibre type. These
results suggest that in humans capillary supply is scaled
according to fibre size and is independent of fibre type.
The change in capillary supply with training showed an
increase in both capillary supply and fibre size: 1P9 + 0 49
vs. 0-62 + 0-15 and 5073 + 1459 vs. 1933 + 904 ,sm2 (C: F
and mean area, respectively). LCFR increased, while LCD
was unchanged after training (1P58 + 0-65 vs. 0 54 + 0-28
and 325 + 129 vs. 306 + 144, respectively), suggesting that
activity-induced changes in capillary supply are also
determined primarily by changes in fibre size.
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